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Abstract 
Prostate cancer (PCa) is the second most common cancer worldwide in men and one of the 
major causes of cancer-related death among men in Australia. In PCa cells, the androgen 
receptor (AR) is the key driver of cell proliferation, cell cycle progression, and metabolism; 
thus, blocking AR activity with androgen deprivation therapy (ADT) is a standard-of-care 
treatment for metastatic PCa. However, ADT is never curative, with all patients eventually 
relapsing with lethal castration-resistant prostate cancer (CRPC). In a paradoxical 
phenomenon, potent activation of AR with high doses of androgens can also inhibit the 
growth of PCa tumours. However, the exact mechanism(s) by which activation of AR can block 
PCa growth is poorly understood. Therefore, in my PhD project, I explored the mechanisms 
underlying PCa growth suppression in response to extreme activation of AR using a potent 
androgen, methyltestosterone (MeT).  
 
I have found that methyl-testosterone (MeT), a synthetic androgen, can potently 
transactivate AR and suppress the proliferation of AR-positive prostate cancer cells (LNCaP, 
C42B, MR49F, and 22RV1) but not an AR-negative cell line (PC3) or a PCa model expressing a 
version of the AR lacking the ligand-binding domain (R1-D567), suggesting that the growth-
inhibitory effects of MeT are AR-dependent. Mechanistically, MeT acts much like high-dose 
dihydrotestosterone (DHT) in terms of genome-wide AR binding (evaluated by ChIP-seq) and 
the transcriptional program activated via AR (evaluated by RNA-seq). However, these 
analyses showed that MeT only extends the AR cistrome and enables AR to act as a potent 
 
6 | P a g e  
 
transcriptional repressor of genes associated with cell cycle, DNA replication, and DNA 
damage responses.  
 
Unexpectedly, our RNA-seq data revealed that MeT dysregulates the expression of 
transposable elements, including endogenous retroviruses (ERVs). Mechanistically, we found 
that MeT suppresses the expression of DNA methyl-transferases (DNMTs) and EZH2, which 
are considered to be key factors repressing the expression of transposable elements. 
Consistent with the proposed hypothesis, my PhD work showed that MeT caused global 
hypomethylation of DNA and re-distribution of H3K27me3. More specifically, my research 
supports a model whereby DNA hypomethylation was linked to the induction of endogenous 
retroviruses (ERVs). Interestingly, I found that ERV induction was associated with a “viral 
mimicry” response characterised by activation of pattern recognition receptors RIG-I and 
STING and subsequent activation of interferon (IFN) signalling. Importantly, I also observed 
increased expression of MHC class I genes with MeT treatment, suggesting that it can enhance 
tumour immunogenicity. Validating this finding, co-culture of a murine model of PCa (RM1) 
with tumour-specific CD8+ T cells revealed that MeT promoted enhanced recognition and 
functional cytokine production by T cells.  
 
Collectively, my work has provided a greater understanding of growth-inhibitory effects of 
androgens on PCa tumours and uncovers a potential new role for high-dose androgen therapy 
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1.1. Prostate gland structure and function 
The prostate is the largest accessory genital gland that secretes material making up 35-30 % 
of the seminal fluid that protects sperm (Resnick and Thompson 2000). This material includes 
high levels of divalent cations and several proteases, the most abundant being prostate-
specific antigen (PSA or kallikrein-related peptidase-3 (KLK3), encoded by the KLK3 gene). PSA 
is responsible for the degradation of the semenogelins I and II in semen after ejaculation, 
which improves sperm motility (Mattsson, Ravela et al. 2014). 
 
The prostate gland consists of 30 to 50 branched tubule-acinar glands surrounded by a 
capsule. As shown in figure 1.1, this gland can be divided into three zones histologically: the 
peripheral zone (about 70% of the glandular tissue of the prostate), central zone (20–25% of 
the glandular tissue of the prostate), and transition zone (5–10% of the glandular tissue of the 
prostate). The central zone is the entire base of the prostate and includes the ejaculatory 
ducts. In the peripheral zone, acini are round to oval and surrounded by a loose stroma of 
smooth muscle and collagen (Figure 1.2a and 1.2b). Central zone acini are complex and large 
(Figure 1.2c and 1.2d). Transition zone glands are simple, small, and round and set in a 

















Figure 1.1. Typical anatomy of the prostate gland. The location of prostate zones in the coronal section 















Figure 1.2. Normal Prostate histology. 1.2a. simple peripheral zone acini. 1.2b. Columnar epithelium 
of normal peripheral zone. 1.2c. Normal, large, complex with papillary infoldings acini of the central 
zone. 1.2d. Cuboidal to columnar epithelium of normal central zone. 1.2e. Normal and simple acini of 
transition zone with compact stroma. 1.2f. Cuboidal or low columnar epithelium of normal transition 
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1.2. Androgen receptor (AR) structure and function  
Androgen receptor (AR), a member of the steroid and nuclear receptor superfamily (NR3C4, 
nuclear receptor subfamily 3, group C, gene 4), plays a critical role in the development and 
homeostasis of the prostate gland. The gene encoding the AR protein is located at the locus 
Xq11-Xq12 on chromosome X with 8 exons and introns varying between 0.7 to 2.6 kb. AR 
protein, as a ligand-dependent transcription factor, is a phosphoprotein of 919 amino acids 
and consists of three main functional domains, including an N-terminal domain (NTD), a DNA-
binding domain (DBD), and a C-terminal ligand-binding domain (LBD). A flexible region named 
hinge connects the LBD domain to the DBD (Lorente, Mateo et al. 2015) (Figure 1.3).  
 
The NTD (residues 1–558) encoded by exon 1 of the AR gene, constitutes approximately 60% 
of the 110 kDa AR protein (Imamura and Sadar 2016). This domain consists of two regions 
termed TAU-1 (residues 101–370) and TAU-5 (residues 360–485), which are involved in the 
transcriptional activity of AR (Jenster, van der Korput et al. 1995). Activation function-1 (AF1) 
in the TAU-1 domain mediates the protein-protein interactions between AR and coregulatory 
proteins (Kumar, Betney et al. 2004, Lavery and McEwan 2008, De Mol, Szulc et al. 2018). 
TAU1 and TAU5 can also mediate the inter-domain interactions between NTD and LBD (N/C 
interaction), which is an important regulatory mechanism for the expression of some AR 
target genes (McEwan and Gustafsson 1997, Reid, Murray et al. 2002). 
 
AR exons 5-8 encode the LBD (residues 666–919), consisting of eleven α-helices (H1 to H12) 
and two β-sheets arranged in a three-layer antiparallel helical sandwich. AR LBD is 
characterized by a ligand-binding pocket, in which lipophilic ligands are captured in a 
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hydrophobic cavity (Tan, Li et al. 2015). In response to structurally different AR ligands, 
hydrophobic amino acids in the LBD can adopt different conformations to maintain the ligand 
in the steroid‐binding cavity. Following the hydrophobic interactions, hydrogen bonds 
between AR and ligands are formed, firmly tethering the steroid molecule (Pereira de Jésus‐
Tran, Côté et al. 2006). Structurally, the H12 helix acts as a lid to close the LBP upon ligand 
binding, leading to the formation of a hydrophobic cleft called the activation function 2 
domain (AF2). AF2 acts as a ligand-dependent docking site for AR coactivators such as steroid 
receptor coactivator-3 (SRC3) (He, Kemppainen et al. 2000, Zhou, Suino-Powell et al. 2010, 





Figure 1.3. A. The structure of the androgen receptor. AR gene consists of 8 exons, encoding three 
main domains of AR protein including an N-terminal domain (NTD), a DNA-binding domain (DBD), and 
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The DBD enables AR to bind the androgen response element (ARE) sequences in promoter 
and enhancer regions of AR-regulated genes. Each ARE consists of two equal, hexameric half-
sites (5′-AGAACA-3′) separated by a three base-pair spacer. Structurally, AR DBD (residues 
556–623) consists of a “core” composed of two Zinc fingers and one carboxyl-terminal 
extension (CTE) region which is encoded by exon 4 (Khorasanizadeh and Rastinejad 2001, 
Gelmann, Sawyers et al. 2013). Formed through hydrophobic interactions, DBD Zinc fingers 
are associated with two zinc ions, leading to the formation of “P-box” and “D-box” in N-
terminal and C-terminal Zinc-fingers, respectively. Molecularly, when AR is liganded with an 
agonist, D-box mediates AR dimerization in a “head-to-head” manner allowing the AR to bind 
as a dimer to the two half-sites of an ARE (Shaffer, Jivan et al. 2004, Lallous, Dalal et al. 2013). 
The N-terminal Zinc-finger, termed the Recognition helix, subsequently inserts into the major 
groove of the chromatin and P-box specifically binds to ARE (Umesono and Evans 1989, 
Khorasanizadeh and Rastinejad 2001). In addition to Zinc fingers, amino acids residues at CTE 








17 | P a g e  
 
1.3. Cellular and molecular phenotypes of prostate epithelial cells 
Based on cellular and molecular phenotypes, the glandular prostate epithelium can be 
categorized into three main cell types including secretory luminal cells, basal cells, and 
neuroendocrine cells (Van Leenders, Gage et al. 2003). Luminal cells, which can be found in 
the luminal layer of prostate epithelium, express a high level of androgen receptor (AR) 
representing the major secretory cells in prostate epithelium. Importantly, in the normal 
prostate gland, luminal cells are androgen-dependent, terminally differentiated with the 
lowest proliferation capability. By contrast, basal cells localised in the basal part of glandular 
epithelium, are androgen-independent, less differentiated, and highly proliferative cells, 
characterized by a low level of AR and without a significant secretory function. Characterized 
as the least terminally-differentiated and androgen insensitive cells, neuroendocrine cells can 
be identified in the prostate epithelium; however, they are less frequent and their function is 
not completely understood (Table 1.1) (Hudson 2004, Lang, Frame et al. 2009).
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Key Morphological  phenotypes in 






Terminally-differentiated cells, characterised 
by lowest proliferative activity and high 
secretory function;  accounting for 73% of the 
total epithelium volume;  androgen-
dependent cells 
 
Cuboidal to columnar, with small, 
round nuclei 
High level of AR (+); PSA 
(+); PAP (+); keratins (K) 8 
and 18 (+) 
(Van Leenders, Gage et al. 2003, Bostwick 
and Cheng 2008) 
Basal cells Less common epithelial cells in prostate 
gland;  relatively undifferentiated cells with  
highest proliferative activity; without 
secretory  function;  androgen-independent 
cells 
 
Flattened and elongate cells 
surmounting the basement 
membrane 
Low level of AR (+), BCL-2 
(+); p63 (+); keratins 5 and 
14 (+) 




Terminally differentiated epithelial cells in 
prostate gland;  Androgen-insensitive cells 
infrequent cells with variability in 
their morphology; cannot be 
identified using conventional H&E 
Staining   
Contain both AR-positive 
and AR-negative cell 
populations; Serotonin (+); 
Chromogranin A (+); 
Neuron-specific enolase 
(+)  
(Nakada, di Sant'Agnese et al. 1993, 
Bostwick and Cheng 2008, Grigore, Ben-
Jacob et al. 2015) 
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1.4. Androgen receptor agonists 
AR agonists consist of small molecules which can interact with AR LBD and stimulate AR 
transcriptional activity function. These AR interacting compounds can be categorised based 
on their chemical structure (steroidal versus nonsteroidal) and also the origin of synthesis 
(endogenous versus synthetic agonist) (Gao, Kim et al. 2006). Testosterone (T) and its potent 
metabolite, dihydrotestosterone (DHT), are the major male sex hormones acting as 
endogenous steroidal AR agonists, inducing both androgenic and anabolic effects in a tissue-
specific manner (Pihlajamaa, Sahu et al. 2015, Feng and He 2019). Androgenic effects are 
associated with androgen effects on male sex characteristics and anabolic effects are mainly 
linked to effects of androgens on skeletal muscle and bones (Bhasin, Taylor et al. 2003). 
 
Another group of AR agonists called anabolic-androgenic steroids (AAS) are synthetic 
derivatives of T, developed to modulate the androgenic effects of endogenous steroids. In 
comparison with endogenous androgens, these compounds have improved bioavailability,  
reduced adverse androgenic effects, and enhanced anabolic features and are clinically used 
as testosterone analogues for hormone replacement therapies (Patt, Beck et al. 2020). 
Structurally, AAS hormones are synthesised either through the esterification (e.g. 
testosterone cypionate) or alkylation (e.g. Methyltestosterone) of the testosterone backbone 
(Salerno, Cascio et al. 2018). These chemical modifications are mainly affecting the 
pharmacokinetics of the hormones; for example, alkylation or esterification of testosterone 
structure at 17-alpha position (Figure 1.4), increases the oral bioavailability and decreases the 
hepatic metabolism of the compound (Fragkaki, Angelis et al. 2009). These chemical 
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modifications on steroids may also affect the AR conformation, potentially affecting the AR 
function through the recruitment of different AR-coregulators in a tissue-specific manner 
(Chang, Norris et al. 1999, Chang and McDonnell 2002, Wang, Lawless et al. 2020).  
 
Another group of synthetic androgens are selective androgen receptor modulators (SARMs). 
To reduce the undesirable androgenic effects of T on prostate cells, nonsteroidal AR ligands 
called SARMs have been also developed to help the patients suffering from skeletal muscle 
wasting. Theoretically, while acting as AR agonist in bone and skeletal muscle, SARMs function 
either as an antagonist or mild agonist in the prostate gland (Fonseca, Dworatzek et al. 2020). 
Mechanistically, the exact mechanism(s) involved in tissue-specific activation of AR by SARMs 
are not fully understood; however, the ligand-dependent surface topology of activated-AR 
and tissue-specific recruitments of unique coregulators may explain the different effects of 
DHT and SARMs in prostate cells (Baek, Ohgi et al. 2006, Pihlajamaa, Sahu et al. 2015). 
 
 



















Figure 1.4. A) Chemical modifications on Testosterone backbone. B) Chemical structure of synthetic-
androgenic AR agonists (Henderson, Penatti et al. 2006, Fragkaki, Angelis et al. 2009). 
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1.5. AR transcriptional activity 
In normal prostate cells, the AR signalling depends on the presence of AR agonists. The 
inactive form of AR preferentially is located in the cytoplasm while bound to heat shock 
proteins (HSPs). Heat shock proteins prevent AR translocation and support the permissive 
conformation of AR for ligand binding (Heinlein and Chang 2002). Upon ligand binding, AR 
undergoes a conformational change leading to its dimerization in the cytoplasm, followed by 
translocation into the nucleus and binding to AREs. AR subsequently recruits the basic 
transcription machinery and related coregulators to trigger the transcription of androgen-
responsive genes (Xu, Shimelis et al. 2009) (Figure 1.5). 
 
1.6. Regulation of AR function by co-regulators and post-translational 
modifications 
In the prostate cells, AR coregulators including co-activators and co-repressors are the key 
determinants of AR function and their quantity and interactions regulate AR’s transcriptional 
activity (Scher, Buchanan et al. 2004). Coactivators consist of a diverse variety of proteins 
assisting AR in ligand binding, nuclear translocation, DNA binding, and recruitment/stabilizing 
of the transcription machinery (Heinlein and Chang 2002). Some coactivators, such as SRC-1 
from p160/SRC family and CBP/p300, possess a histone modification activity modulating the 
AR signalling through chromatin remodelling (Spencer, Jenster et al. 1997, Aarnisalo, Palvimo 
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Figure 1.5. Activation of AR signalling by Androgens in prostate cancer cells. T: Testosterone; DHT: 
Dihydrotestosterone; AR: Androgen receptor; HSP: Heat shock proteins; p: phosphorylation; CoReg: 
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Corepressors, in contrast, suppress the transcriptional activity of AR. This group of proteins 
can modulate the AR signalling by interfering in mechanisms such as AR N/C interactions, 
translocation, DNA binding, interaction with coactivators, and recruitment of basal 
transcriptional machinery (Wang, Hsu et al. 2005).  
 
Posttranscriptional modifications of AR protein are another regulatory layer in the fine-tuning 
of AR function. Phosphorylation, acetylation, methylation, and ubiquitination can either 
positively or negatively affect AR signalling in response to different signal transduction 
pathways (Wen, Niu et al. 2019). For example, phosphorylation of Serine 81 (S81) in the AF1 
region of the AR NTD domain mediated by different cyclin-dependent kinases (CDKs) 
regulates AR protein stability, localization, and transactivation (Hsu, Chen et al. 2011).  
 
1.7. AR function in normal prostate gland 
Androgens, acting via AR, have a crucial role in male phenotype formation, sexual maturation, 
and reproductive function. Also, non-reproductive tissues such as muscle, bone, skin, and 
adipose tissues are affected by androgens (Heemers and Tindall 2007). In the normal prostate 
gland, AR regulates the homeostasis between cell proliferation and cell death and maintains 
the differentiated phenotype of prostate epithelial cells (Carson and Rittmaster 2003). To this 
end, AR in stromal cells induces the expression of growth factors called Andromedins, 
stimulating the proliferation of epithelial cells in paracrine-manner. By contrast, in luminal 
cells, while androgens activate AR and stimulate KLK3 expression, however, it causes cell 
growth suppression (Figure 1.6) (Isaacs and Isaacs 2004). Mechanistically, the growth 
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inhibitory effect of androgens in normal prostate epithelial cells is linked to AR-mediated 
repression of c-Myc and upregulation of p21, p27, and SKP-2, leading to G0/G1 cell cycle arrest 


















Figure 1.6. AR signalling in normal luminal and stromal cells regulates homeostasis (Isaacs and Isaacs 
2004). In normal prostate, AR in stromal cells is activated by androgens, which leads to production of 
Andromedins, regulating the growth and maintenance of epithelial cells in a paracrine manner. In 
epithelial cells, however, AR activation by androgens is not associated with growth, but rather 
mediates the production of secretory proteins such as PSA. T: Testosterone; DHT: 
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1.8. Prostate malignancy 
The peripheral zone in the prostate gland is responsible for about 70% to 80% of prostatic 
intraepithelial neoplasia (PIN) and carcinoma cases (6, 8). Figure 1.7 illustrates the 
morphologic features of prostate tissue from normal prostatic epithelium to early invasive 
carcinoma. In low-grade PIN, there is a mild dysplasia which may progress to moderate-to-
severe dysplasia, high-grade PIN, and carcinoma. Malignant cell invasion to the stroma, 





Figure 1.7. Morphologic changes of prostate tissue from normal prostatic epithelium towards early 







28 | P a g e  
 
1.8.1. Epidemiology of Prostate cancer: 
Prostate cancer is the second most common cancer worldwide in men after lung cancer (Bray, 
Ferlay et al. 2018) and is one of the major causes of cancer-associated death in men in western 
countries (Rebello, Oing et al. 2021).  
 
The incidence of PCa in developed western countries is higher than developed Asian nations 
(e.g. Japan and South Korea) and also developing countries in the rest of the world (Kimura 
and Egawa 2018). Currently, Australia, New Zealand, North America and Europe, as well as 
regions in South America such as Brazil, have the highest incidence rates of PCa. Incidence 
rates are influenced by many factors, including: awareness of prostate cancer and diagnostic 
screening rates (Loeb, Bjurlin et al. 2014); life expectancy, since risk of prostate cancer is 
strongly associated with age (i.e. more than 85% of patients newly diagnosed with PCa are 
more than 60) (Bray, Ferlay et al. 2018); racial differences, as the development and 
progression of PCa are more likely in African Americans compared to individuals of European 
ancestry (Hur and Giovannucci 2020); and ethnic diets, since saturated fat intake has been 
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1.9. AR malignancy switch in Prostate Cancer 
Changes in the genetic and environment of prostate epithelial cells mediate the 
carcinogenesis process, which ultimately leads to AR’s signalling outputs shift from pro-
differentiative and anti-proliferative to anti-differentiative and pro-proliferative (Berger, 
Febbo et al. 2004). As part of malignant transformation in prostate cells, therefore, AR is 
switched to an oncogenic factor, considered as a central event in the development and 
progression of both localized and advanced metastatic prostate cancer (Tomlins, Mehra et al. 
2007). The malignancy switch of AR can be characterized by reprogramming of AR cistrome. 
A comparison of AR cistrome between normal and cancerous cells reveals that the pattern of 
genome-wide AR binding sites between normal and cancerous tissues is different, which can 
drive distinct transcriptional programs leading to tumour progression (Pomerantz, Li et al. 
2015). Alteration in AR cistrome can be related to the recruitment of unique coregulators in 
cancerous cells. For example, FOXA1 and HOXB13, only co-expressed in prostate tumour cells, 
are co-localised with AR at tumor-specific AR binding sites (Pomerantz, Li et al. 2015). This 
observation suggests that the association of AR with new coregulators such as ERG, FOXA1 
and HOXB13 can change the AR function through reprogramming the AR cistrome. 
 
Gene fusions between AR-regulated genes and coding regions of oncogenic transcription 
factors is another potential oncogenesis process in prostate epithelial cells (Marx 2005, 
Tomlins, Rhodes et al. 2005). For example, TMPRSS2–ERG is the most common gene-fusion 
occurring in about 50% of all localised prostate cancer, in which promoter region of AR-
regulated gene called TMPRSS2 is fused with the coding region of ERG, an ETS transcription 
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factors (Kumar-Sinha, Tomlins et al. 2008). TMPRSS2–ERG expression is constantly induced by 
androgens, which causes the upregulation of genes associated with cell invasion and 
epithelial-mesenchymal transition (EMT) (Wang, Cai et al. 2008, Adamo and Ladomery 2016).  
 
1.10. Histologic grading of prostate cancer: 
The histologic grade of the tumour is a useful prognostic factor in prostatic adenocarcinoma. 
Although there are different histologic grading systems, the Gleason system is the best 
predictor of survival in men suffering from prostate cancer. The Gleason grade is a measure 
of the level of differentiation in the tumour, ranging from well-differentiated (score 1) to 
poorly differentiated (score 5). The Gleason score (GS), which ranges from 2-10, is the sum of 
the primary and secondary Gleason grades which refer to the dominant and second-most 
frequent pattern of tumour, respectively (Figure 1.8)(Short, Warren et al. 2019). The grading 
system was modified based on the 2014 ISUP consensus conference and Gleason scores were 
assigned to 5 prognostically distinct Grade groups for improved prognostication and to reduce 
overtreatment of indolent cancer (Egevad, Delahunt et al. 2016). The modified ISUP grading 
system includes all Gleason scores of 6 or less in grade I, Gleason 3+4=7 in grade II, Gleason 
4+3=7 in grade III, Gleason 4+4=8 in grade IV, and all Gleason 9 and 10 in grade V (Egevad, 
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1.11. Treatment of localized prostate cancer  
PCa has a highly variable prognosis, which mainly depends on tumour grade at primary 
diagnosis time. Generally, the majority (~80%) of patient with PCa are diagnosed with organ-
confined disease. In patient with localized prostate cancer, the survival expectancy can be 
about 99% over 10 years if diagnosed at an early stage (Siegel, Miller et al. 2016). However, 
~15% of patients are diagnosed with metastases within the region of primary tumours or ~5% 
with distant metastases (Siegel, Miller et al. 2016). For men diagnosed with metastatic 
disease, the prognosis is much poorer; indeed, the overall survival rate in PCa patient 
diagnosed with a distant metastasis is only about 30% at 5 years (Siegel, Miller et al. 2016). 
 
Based on a recommendation by the European Association of Urology, there is a wide variation 
in treatment intensity that can be applied for localized prostate cancer (Mottet, Bellmunt et 
al. 2017). Over the last years, active surveillance has been applied as an alternative to 
intensive treatment of low-risk prostate cancer. Active surveillance is described as close 
monitoring of cancer progression using PSA and without intensive therapies such as surgery 
(Haymart, Miller et al. 2017). This strategy is carried on men with low to intermediate grade 
prostate cancer. However, among these patients, 20% to 41% will need definitive treatment 
in the following 5 years to control tumour growth. Radical prostatectomy is one of the most 
common major treatment measures in patients with localized prostate cancer. Mortality and 
risk of local progression and metastasis are decreased by radical prostatectomy (Bill-Axelson, 
Holmberg et al. 2005).  
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Another major treatment method for localised prostate cancer is radiotherapy, comprising 
radioactive isotopes, photons, and particle beams (Bagshaw, Kaplan et al. 1993). In a study by 
Hamdy, Freddie C., et al. (Hamdy, Donovan et al. 2016), the effectiveness of external-beam 
radiotherapy compared to active monitoring and radical prostatectomy was evaluated in 
terms of mortality and the incidence of metastases and disease progression at a median of 10 
years of follow-up. The results of this randomized trial found that radiotherapy (and 
prostatectomy) were associated with lower rates of disease progression and metastases than 
active monitoring (Hamdy, Donovan et al. 2016). 
 
However, while surgery and radiation therapies cure a substantial proportion of men, 
approximately 30% experience recurrence with metastatic disease (Singh, Febbo et al. 2002). 
Additionally, some men are diagnosed with metastatic PCa, which cannot be treated with 
surgery or radiation therapy  (Aus, Robinson et al. 2005). Androgen deprivation therapy is the 
key strategy for men who fail treatment for localised disease or who are diagnosed with 




























Figure 1.8. The Gleason score ranges and pathological features in different clinical stages of prostate 
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1.12. Treatment of Metastatic Prostate Cancer 
As described earlier, the growth and progression of prostate cancer rely heavily on AR 
activation by T and DHT. Consequently, androgen deprivation therapy (ADT) has been the 
main therapeutic strategy for metastatic prostate cancer for many decades (Thompson, 
Goodman et al. 2003, Vignozzi, Rastrelli et al. 2014). ADT comprises surgical or medical 
castration, which greatly reduces the levels of circulating testicular androgens and thereby 
reduces prostate cancer growth (Heinlein and Chang 2004). Surgical castration includes 
orchiectomy, in which the testicles are removed, but this approach is very rare now. Medical 
castration is primarily achieved using gonadotropin-releasing hormone (GnRH) agonists 
(Leuprolide and Goserelin) and antagonists (Degarelix), which act through the anterior 
pituitary gland. GnRH agonists cause a decrease in luteinizing hormone (LH) levels by down-
regulation of GnRH receptors, whereas GnRH antagonists inhibit GnRH receptors. In addition 
to medical/surgical castration, ADT can also incorporate the application of antiandrogens (AR 
antagonists), such as cyproterone acetate, bicalutamide, nilutamide, and flutamide, which 
directly bind to the AR LBD and block its activity (Thomas and Neal 2013). More recently, 
chemotherapy has been combined with ADT, which can improve outcomes for some patients 
(Sweeney, Chen et al. 2015). Chemotherapy is a process in which a tumour is treated with 
one or more cytotoxic drugs (Panda, Chakraborty et al. 2017). 
 
Unfortunately, ADT for metastatic PCa, alone or in combination with chemotherapy, is never 
curative (Figure 1.9) and patients will eventually relapse with what is termed castration-
resistant prostate cancer (CRPC). CRPC is defined as an increase in PSA levels or tumour size 
despite castrate levels of circulating androgens (<0.50 ng/ml) (Komiya, Yasuda et al. 2013, 
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Fizazi, Massard et al. 2015). Also, reduction in androgen levels using ADT or antiandrogens 
have some adverse clinical side effects on a patient’s life including a decrease in muscle 
strength, reduced lean and bone mass, higher risk of fracture and unusual lipid profile 































Figure 1.9. The progression pattern of prostate cancer in patients with disease recurrence (Crea, Saidy 
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1.13. Treatment of CRPC 
In recent years, next-generation ADT agents have been introduced which provide a survival 
benefit in CRPC. These agents are apalutamide, darolutamide, enzalutamide, as AR 
antagonists, and abiraterone acetate, a CYP17A1 inhibitor. In CRPC patients and after 
chemotherapy, administration of AR antagonists blocks the AR signalling by binding to the 
LBD of AR and inhibiting the transactivation of AR and also by preventing the AR nuclear 
translocation, which ultimately results in median overall survival by 18.4 months compared 
to placebo (13.6 months) (Scher, Fizazi et al. 2012). Abiraterone acetate functions as an 
irreversible inhibitor of CYP17A1, an enzyme that converts pregnenolone to 
dehydroepiandrosterone (DHEA), a precursor of T and DHT, resulting in a significant decrease 
in androgen synthesis (Chandrasekar, Yang et al. 2015). After chemotherapy, the median 
overall survival benefit of Abiraterone acetate was reported as 14.8 months vs. 10.9 months 
in the placebo group (De Bono, Logothetis et al. 2011). Other therapies for CRPC include the 
chemotherapeutics docetaxel (Sweeney, Chen et al. 2015) and cabazitaxel (Chandrasekar, 
Yang et al. 2015). Both Cabazitaxel and Docetaxel belongs to the same family of taxane 
chemotherapies, however, the TROPIC trial showed that Cabazitaxel was active after 
docetaxel failure and can prolong overall survival (Shiota, Yokomizo et al. 2016). Radium-223 
dichloride is a targeted alpha emitter that can selectively bind to areas of bone with increased 
turnover and emit alpha particles of extremely short range with high energy. Radium-223 is 
considered an effective and well-tolerated treatment in men with CRPC and bone metastases 
(Hoskin, Sartor et al. 2014). However, unfortunately, none of these therapeutic strategies is 
curative, and all only provide a survival benefit in the order of months. Therefore, there is a 
major unmet need for new therapies that can effectively control CRPC.  
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1.14. AR-mediated Therapy Resistance in CRPC: 
Persistent AR signalling following the ADT is the major mechanism driving CRPC growth 
(Coutinho, Day et al. 2016). It has been shown that approximately 80% of CRPC tumours 
demonstrate persistent AR signalling (Ylitalo, Thysell et al. 2017), highlighting the addiction of 
prostate cancer cells to this pathway. Illustrating the importance of AR signalling for prostate 
epithelial cells, therapy-mediated selection pressure causes genomic alterations in genes 
involved in the regulation of AR signalling such as AR gene itself and AR coregulators such as 
FOXA1 (pioneer factor) and  NCOR1/2 (corepressor), aiming to sustain the AR transcriptional 
function in cells (Parolia, Cieslik et al. 2019). 
 
ADT-mediated genomic alterations in the AR gene is one of the most frequent mechanisms, 
leading to the persistent oncogenic function of AR in prostate cancer cells. Despite being 
castrated, the oncogenic activity of AR following the ADT will be sustained by several 
mechanisms including hypersensitivity of cancer cells to low levels of androgens, antagonist-
agonist switching, AR activation by non-canonical ligands, and ligand-independent 
transactivation of AR (Table 2). These mechanisms are mainly associated with overexpression 
or point mutations of the AR gene. AR gene overexpression, which makes cells hypersensitive 
to very low levels of androgens is achieved either through AR gene copy-number amplification 
(DNA level) or transcriptional upregulation of the AR gene (RNA level) (Coutinho, Day et al. 
2016). Genetic analyses of prostate cancer tumours show that AR gene copy-number 
amplification is largely present in CRPC but not in primary tumours, accounting for 50% CRPC 
samples, approximately (Barbieri, Bangma et al. 2013). AR point mutations also can cause 
oncogenic activation of AR, accounting for 20% of CRPC tumours, approximately (Beltran, 
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Yelensky et al. 2013). These mutations have been mainly identified in AR ligand-binding 
domain or AR (AR-LBD) transactivation activity (AR-NTD), which can result in ligand 
promiscuity causing AR transactivation with a very low level of androgens, AR interaction with 
non-specific ligands, and/or an antagonist-to-agonist switch (Table 2)(Coutinho, Day et al. 
2016). ADT-induced selection pressure is also associated with constitutively active AR variants 
including AR-V7, AR-V567es and AR-V3 (Jernberg, Bergh et al. 2017).  
 
As an emerging clinical issue, a subpopulation of CRPC patients (accounting for 20%, 
approximately) can relapse with clinically aggressive variants of prostate cancer, exhibiting an 
AR-independent phenotype, in which AR expression is reduced or absent (Watson, Arora et 
al. 2015, Chen, Dong et al. 2018, Handle, Prekovic et al. 2019). Therefore, they are resistant 
to all current AR signalling inhibitors. Given the continued relevance of AR in the CRPC state 
and the fact that new AR pathway inhibitors only provide minor survival benefits, smarter AR-
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Table 1.2. ADT-mediated resistance mechanism 
ADT-mediated resistance mechanisms  Genetic alteration in the AR gene Outcome Representative  in vitro 
model 
Reference 
Hypersensitivity to low levels of 
androgens 
AR gene amplification Transcriptional upregulation AR 
gene 
VCaP cell line (Korenchuk, Lehr et al. 2001, Liu, 
Xie et al. 2008) 
Antagonist–agonist switching  
T878A gain-of-function mutation   Flutamide and nilutamide act as 
AR agonists 
LNCaP cell line (Veldscholte, Ris-Stalpers et al. 
1990) 
H875Y  gain-of-function mutation   Nilutamide  acts as an  AR agonist 22rv1 cell line (Marcias, Erdmann et al. 2010) 
F877L  gain-of-function mutation   Enzalutamide act as an AR agonist MR49F (Korpal, Korn et al. 2013, 
Coleman, Van Hook et al. 2016) 




(Terada, Shimizu et al. 2010, 
Sugawara, Baumgart et al. 2019) 
S889G gain-of-function mutation   Flutamide and Bicalutamide act as  
AR agonists 
- (Prekovic, Van den Broeck et al. 
2018) 
M896V gain-of-function mutation   Flutamide and Bicalutamide act as  
AR agonists 
- (Prekovic, Van den Broeck et al. 
2018) 
AR activation by non-canonical ligands L702H gain-of-function mutation   Glucocorticoids act as an AR 
agonist  
MDA PCa 2b cell line (Sumiyoshi, Mizuno et al. 2019) 
L701H gain-of-function mutation   Cortisol  act as an AR agonist - (van de Wijngaart, Molier et al. 
2010) 
AR splice variants 
AR-V3 Constitutively-active AR variant - (Kallio, Hieta et al. 2018, Tagawa, 
Antonarakis et al. 2019) AR-V7 Constitutively-active AR variant 22rv1 cell line 
ARv567es Constitutively-active AR variant D567 cell line 
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1.15. Bipolar androgen therapy; a potential strategy for prostate cancer therapy 
As described above, blocking AR signalling is the main therapeutic strategy for the treatment 
of patients with advanced metastatic prostate cancer. While attempts to develop more 
potent AR antagonists are being made, the adaptation mechanisms that lead to the failure of 
AR pathway inhibitors are a major concern. Therefore, there is an unmet need for an “out of 
box” approach avoiding the lethal adaptation stage in the treatment of advanced metastatic 
prostate cancer tumours.  
 
Bipolar Androgen Therapy (BAT) is one of the emerging concepts in the treatment of prostate 
cancer, which can potentially overcome the innate ability of prostate cancer cells to adapt to 
castrate level of androgens. In this strategy, rapid cycling between two polar extremes of 
androgen levels, namely supraphysiologic and castration levels, within a short period can 
avoid the therapy adaptation due to the abrupt changes in androgen levels. More 
importantly, while activating the AR transcriptional activity in prostate cancer cells, high-dose 
of androgens paradoxically inhibits the tumour progression and renders cancer cells 
vulnerable to death (Schweizer, Antonarakis et al. 2015). This unexpected therapy response 
is illustrated in figure 1.10 showing the PSA response of a patient who received 16 cycles of 
BAT having led to a dramatic decrease in tumour progression. 
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Figure 1.10. PSA response in an individual patient (patient 9) receiving a total of 16 cycles of BAT. 
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Currently, synthetic testosterone derivatives such as Testosterone cypionate and 
Testosterone Enanthate are widely used in clinical trial studies aiming to treat prostate cancer 
with high-dose androgen therapy (e.g. NCT03522064, NCT02090114, NCT03554317, 
NCT03516812, and NCT01750398). 
 
1.16. Proposed Mechanisms for therapeutic effects of high-dose androgens: 
Exposing AR-positive prostate cancer cells to a high dose of androgens can inhibit their 
proliferation (Joly-Pharaboz, Soave et al. 1995). The apparent paradox that AR inhibition and 
potent activation can both exert anti-cancer effects raises the question as to which 
mechanisms are involved in tumour suppression by high-dose androgens in CRPC patients. 
Preclinical studies have proposed some mechanisms for therapeutic effects of high-dose 
androgen (see below); however, regarding the variation in response to BAT in clinical settings 
(Schweizer, Antonarakis et al. 2019), the exact tumour suppressive mechanism(s) remains 
uncertain. Therefore, it is imperative to identify the potential antitumor mechanism following 
the AR activation by high-dose androgens.  
 
1.16.1. High-dose androgen therapy interrupts cell cycle progression 
In prostate cancer cells, liganded-AR has a key role in the progression of the cell cycle either 
through physical interactions with cell cycle-associated proteins or by driving phase-specific 
transcriptional networks. Indeed, the interplay between AR and cell cycle proteins induces a 
phase-specific AR cistrome and transcriptome, governing the proliferation of prostate cancer 
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cell through the cell cycle progression (Murthy, Wu et al. 2013, McNair, Urbanucci et al. 2017). 
However, evidence indicates that AR function in the cell cycle depends on the concentration 
of its agonist. Enigmatically, the proliferative effects of androgens depend on their 
concentration, exhibiting a biphasic response in prostate cancer cells. More specifically, dose-
responses of LNCaP cells treated with R1881 (synthetic androgen) can be divided into 
proliferative and antiproliferative phases (Figure 1.11). Importantly, cell cycle analysis 
revealed that antiproliferative doses of androgens cause cell cycle arrest arrested in the G1 










Figure 1.11. Biphasic response of LNCaP cells treated with increasing doses of R1881 for 72h 
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These observations support the idea that AR liganded with an antiproliferative 
supraphysiologic dose of androgens causes an interruption in the cell cycle progression, 
leading to cell cycle arrest. Although the key mechanism triggering this cell cycle arrest have 
not been precisely determined, several mechanisms have been suggested. First, GSEA analysis 
on transcriptomic data generated from different AR-positive prostate cancer cell lines shows 
that treatment with 10 nM R188 significantly represses the expression of some gene sets 
including Myc and E2F1 target genes (Figure 1.12). Since the integrated function of Myc and 
activated E2F1 is required for S phase entry (Leung, Ehmann et al. 2008), suppression of Myc 
expression by high-dose androgens may lead to repression of E2F1/E2F1 target genes, which 

























Figure 1.12. Results of GSEA analysis showing enriched significant Hallmark genes sets (FDR < 0.05) in 
4 cell lines treated with 10 nM R1881. Red dots: Androgen receptor-related gene sets; Blue dots: cell 












Figure 1.13. Model of AR interaction with replication machinery in the cell cycle. High-dose Androgen 
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Linked to a non-transcriptional function of AR, another mechanism has been also proposed 
for cell cycle arrest by high-dose androgens. According to the proposed model, AR has a role 
in DNA licensing in androgen-sensitive prostate cancer cells, required for DNA replication in 
the S phase (Litvinov, Vander Griend et al. 2006). This AR function is mediated through the AR 
interactions with some DNA licensing factors such as Orc2, Cdc6 and MCM7 (Shi, Yan et al. 
2008, Jin and Fondell 2009) (Figure 1.13). In this mechanism, liganded-AR binds to the origins 
of replication sites in the G1 phase and forms a complex with other factors, licensing these 
sites for replication within the S phase. In the G2 phase, AR remains bound to DNA, which 
prevents the re-licensing and subsequently re-initiation of DNA replication before the next 
cell cycle. However, following the G2 phase and in mitosis, AR is excluded from DNA and 
degraded, which allows the initiation of a new DNA licensing and re-initiation of DNA 
replication in the next cell cycle (D'Antonio, Vander Griend et al. 2009). Current evidence 
suggests that high-dose androgens may interrupt the DNA licensing role of AR, arresting the 
cell cycle progression from G1 to S. In this model, acute increase in the androgen levels up to 
supraphysiological levels causes insufficient degradation of AR during the mitosis/early G1 
leading to interruption in DNA re-licensing and re-initiation of DNA replication (Figure 1.13).  
 
Mechanistically, the function of cell cycle proteins including licensing factors is precisely 
regulated through the phase-specific cyclin-dependent kinases (CDKs)(Reusswig, 
Zimmermann et al. 2016). For example, CDK1, overexpressed in prostate cancer tumours, is 
an M-phase protein involved in G2-to-M transition (Liu, Kao et al. 2008). Expression of CDK1 
is induced directly by AR and the association of CDK1 with AR tightly binds to increase the AR 
stability, localization, and chromatin binding, which are mainly mediated by AR S81 
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phosphorylation (Lee and Chang 2003, Chen, Xu et al. 2006, Wang, Li et al. 2009, Sharma, 
Yeow et al. 2010, Chen, Gulla et al. 2012). Suppression of AR transcriptional activity following 
CDK1 inhibition supports the importance of this CDK1-AR feedback loop (Liu, Gao et al. 2017). 
Interestingly, a study by Koryakina et al. (Koryakina, Knudsen et al. 2015) demonstrated that 
AR S308 phosphorylation by CDK1 in the nucleus of mitotic prostate cancer cells is crucial for 
AR exclusion from chromosomes and nucleus. Therefore, given the proposed role of AR as a 
licensing factor, high-dose androgens may also, either directly or indirectly, interrupt the 
post-transcriptional regulation of AR by CDKs, leading to insufficient AR 
dissociation/degradation in mitosis.  
 
1.16.2. AR-induced cell cycle arrest accumulates activated-Retinoblastoma protein inducing 
tumour suppressor function to AR 
AR activation by a high dose of androgens can trigger the repression of gene sets required for 
cell cycle progression including DNA repair/replication genes (Niu, Altuwaijri et al. 2008). 
Analysis of AR binding profiles shows that high-dose androgens cause recruitment of AR 
proteins to gene sets involved in DNA replication/repair and integration of AR cistrome with 
transcriptomic data confirms the repression of those gene sets, suggesting a direct tumour 
suppressor function of AR through its transcriptional activity (Figure 1.14) (Gao, Gao et al. 
2016).  
 
AR transcriptional repressor function can be mediated through the recruitment of 
transcriptional repressor proteins (Cai, He et al. 2011). One of the key transcriptional 
repressors, which can be activated as a consequence of androgen-induced cell cycle arrest, is 
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Rb protein. Genomic studies on Rb cistrome revealed that AR and Rb are co-localised on the 
promotor of DNA replication genes suppressed by high-dose androgens. Given that activated 
Rb can bind to the promoter of E2F1 target genes (Sharma, Yeow et al. 2010), current 
evidence suggests that Rb acts as an AR coregulator to repress E2F1 target genes. Importantly, 
although androgen-induced cell cycle arrest seems to be Rb-independent (Vander Griend, 
Litvinov et al. 2014); however, Rb deficiency, which is significantly overrepresented in CRPC 
tumours, may interfere with AR-dependent repression of DNA replication genes (Sharma, 
Yeow et al. 2010). Therefore, coupling the BAT with other therapeutic strategies can 








Figure 1.14. Rb activation by high-dose androgens leads to co-localisation of AR and Rb on the 








51 | P a g e  
 
 
1.16.3. High dose androgen can induce lethal dsDNA breaks  
Chromosomal translocations in prostate epithelial cells is one of the key mechanisms leading 
to the development and progression of prostate cancer. As described in section 1.8, ERG-
TMPRSS2 fusion is the most frequent genomic rearrangements presented in 50%–70% of 
prostate tumours resulting in overexpression of ETS oncogenes in an androgen-dependent 
manner, which can help in the progression of prostate cancer (Carver, Tran et al. 2009, Li, 
Yuan et al. 2020).  
 
Rearrangements of DNA fragments in prostate cancer cells is mediated by inducing site-
specific double-stranded DNA breaks (DSBs)(Kloosterman, Tavakoli-Yaraki et al. 2012). In 
prostate cancer cells, AR has two key roles in inducing the DSBs: 1) binding to specific regions 
on DNA and 2) inducing spatial proximity between DNA fragments. Toward this end, liganded-
AR binds to specific intronic regions mediating intra- and interchromosomal interactions 
through the recruitment of enzymes needed for alterations in local epigenetic markers. Local 
epigenetic remodelling by liganded-AR not only causes chromosomal movement but also 
makes these regions accessible for enzymes generating DSBs (Lin, Yang et al. 2009).  
 
Multiple enzymes can induce DSBs at AR binding sites. For example, Lin et al (Lin, Yang et al. 
2009) reported that exogenous genotoxic stresses can cause the expression of genotoxic-
associated enzymes including activation-induced cytidine deaminase (AID) and LINE-I repeat-
encoded ORF2 endonucleases, which can bind to AR-induced accessible sites on DNA and 
establish DSBs. In this study, the presence of genotoxic stresses has been shown to be crucial 
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for causing the genomic breaks. However, a study by Haffner et al. (Haffner, De Marzo et al. 
2011) supports the notion that intrinsic androgen signalling could also be sufficient to 
generate transient genomic breaks needed for genomic rearrangement in prostate cancer 
cells. Based on this mechanism, androgen stimulation causes the recruitment of TOP2B at 
specific AR binding sites inducing extremely fleeting recombinogenic DSBs. Subsequently, 
androgen-induced DSBs are quickly targeted by DSB repair machinery. More importantly, 
TOP2B-mediated DSBs has been shown to be crucial for AR transcriptional activity since 
targeting TOP2B leads to the interruption in the expression of AR-target genes (Ju, Lunyak et 
al. 2006, Haffner, De Marzo et al. 2011).  
 
In the context of bipolar androgen therapy, current evidence suggests that cyclic activation 
of AR by supraphysiologic levels of an androgen and castration may lead to unrepaired DSBs, 
which can induce cell cycle arrest and cell death (Chatterjee, Schweizer et al. 2019). 
Theoretically, DNA damage could be exacerbated by AR’s ability to down-regulate DNA repair 
gene pathways (see section above) (Gao, Gao et al. 2016). This hypothesis can explain why a 
patient with BRCA2/ATM deficiency showed an extreme response to high-dose androgen 
therapy (Teply, Kachhap et al. 2017). 
 
However, the negative feedback loop between androgen level and AR gene expression and/or 
a lower level of AR protein in a subset of tumours with AR-indifferent phenotype may 
attenuate the DSBs generation (Chatterjee, Schweizer et al. 2019, Handle, Prekovic et al. 
2019). More importantly, the highest frequency of Rb deficiency in a patient with CRPC can 
also restrict the repression of DNA repair/replication genes in an Rb-dependent manner 
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(section 1.14.2) (McNair, Xu et al. 2018). Another important point to raise is that, although 
patients with a deficiency in DNA repair pathways are expected to show better response; 
however, there is a considerable variation among patients with different genomic aberrations 
in terms of response to BAT (Figure 1.15) (Schweizer, Antonarakis et al. 2019), indicating that 
genomic deficiency in DNA repair pathways cannot be a reliable index for segregation of 
patients in terms of response to BAT. Therefore, the exact mechanism(s) involved in response 
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1.17. Hypothesis and aims 
The preliminary data from high-throughput screening of nuclear receptor ligands by my host 
lab suggests that a synthetic Testosterone analogue, named Methyl-Testosterone (MeT), 
potently suppresses the proliferation of LNCaP cells. Therefore, we hypothesized that MeT 
acts as a potent androgen suppressing cell proliferation. As outlined above, while several 
mechanisms underlying the efficacy of supraphysiological androgen treatment in PCa have 
been described, many questions still remain. We hypothesised that a potent androgen like 
MeT could be a useful tool to gain a more complete understanding of these mechanisms as 




1. Characterise the antiproliferative effects of MeT in different prostate cancer models.  
2. Define the AR cistrome and AR-induced transcriptome after activation with MeT. 
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2.1. Material 
Table 2.1: Common chemical and reagents 
Reagents Supplier Catalogue number 
Dulbecco’s Modified Eagle’s 
Medium-high glucose 
Sigma Aldrich  D6429 
RPMI 1640 liquid media  Sigma Aldrich  R8758  
RPMI 1640 phenol red free  Sigma Aldrich  R7509  
Trypsin EDTA solution  Sigma Aldrich  T4049  
Bradford assay reagent BioRad 500-0006 
BSA (bovine serum albumin)  Sigma Aldrich  A9647  
Chloroform  Sigma Aldrich  C2432  
DMSO (dimethyl sulfoxide)  BDG Laboratory Supplies  D2650  
Ethanol, molecular grade  Scharlau  ET00110500  
FBS (fetal bovine serum)  Sigma Aldrich  14M357  
Glycerol  Chem Supply  GA010-2.5L-P  
iScirpt cDNA synthesis kit  BioRad  170-8891  
iQ SYBR Green Supermix  BioRad  170-8885  
Inactivation buffer (supplied 
with Turbo free)  
Ambion Inc.  AM1907  
Methanol  Chem Supply  MA004-2.5L-P  
Nitrocellulose membrane (0.4 
μm)  
Amersham  GEHE10600016  
Nuclease free water  Qiagen  129114  
PBS (phosphate-buffered saline)  Gibco  14190  
Ponceau S  Sigma Aldrich  P3504  
LEGENDplex™ Human Type 
1/2/3 Interferon Panel (5-plex) 
with V-bottom Plate 
Biolegend 740396 
 
SDS (sodium dodecyl sulphate)  Sigma Aldrich  75746  
Triton-X 100  Sigma Aldrich  T8787  
TRIZOL Reagent  Sigma Aldrich  T9424  
100 bp DNA ladder  New England Biolabs  N3231S  
Agarose, analytical grade  Sigma Aldrich  A6013  
Poly(I:C) (LMW) / LyoVec™ Invivogen tlrl-picwlv 
Criterion precast gel (4-12%)  BioRad  567-1084  
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Table 2.2: Commonly Used Buffers and Media 
Buffer/Medium Name  Buffer/Medium Components  
RIPA Buffer for protein 
extraction 
 
1 g SDS; 0.93 g DTT; 1.2 mg Bromophenol blue; 7 mL Tris-Cl/SDS (4x); 
3 mL Glycerol, 10 mL Milli-Q water; Store at -20°C 
Running Buffer (10x) 77.5 g Tris Base; 360g Glycine; 25g SDS; 2.5L RO H2O  
TBS (10x)  151.5 g Tris ; 219 g NaCl ; Volume to 2.5 L with water (pH 7.4)  
TBST (1x)  2.5 mL Tween20 ; 250 mL 10x TBS ; 2.25L RO H2O  
Transfer Buffer (10x)  77.5 g Tris ; 360 g Glycine ; Volume to 2.5 L with water  
Tris-HCl (0.5M), pH 8.0 and pH 
7.6 
12.1 g Tris-HCl; 200 ml Milli-Q water  
HEPES-KOH (0.5M), pH 7.5 59.5 g HEPES; 500 ml Milli-Q water  
NaCl (5M) 29 g NaCl; 100 ml Milli-Q water 
EDTA (0.5M) 9.3 g EDTA; 50 ml Milli-Q water 
EGTA (0.1M) 1.9 g EGTA; 50 ml Milli-Q water 
LiCl (5M) 21.1 g LiCl; 100 ml Milli-Q water 
SDS (10%) 20g SDS; 200 ml Milli-Q water 
Na-Deoxycholate (5%) 10 g Na-Deoxycholate; 200 ml Milli-Q water 
N-laurylsarcosine (5%) 10 g N-laurylsarcosine; 200 ml Milli-Q water 
PBS + PI 1x tablet of Complete Mini Protease Inhibitor Cocktail in 10 ml PBS 
Triton Extraction Buffer (TEB) 0.5% Triton-X 100, 2 mM phenylmethylsulfonyl fluoride (PMSF), and 
0.02% (w/v) NaN3 
NaCl 500mM 2 µl of NaCl 5M ; 18 µl sterile water 
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Table 2.3: Chromatin immunoprecipitation (ChIP) Buffers 
Solution name Final Conc Stock concentration  Volume 
Solution A 
1% Formaldehyde 40% 2ml 
50mM HEPES-KOH, pH 7.5 0.5M 8ml 
100mM NaCl 5M 1.6ml 
1mM EDTA 0.5M 160ml 




Total volume 80ml 
Block Solution 
 
0.5% BSA  250mg 
PBS  to 50ml 
LB1 
50mM HEPES-KOH, pH 7.5 0.5M 10ml 
140mM NaCl 5M 2.8ml 
10% glycerol 100% 10ml 
1mM EDTA 0.5M 200ml 
0.5% NP-40 100% 500ml 
0.25% Triton X-100 100% 250ml 
water  76.25ml 
Total volume 100ml 
LB2 
10mM Tris-HCl, pH 8.0 0.5M 2ml 
200mM NaCl 5M 4ml 
1mM EDTA 0.5M 200ml 
0.5mM EGTA 0.1M 500ml 
water  93.3ml 
TOTAL  100ml 
LB3 
10mM Tris-HCl, pH 8.0 0.5M 1ml 
100mM NaCl 5M 1ml 
1mM EDTA 0.5M 100ml 
0.5mM EGTA 0.1M 250ml 
0.1% Na-Deoxycholate 5% 1ml 
0.5% N-laurylsarcosine 5% 5ml 
water  41.65ml 
Total volume 50ml 
RIPA Buffer 
50mM HEPES-KOH, pH 7.5 0.5M 10ml 
500mM LiCl 5M 10ml 
1mM EDTA 0.5M 200ml 
1% NP40 100% 1ml 
0.7% Na-Deoxycholate 5% 14ml 
water  64.8ml 
Total volume 100ml 
TBS 20mM Tris-HCl, pH 7.6 0.5M 2ml 
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150mM NaCl 5M 1.5ml 
water  46.5ml 
Total volume 50ml 
Elution Buffer 
50mM Tris-HCl, pH 8.0 0.5M 1ml 
10mM EDTA 0.5M 200ml 
1% SDS 10% 1ml 
water  7.8ml 
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Table 2.4: Primers 
Primer Name  Sequence  Use  
FANCI-RT-Fwd CTGCCCTGGCTACGAAAAAG ChIP-PCR 
FANCI-RT-Rev CATATTGCTGATCCCACCTGC ChIP-PCR 
LMNB1-RT-Fwd TGCCCTTTGTGCTGTAATCG ChIP-PCR 
LMNB1-RT-Rev GACCGTGATAAGGAGGGGAC ChIP-PCR 
MCM7-RT-Fwd CCTACCAGCCGATCCAGTCT ChIP-PCR 
MCM7-RT-Rev CCTCCTGAGCGGTTGGTTT ChIP-PCR 
BLM-RT-Fwd CAGCAGCGGAACATAAGAAGG ChIP-PCR 
BLM-RT-Rev GCCAAGAAGACTGGCATCAC ChIP-PCR 
FANCI-Fwd CTGCCCTGGCTACGAAAAAG qRT-PCR 
FANCI-Rev CATATTGCTGATCCCACCTGC qRT-PCR 
LMNB1-Fwd TGCCCTTTGTGCTGTAATCG qRT-PCR 
LMNB1-Rev GACCGTGATAAGGAGGGGAC qRT-PCR 
MCM7-Fwd CCTACCAGCCGATCCAGTCT qRT-PCR 
MCM7-Rev CCTCCTGAGCGGTTGGTTT qRT-PCR 
CCNA2-Fwd CAGAAAACCATTGGTCCCTC qRT-PCR 
CCNA2-Rev CACTCACTGGCTTTTCATCTTC qRT-PCR 
STING-Fwd AGCATTACAACAACCTGCTACG qRT-PCR 
STING-Rev GTTGGGGTCAGCCATACTCAG qRT-PCR 
ERV3-env-Fwd CCATGGGAAGCAAGGGAACT  qRT-PCR 
ERV3-env-Rev CTTTCCCCAGCGAGCAATAC  qRT-PCR 
HERV‐W-Fwd TGAGTCAATTCTCATACCTG qRT-PCR 
HERV‐W-Rev AGTTAAGAGTTCTTGGGTGG qRT-PCR 
HERVE Fwd GGTGTCACTACTCAATACAC qRT-PCR 
HERVE-Rev GCAGCCTAGGTCTCTGG qRT-PCR 
HERV F-Fwd CCTCCAGTCACAACAACTC qRT-PCR 
HERV F-Rev TATTGAAGAAGGCGGCTGG qRT-PCR 
ERVL-Fwd ATATCCTGCCTGGATGGGGT qRT-PCR 
ERVL-Rew GAGCTTCTTAGTCCTCCTGTGT qRT-PCR 
HERV-K-Fwd ATTGGCAACACCGTATTCTGCT  qRT-PCR 
HERV-K-Rev CAGTCAAAATATGGACGGATGGT qRT-PCR 
DNMT1-Fwd GCGTTCCGGCTGAACAAC qRT-PCR 
DNMT1-Rev GCATCTCCACGTCTCCCT qRT-PCR 
EZH2--RT-fwd GTGGAGAGATTATTTCTCAAGATG qRT-PCR 
EZH2-RT-Rev CCGACATACTTCAGGGCATCAGCC qRT-PCR 
B2M-RT-fwd TGACTTTGTCACAGCCCAAG qRT-PCR 
B2M-RT-Rev AGCAAGCAAGCAGAATTTGG qRT-PCR 
HLA-A-RT-fwd GGCCCTGACCCAGACCTG qRT-PCR 
HLA-A-RT-Rev GCACGAACTGCGTGTCGTC qRT-PCR 
HLA-B-RT-fwd ACTGAGCTTGTGGAGACCAGA qRT-PCR 
HLA-B-RT-Rev GCAGCCCCTCATGCTGT qRT-PCR 
HLA-C-RT-fwd CTGGCCCTGACCGAGACCTG qRT-PCR 
HLA-C-RT-Rev CGCTTGTACTTCTGTGTCTCC qRT-PCR 
IFN-beta-RT-fwd GCCATCAGTCACTTAAACAGC qRT-PCR 
IFN-beta-RT-Rev GAAACTGAAGATCTCCTAGCCT qRT-PCR 
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ISG15-RT-fwd CCTTCAGCTCTGACACC qRT-PCR 
ISG15-RT-Rev CGAACTCATCTTTGCCAGTACA qRT-PCR 
IRF7-RT-fwd GTGGACTGAGGGCTTGTAG qRT-PCR 
IRF7-RT-Rev TCAACACCTGTGACTTCATGT qRT-PCR 
MDA5-RT-fwd GAGCAACTTCTTTCAACCACAG qRT-PCR 
MDA5-RT-Rev CACTTCCTTCTGCCAAACTTG qRT-PCR 
MAVS-RT-fwd AGGAGACAGATGGAGACACA qRT-PCR 
MAVS-RT-Rev CAGAACTGGGCAGTACCC qRT-PCR 
RIG-I-RT-fwd CCAGCATTACTAGTCAGAAGGAA qRT-PCR 
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Table 2.5: Antibodies 
Primary Antibody  Dilution  Application Catalogue 
number/Supplier  
mouse anti-dsRNA  1:1000 IF Scicons English 
MHC class I 1:1000 Flow cytometry BioLegend 
p-STAT1 1:1000 Western Blotting Cell Signalling Technology 
STAT1 1:1000 Western Blotting Cell Signalling Technology 
Phospho-Rb (Ser780) 
Antibody 
1:1000 Western Blotting Cell signalling 
Rb (4H1) Mouse mAb 1:1000 Western Blotting Cell signalling 
TBK1/NAK Antibody 1:1000 Western Blotting Cell signalling (#3013) 
Phospho-TBK1/NAK (Ser172) 
(D52C2) XP® 
1:1000 Western Blotting Cell signalling (#5483) 
Tri-Methyl-Histone H3 
(Lys27) (C36B11) 
1:1000 ChIP, Western 
Blotting 
Cell signalling 
Anti-phospho-Histone H2A.X 1:1000 Western Blotting Merck Millipore  
Tubulin  1:5000 Western Blotting Merck Millipore  
GAPDH  1:5000 Western Blotting MAB374, Merck 
Millipore  
Goat anti-rabbit  1:2000 Western Blotting PO448, DAKO  
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2.2. Methods  
2.2.1. Reviving, maintaining, passaging and freezing of cell lines 
The human prostate carcinoma cell lines, LNCaP, VCaP, PC3, and, 22Rv1 C4-2B, were obtained 
from the American Type Culture Collection (ATCC). The LNCaP-V16D, LNCaP-MR42D and 
LNCaP-MR49F cell lines were obtained from Dr Amina Zoubeidi’s lab at the Vancouver 
Prostate Centre. WPMY-1 was obtained from Dr Mitchell Lawrence’s lab at Monash University 
and CWR-R1-D567 was obtained from Dr Scott Dehm’s lab at Masonic Cancer Centre of the 
University of Minnesota.  
 
C4-2B, 22Rv1, LNCaP, and LNCaP-V16D cell lines were maintained in RPMI-1640 containing 
10% Fetal Bovine Serum (FBS) and 2 mM L-Glutamine. PC3 and WPMY-1 cell lines were 
cultured in RPMI-1640 containing 5% FBS and 2 mM L-Glutamine. LNCaP-MR42D and LNCaP-
MR49F were maintained in RPMI-1640 containing 10% FBS, 10 uM Enzalutamide and 2 mM 
L-Glutamine. CWR-R1-D567 cells were maintained in RPMI-1640 containing 10% CSS and 2 
mM L-Glutamine. VCaP cells were maintained in DMEM high glucose containing 10% FBS, 2 
mM L-Glutamine, 2 mM Sodium Pyruvate, and 2 mM of non-essential amino acids solution. 
All cell lines were authenticated by short tandem repeat profiling by CellBank Australia and 
were regularly screened for potential mycoplasma contamination. Cell revival was carried out 
through a quick throwing of vials in a 37°C water bath, followed by slowly mixing with 7ml of 
appropriate cell culture media. The cell suspension was centrifuged at 252 g for 5 minutes, 
and then, pellets were resuspended in 2ml of media and transferred into a T25 culture flask 
with 5 ml fresh media. Flasks were incubated at 37 °C and 5% CO2 to be passaged when 70-
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80% confluency was reached. Passaging was initiated by removing the media, washing the 
cells with PBS, and trypsinization with 0.25% trypsin. After a short incubation time after 
trypsinization, trypsin was neutralized with a full medium containing 10% FBS and cell 
suspension were spun down at 252 g for 5 minutes to resuspend and plate the required 
number of cells into flasks or plates. For cryopreserving cultured cells, a flask with about 70-
80% cell confluency was washed and trypsinized, and after trypsin neutralization, the cell 
suspension was centrifuged at 252 g for 5 minutes and cell pellets were suspended in freezing 
media containing 10% DMSO, 40% FBS, 50% culture media at a cell density of 1-2 million 
cells/ml. Finally, 1 ml of cell suspension was added to labelled cryo-vials, and placed in 
isopropanol filled freezing container at -80 °C before transferring the frozen cells into liquid 
nitrogen. 
 
2.2.2. Trypan blue exclusion assay  
Depending on the doubling time and length of proliferation assay, cells were seeded at 
specific densities in multi-well plates. After cell seeding, plates were incubated at 37 °C and 
5% CO2 for at least 24 hours to allow cells to be attached to the plate surface before 
treatment. At the appropriate time-points, cells were treated with androgens prepared 
freshly in cell culture media, followed by incubation at 37 °C and 5% CO2 until the next time-
point. Past studies indicate that for1 nM DHT is considered to recapitulate a physiological 
dose (i.e. a dose replicating normal DHT levels in prostate tumours) whereas 100 nM is used 
to recapitulate a supraphysiological level of DHT (Jaaskelainen, Deeb et al. 2006, Li, Chan et 
al. 2013, Schweizer, Antonarakis et al. 2015, Hedayati, Haffner et al. 2016). We used these 
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studies to guide our dosing of in vitro PCa models to mimic physiological and 
supraphysiological conditions.   
 
At the end of each time-point, cell viability in allocated plates was assessed using the Trypan 
blue exclusion assay. To determine the number of live cells in allocated plates, the culture 
media, and the PBS used for washing were collected followed by treatment of cells with 0.25% 
trypsin. After 2-3 minutes of incubation at 37°C, trypsin was neutralised through adding a 
culture media containing FBS or CSS, and then the cell suspension was added to the previously 
collected media and PBS. Subsequently, the cell suspension was spun down at 252 g for 5 
minutes and after removing the supernatants, cell pellets were re-suspended in an 
appropriate volume of media. The cell suspension was mixed with Trypan Blue at a 1:1 ratio 
and live cells were counted using the haemocytometer. 
 
2.2.3. Cell growth assay using an IncuCyte platform 
IncuCyte is a live-cell imaging and analysis platform, allowing to monitor and quantify the cell 
behaviour over time. For assessment of cell proliferation using the IncuCyte, 50 µl of cell 
suspension at the appropriate cell density was seeded in 96-well plates and plates were 
incubated overnight at 37 °C and 5% CO2.  On day 0, 50 µl of media containing freshly prepared 
drugs and IncuCyte dyes were added to the wells. IncuCyte™ NucLight™ (1:1500) was used 
for labelling the live cells, and Sytox Green dye (1:1000 from 100 nM stock) was used to 
identify the dead cells. Following the treatment at day 0, automated imaging was carried out 
until day 7 as the final time-point. Drug re-treatment was carried out on day 3. Image analysis 
was performed using IncuCyte™ software.  
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2.2.4. Western Blotting  
2.2.4.1. Preparation of Cell Lysates  
To prepare protein lysates, cells were plated at the appropriate seeding density in 6-well 
plates. To collect cells, media was removed and cells were washed with ice-cold PBS and 
subsequently, cells were scrapped on ice into 100 µl of RIPA buffer. Protein lysates were spun 
down at 10,000 g for 10 min and supernatants were stored at -80 °C. 
 
2.2.4.2. Bradford Assay  
The total protein concentration of extracted cell lysates was determined using the Bradford 
assay. The assay was carried out in a 96-well flat-bottomed plate. In this experiment, 1 µl of 
each sample was added in wells contained 159 µl Baxter water for irrigation. To quantify the 
protein concentration in cell lysates, a standard curve was prepared by adding an increasing 
amount of Bovine Serum Albumin (BSA) (1 mg/mL) ranging from 0 to 6 µg in wells allocated 
for standard samples (in duplicate). 40 µl of Bradford reagent was pipetted into each well to 
a total volume of 200 µl. The plate was mixed and incubated at RT for 5 min before being read 
at 595 nm on a PolarStar microplate reader. The quantification of protein in each sample was 
performed using the standard curve. 
 
2.2.4.3. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Western immunoblotting was carried out in BioRad precast SDS-PAGE gels (4–12%). 20 µg of 
total protein was mixed with 6x loading dye and heated at 95 °C for 5 minutes, after which 
samples were loaded in the gel to run at a constant 120V for 90 min. Gels were run in an 
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immunoblotting running buffer. 6 µl of Precision Plus Protein Dual Color Standards was used 
as a size marker. 
2.2.4.4. Western Transfer and Immunoblotting  
After running the SDS-PAGE gel, proteins were transferred to a nitrocellulose membrane in a 
1x Transfer Buffer using the BioRad Criterion Blotter at a constant 400 mA for 60 minutes. To 
verify the protein transfer, the membrane was stained with Ponceau S, followed by overnight 
blocking at 4 °C in a blocking buffer containing 1% skim milk powder or 2% BSA dissolved in 
TBST (1x). Subsequently, the membrane was probed using primary and then HRP-conjugated 
secondary antibodies at room temperature (for 2 hours each). HRP-bound antibody-protein 
complex was detected using ECL solution, imaged on a BioRad Chemidoc MP imaging system 
and analysed using Image Lab Software.  
 
2.2.5. Gene expression and transcriptome analysis 
2.2.5.1. RNA isolation from cell lines 
To isolate RNA from cells, they were grown and treated in 6-well plates. At appropriate time 
points, media was removed from wells and cells were harvested in 1 mL Trizol per well and 
collected into 1.5 ml Eppendorf tubes. Following a 15-minutes incubation at 37 °C, 200 µl of 
chloroform was added into each tube which was then vigorously shaken for 15 s before a 3 
min incubation at room temperature. Then, samples were centrifuged at 12,000 g at 4 °C to 
isolate the aqueous phase on the top layer. The supernatant was transferred into a new tube 
containing 2 µl of Glyco-blue (Life Technologies), 2.5 volume 100% ethanol, 10 mM MgCl2, 
and 0.1 volume 5M NaCl. Samples were incubated overnight at -20 ˚C, followed by spinning 
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down at 12,000 g for 30 min at 4 °C. RNA pellets then were washed using 80% EtOH and 
resuspended in 20 µl nuclease-free water. RNA concentration and quality were quantified 
using Thermo Scientific NanoDrop 2000. Samples were stored at -80 ˚C until further use for 
qRT-PCR or sequencing (RNA-seq). 
 
2.2.5.2. DNase Treatment  
To avoid the interference of DNA in downstream applications, RNA samples were treated with 
a TURBO DNA-freeTM DNase Treatment kit according to the manufacturer's instruction 
(Ambion cat#AM1907). For DNase treatment, 2 to 4 ug of RNA dissolved in 44 µl RNase free 
water was mixed with DNase reaction mixture containing 5 µl of 10xTurbo DNAse Buffer and 
1 µl TURBO DNase enzyme, followed by a 30-minutes incubation at 37 °C. Following the 
incubation, 5 µl of DNase inactivation reagent was added to the samples and after a 5-minutes 
incubation at room temperature, samples were spun down at 10000 g for 1.5 minutes. 47 µl 
of supernatant was transferred into new tubes containing 50 µl 75% isopropanol and 2 µl 
Glycoblue and incubated overnight at -80 °C. Samples were centrifuged at 16.1 g for 20 
minutes at 4 °C and RNA pellets were dried after washing with 1 ml of 75% ethanol. Dried 
RNA pellets were re-suspended in 20 µl of TE buffer, and after a 10 minutes incubation at 55 
°C, they were quantified using the Nanodrop. 
 
2.2.5.3. Reverse Transcription  
Using the iScriptTM Reverse Transcription kit, DNase-treated RNA samples were converted 
into cDNA according to the manufacturer's instruction. For a reverse transcriptase (RT) 
reaction, 500 ng of RNA sample (diluted to 15 µl with TE buffer) was mixed with iScript master 
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mix containing 4 µl of iScript reaction mix and 1 µl of reverse transcriptase enzyme. Two 
control samples also were prepared including one “No-RNA” sample and one “No-RT” sample; 
the No-RNA sample contained 15 µl nuclease-free water and 5 µl iScript master mix and the 
No-RT sample contained all components (including RNA) except for reverse transcriptase. RT 
reactions were performed by incubating samples at room temperature for 5 minutes, 42 °C 
for 30 minutes and 85 °C for 5 minutes. The prepared cDNA samples were diluted 1:5 in 
nuclease-free water and stored at -20 °C until running the polymerase chain (PCR) reaction. 
 
2.2.5.4. Quantitative polymerase chain reaction (qRT-PCR) 
Gene expression was examined via quantitative RT-PCR (qRT-PCR) assay using a BioRad C1000 
Thermal Cycler and CFX384TM Real-Time System. The qRT-PCR reaction was performed by 
preparing a mixture of 0.5 µl forward primer (5 pmol/ µl), 0.5 µl reverse primer (5 pmol/ µl), 
5 µl iQ-SYBR Green Supermix, 2 µl RNase free water, and 2 µl cDNA. The qRT-PCR samples 
were prepared in three biological and three technical replicates, followed by a 3-step PCR 
program including 1) 3 minutes in at 95 °C, 2) 40 cycles of 15 sec at 95 °C, 15 sec at 55 °C- 62 
˚C (depending on the annealing temperature of primers used), and 30 sec at 72 °C and 3) 1 
minute at 95 °C, 1 minute at 55 °C and 10 sec 60 °C. Data were analysed using CFX Manager 
Software Version 3.0 (Bio-Rad Laboratories, Inc.). Expression of target genes was calculated 
by the 2-ΔΔCt method relative to the expression of GAPDH (reference gene) as described 
previously (Schmittgen and Livak 2008).   
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2.2.5.5. RNA-seq 
LNCaP cells were seeded at the appropriate seeding density in 6-well plates and treated with 
Vehicle, MeT 1 nM, DHT 1 nM, and a combination of MeT 1 nM + DHT 1 nM and total RNA 
was extracted at 6 hours and 24 hours after treatment as described in section 2.2.5.1. For 
each treatment condition, three biological replicates were used to generate samples for RNA-
seq. RNA concentration was quantified by Nanodrop 2000 (Thermo Fisher Scientific) and total 
RNA (2 µg) was supplied to the South Australian Health and Medical Research Institute 
(SAHMRI) for RNA integrity check, library preparation and high throughput sequencing. The 
integrity of RNA samples was assessed using The 2100 Bioanalyzer system (The Agilent). RNA 
sequencing libraries were constructed with TruSeq® Total RNA HT kit (Illumina) and libraries 
were sequenced on the Illumina NextSeq 500 platform with the stranded, paired-end read of 
80bp.  
 
2.2.6. Immunofluorescence  
LNCaP cells were seeded on glass coverslips in 6-well plates. To improve cell adhesion, glass 
coverslips were coated with 1:8 diluted L-Poly-Lysine. After treating the cells, at appropriate 
time points, cells were fixed in 4% paraformaldehyde for 10 minutes, permeabilized in 0.1% 
Triton X-100 for 15 minutes, and blocked in 2.5% BSA solution for 1 hour. The coverslips then 
were incubated with a primary antibody and incubated overnight at 4 °C, followed by washing 
(twice with 5 min intervals) and then incubation with a fluorescent-tagged secondary 
antibody for 1 hour at room temperature. Cell nuclei were visualised by co-staining the cells 
with 4´-6-Diamidino-2-phenylindole (DAPI; Invitrogen) for 1 min. Imaging was carried out 
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using a confocal microscope (Olympus FV3000 Confocal Microscope) and analysed using the 
Image J software (Schneider, Rasband et al. 2012).  
 
2.2.7. Cell cycle analysis by fluorescence-activated cell sorting (FACS) 
Cells were seeded in 6-well plates and incubated overnight at 37 °C and 5% CO2. At 
appropriate time points, cells were trypsinized after washing with a freshly prepared wash 
buffer containing PBS with 2% FBS. After trypsin treatment, the cells were pipetted to 
resuspend and break up any clumps. The cell suspension was added to a 5 ml FACS tube 
(containing previously collected cell culture media), each well was washed with PBS, and then 
this wash was added to tubes. Tubes were centrifuged at 700 g for 5 min. Cell pellets were 
re-suspended and washed with 1ml PBS, followed by centrifugation at 700 g for 5 minutes. 
After removing supernatants, cell pellets were resuspended in residual liquid by flicking the 
tubes and at the end, 1ml ice-cold 70% EtOH in PBS was added into each tubes containing the 
cell suspension to be fixed overnight at 4 °C. Following cell fixation with ethanol, cells were 
centrifuged at 700 g for 5 minutes and the cell pellets were washed twice with 1 ml HBSS + 
2% FBS. Cells were then stained with 1 ml of DAPI (10 ug/mL). The prepared cell suspension 
was used for cell cycle analysis based on DNA content using BD FACSCanto II flow cytometer 
(Analyser). Following values/options were applied as a Cytometer Settings: FSC (forward 
scatter): 284, linear, signal height (H) and area (A) were measured; SSC (side scatter): 236, log, 
signal height (H) and area (A) were measured; DAPI: 277, linear, signal height (H), width (W) 
and area (A) were measured. FSC threshold was adjusted to 1200. After acquiring 50,000 
events from each tube, the analysis was carried out using the FlowJo software program.  
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2.2.8. LINE-I ELISA assay for assessment of DNA methylation  
The Global DNA Methylation-LINE-I Kit was used to assess the DNA methylation status of Long 
Interspersed Nucleotide Element 1 (LINE-I) repeat elements, which serves as a proxy for global 
DNA methylation level.  
 
2.2.8.1. Extraction of genomic DNA  
Genomic DNA was isolated using the QIAamp® DNA Mini kit according to the manufacturer's 
instruction. Cells were grown and treated in a 6-well plate and at the appropriate time points, 
(see Chapter 3) media was removed. Cells were washed with PBS and then treated with 
trypsin as described above, followed by the addition of media containing FBS to neutralise 
the trypsin. Subsequently, the cell suspension was centrifuged at 300 g for 5 min, and the 
supernatant was removed. Cell pellets were re-suspended in 200 µl PBS and 20 µl proteinase 
K was added into cell suspension. After adding the proteinase K, 200 µl of Buffer AL was added 
and the mixture was mixed by pulse-vortexing for 15 sec, followed by incubation at 56 °C for 
10 minutes. After brief centrifugation, 200 µl of 96–100% ethanol was added to the samples 
and mixed by pulse-vortexing for 15 sec. Samples were then applied to a QIAamp Mini spin 
column and spun down at 6000 g for 1 minute. The tubes containing the filtrates were 
discarded and the spin columns were placed in clean 2 ml collection tubes. 500 µl of Buffer 
AW1 was then added into each column, which was followed by spinning down at 6000 g for 
1 minute, and then replacing the tubes containing the filtrates with clean 2 ml collection 
tubes. 500 µl of Buffer AW2 was then added into the columns, after which they were 
centrifuged at 16.1 g speed for 3 minutes. After replacing the collection tubes with clean 
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tubes, columns were centrifuged at 16.1 g speed for 1 minute and then collection tubes were 
replaced with 1.5 ml microcentrifuge tubes. Finally, 200 µl of AE buffer was added to each 
column and after incubation at room temperature for 1 min the columns centrifuged at 6000 
g for 1 min to elute DNA. DNA yield was assessed by Nanodrop and samples were stored at -
20 °C. 
 
2.2.8.2. MseI Digestion of Genomic DNA 
The methylation status of LINE-I elements is detected through the hybridization of LINE-I 
probes with DNA fragments generated by MseI-mediated digestion reaction. Digestion 
reactions were performed by adding 10 µl of genomic DNA (100 ng/ µl) into a reaction mixture 
consisting of 2 µl reaction buffer (10x), 0.5 µl of MseI enzyme (10U/ µl), and 7.5 µl sterile 
water. Sample tubes were mixed by pipetting and incubated at 37°C. After 4 hours of 
incubation, Msel enzymatic activity was stopped by heating the tubes at 65°C for 20 minutes. 
After digestion, DNA concentration was measured by Nanodrop. Digested DNA samples were 
stored at -20 °C until further use. 
 
2.2.8.3. DNA Sample Hybridization 
For DNA hybridization, 25 µl of digested DNA samples (4 ng/ µl) was added into 0.2 ml PCR 
tubes (in triplicates) followed by adding 25 µl of LINE-I probe solution. For quantification of 
DNA methylation in experimental samples, a standard curve was needed to be prepared using 
standards provided in the kit. Methylated and non-methylated DNA standards were mixed in 
different combinations to prepare seven standard samples with a known DNA methylation 
status. Then, in labelled PCR tubes, 25 µl of each standard sample (100 ng DNA/well) was 
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mixed with 25 µl of LINE-I probe solution. Finally, all samples were placed in a thermal cycler 
and incubated as following: 98 °C for 10 minutes, 68 °C for 1 hour, and a quick ramp to 25 °C. 
 
2.2.8.4. DNA binding to the streptavidin-coated plate and colorimetric detection 
After DNA hybridization, the content of each PCR tube was transferred into an allocated well 
coated with streptavidin and then the plate was incubated at room temperature for 1 hour 
with mild agitation. Subsequently, the contents of each well were removed by quickly 
inverting the plate, followed by washing wells 3x with 200 µl 1X Buffer W (10 minutes each 
wash). After each wash, the contents of wells were removed by pipette and 200 µl of Assay 
Buffer AM3 (blocking buffer) was added to each well and then incubated for 30 minutes. After 
removing the blocking buffer, 100 µl of diluted 5-Methylcytosine antibody was added per well 
and incubated for 1 hour, followed by 3x washes with 200 µl 1X Wash Buffer. 100 µl of diluted 
HRP-conjugated anti-mouse antibody was then added to each well for 1 hour at room 
temperature. Wells were then washed 3x using 200 µl of 1X Wash Buffer before adding 100 
µl developing solution to each well. The reaction was stopped by adding 100 µl of stop 
solution when a medium to dark blue colour was evident in the standard well with the highest 
concentration of methylated DNA. Absorbance was read using a spectrophotometer at 
450nm. The percentage of 5-mC associated with each sample was analysed using the 
prepared standard curve. 
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2.2.9. Chromatin immunoprecipitation (ChIP) 
2.2.9.1. Cell treatment and cross-linking  
LNCaP cells were seeded in 15 cm culture dishes at 5×106/plate (for AR-ChIP; three plates per 
replicate) and ×106/plate (for H3K27me3-ChIP; one plate per replicate) in their normal growth 
medium. For AR-ChIP, phenol-red-free medium supplemented with 5% DCC-stripped FBS was 
used and cells were allowed to grow for 2 days prior to treatment with Vehicle (Ethanol), MeT 
1 nM, and DHT 1 nM for 4 hours. For H3K27me3 ChIP, phenol-red-free medium supplemented 
with 5% FBS was used and cells were allowed to grow for 1 day before treating the cells with 
Vehicle (Ethanol), MeT (1nM and 100nM), and DHT (1nM and 100nM) for 72 hours. To cross-
link, the target protein to DNA, 20ml of pre-warmed Solution A containing freshly added 1% 
formaldehyde was added to each 15cm-cell culture dish. Plates were incubated for 10 
minutes in the fume hood, and then formaldehyde was quenched by adding 2 ml of 1 M 
glycine (pH 7.5) and incubating for 5 minutes. Subsequently, cells were washed twice with 
ice-cold PBS, after which cells were scraped into 500 µl PBS + PI per 15 cm dish. After 
transferring the harvested cells into 2.0 ml Eppendorf tubes, they were centrifuged at 7,168 
g for 3 minutes at 4 ºC and cell pellets were resuspended in 500 µl PBS + PI. Centrifugation 
and removal of the supernatant were repeated and then cell pellets were frozen in liquid 
nitrogen and stored at -80 ºC until further use. 
 
2.2.9.2. Preparation of magnetic beads 
Dynabeads (Protein A, Invitrogen) were used for conjugation with AR antibody (Abcam; 
ab108341) or H3K27me3 antibody (cell Signalling; C36B11). Dynabeads were vortexed to be 
ensured they were fully resuspended. Then, 100 µl per ChIP was added into a 2 ml, round-
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bottomed, Eppendorf tube and put in a magnetic stand, on ice. The supernatant was removed 
and beads were washed and blocked three times with cold 1ml PBS + 5 mg/ml BSA. After 
washing, beads were re-suspended in 500 µl of cold PBS/BSA and 10 µg /IP of AR antibody or 
7.5 µg /IP H3K27me3 antibody was added into the tubes containing the prepared dynabeads. 
Tubes were rotated at 12-20 rpm overnight at 4 °C. 
 
2.2.9.3. Sonication and immunoprecipitation  
Cell pellets were resuspended in 1 ml of Lysis Buffer 1 (LB1) + PI and then tubes were rotated 
at 4 C for 10 minutes, centrifuged at 2,000 g for 5 min at 4 oC, after which supernatants were 
removed. Cell pellets were then resuspended in 1 ml LB2 + PI, rotated at 4 oC for 10 minutes, 
centrifuged at 2000 g for 5 minutes at 4 ºC, after which supernatants were removed. Cell 
pellets were then resuspended in 300 µl of LB3 + PI per each 15 cm plate. 300 µl of cell 
suspension from each replicate were transferred into 1.5 ml TPX sonication tubes (Diagenode) 
and they were sonicated (Bioruptor Plus, Diagenode) as follows: 30s on and 30s off, on high, 
for 10 cycles. Ice was added to water in the sonicator after every round to avoid increasing 
the temperature. Sonicated samples from each replicate were re-pooled and 10 µl aliquot of 
the sonicated chromatin was evaluated by agarose gel electrophoresis as following protocol. 
5 µl of sonicated DNA was transferred into a 250 µl PCR tube containing 2 µl of NaCl 500 mM 
and the final volume was adjusted to 20 µl with sterile water. Samples were heated in a 
thermocycler at 100 oC for 20 minutes, followed by ramping the temperature down to 50 oC. 
Then, tubes were removed from the thermocycler and incubated at room temperature for 5 
minutes. Reverse cross-linked samples were run on 1.2% agarose gel to check the sonication. 
Fragment sizes should be ideally approximately 200-500 bp.  
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After confirming the sonication efficiency on an agarose gel, 10% Triton X-100 dissolved in 
LB3+PI was added into pooled sonicated samples to a final concentration of 1%. Tubes were 
then centrifuged at 20,000 g for 10 minutes at 4 oC. In the meantime, magnetic beads 
prepared in 2.2.9.2 were washed 3x using 1ml ice-cold PBS/BSA using a magnetic stand to 
remove unbound antibodies, followed by re-suspending in 100 µl of LB3+PI+1% triton. 
Sonicated chromatin supernatants were transferred into fresh 2ml tubes and 50 µl from each 
sample was kept as an Input sample. Then, 100 µl of conjugated magnetic beads were added 
to the tubes containing sonicated chromatin and diluted with LB3 (+PI) with a final 
concentration of 1% Triton X-100 to ~1.8 ml. tubes were rotated overnight at 4 ºC.  
 
2.2.9.3. Reverse cross-linking and DNA isolation 
After overnight incubation of beads with chromatin samples, beads were washed 6x with 1ml 
ice-cold ChIP-RIPA buffer using a magnetic stand. 200 µl of elution buffer was then added into 
each tube and incubated on a thermal shaker at 65 °C for 15 min, with a brief vortexing every 
5 min. Reverse crosslinking of samples was performed by 18 hours incubation at 65 °C. At the 
same time, 150 µl of elution buffer was also added to each Input sample which was prepared 
after sonication and had been stored at -80 °C, followed by 18 hours incubation at 65 °C. After 
incubation time, tubes were placed on a magnetic stand and supernatants containing eluted 
antibody: target: DNA complexes were transferred into fresh Eppendorf tubes. 
 
In the next step, 200 µl of TE buffer and 8 µl of 1mg/ml RNAse A were added into each sample, 
and then the tubes were incubated at 37 ºC for 1 hour. Subsequently, 4 µl of 20 mg/ml 
Proteinase K was added per sample and tubes were incubated at 55 ºC for 2 hours. 400 µl of 
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Phenol: Chloroform: Isoamyl alcohol (25:24:1) was added per tube and after mixing for 15 sec 
the suspension was added into pre-spun 5PRIME phase-lock gel column (Quanta Biosciences). 
Phase-lock columns were centrifuged for 5 minutes at 10,000 g at room temperature, 
followed by transferring the upper layer (~ 400 µl) into an Eppendorf tube containing 16 µl of 
5 M NaCl and 2 µl glycogen (20 µg/ µl). 800 µl 100% ethanol was added per tube and samples 
were incubated overnight at -80 ºC. The next day, samples were centrifuged at 4 ºC at 16.1 g 
for 20 minutes. The supernatant was removed and DNA pellets were washed using 500 µl cold 
70% ethanol. After spinning down at full speed for 5 minutes at 4 ºC, ethanol was removed 
and pellets were air-dried at room temperature. After drying the pellets, DNA samples were 
resuspended in 20 µl of 10mM Tris HCl pH 8.0. Samples were stored at -80 ºC until analysis 
by qPCR or Illumina sequencing. 
 
2.2.9.4. Preparing the ChIP DNA samples for next-generation sequencing  
DNA concentration was measured by Qubit dsDNA HS assay, according to the manufacturer's 
instruction (Thermo Fisher Scientific). Briefly, 200 µl of Qubit working Solution for each 
standard and sample was prepared by diluting the fluorescent reagent 1:200 in the kit buffer. 
To prepare the standards, 10 µl of each standard vials (low and high) were mixed with a 190 
µl working solution. Qubit samples were prepared by mixing 1 µl of each sample with 199 µl 
of working solution. Samples were vortexed briefly and incubated for 2 minutes at room 
temperature. Using the standards, DNA concentration in each sample was measured by the 
Qubit Fluorometer. 5 ng of ChIP DNA (ChIP-enriched or input) were used for ChIP-sequencing 
library preparation using an Illumina TruSeq ChIP Library Prep kit (Illumina). Prepared samples 
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were sequenced on the Illumina Nextseq 500 platform using the single-end protocol with a 
read length of 75 bp at the South Australian Health and Medical Research Institute (SAHMRI). 
 
2.2.9.5. PCR analysis of ChIP DNA 
For ChIP–PCR reactions, iQ SYBR Green Supermix (BIO-RAD) and primers as listed in Table 2.5 
were used. For the AR-ChIP PCR experiment, KLK3 was used as a positive control for AR 
binding, and a non-coding region of DNA named NC2 was used as a negative control. PCR was 
performed using the CFX384 Real-Time PCR Detection System (BIO-RAD) and standard cycling 
conditions at the optimised annealing temperature. Enrichment of target factor in ChIP–PCR 
was analysed as the percentage of input. 
 
2.2.10. RNA-seq analysis: 
The quality of raw data was initially assessed using the FastQC platform 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The raw FASTQ files were 
then filtered for short sequences using Cutadapt v1.16.6 (Martin 2011) with the following 
settings:  minimum overlap length in Adaptor options: 3, Minimum length in filter options: 
20, maximum error rate: 0.1, quality cut-off: 20. The quality of filtered FASTQ files (averaging 
30 million read pairs per sample) were checked again using the FastQC program. Reads were 
mapped against the human reference genome (hg38) using the STAR spliced alignment 
algorithm version 2.6.0 b-2 (Dobin, Davis et al. 2013) with default parameters. FeatureCounts 
was used to count and assign the reads in generated BAM files to genomic features (Liao, 
Smyth et al. 2014). Count tables generated by featureCount were used for differential 
expression analysis using DESeq2 (Love, Huber et al. 2014). Statistically, p-adj ≤ 0.05 were 
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used to identify the differentially expressed genes (DEGs). Principal component analysis and 
the gene expression visualisation were performed using ClustVis (Metsalu and Vilo 2015).  
 
2.2.11. ChIP-seq analysis: 
The quality of raw FastQ files was checked using FastQC v0.72 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The poor-quality reads were 
removed using Trimmomatic Galaxy v.0.35 (Bolger, Lohse et al. 2014) and subsequently, raw 
data were aligned to GRCh37 (hg19 ) genome assembly using Bowtie2 version: 2.3.4.3 with 
default parameters (Langmead, Trapnell et al. 2009). SAMtools was used to remove the low-
quality mapped reads (MAPQ < 10), multi-mapping reads, and PCR duplicates (Li, Handsaker 
et al. 2009). Peak calling from alignment results were carried out using MACS2 callpeak v 
2.1.1.20160309.6, with minimum FDR (q-value) cutoff for peak detection 0.05  (Zhang, Liu et 
al. 2008, Feng, Liu et al. 2012). BAMCoverage was used to convert BAM files to bigwig, 
followed by data visualisation using the Integrative Genomics Viewer (Ji, Jiang et al. 2008, 
Robinson, Thorvaldsdóttir et al. 2011). deepTools was used to generate the Heatmaps (Galaxy 
Version 3.3.2.0.0) (Ramírez, Ryan et al. 2016). Peak annotations were performed using 
Cisgenome v2.0 (Ji, Jiang et al. 2008). 
 
2.2.12. Statistical analyses: 
Statistical analyses were done using GraphPad Prism 9. Detailed methods for statistical 
analysis are included in figure legends or the individual Chapter methods. 
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ABSTRACT 
Inhibiting the androgen receptor (AR), a ligand-activated transcription factor, with androgen 
deprivation therapy is a standard-of-care treatment for metastatic prostate cancer (PCa). 
Paradoxically, recent studies have suggested that “extreme” activation of AR using high doses of 
androgens can - similarly to suppression of AR activity - inhibit the growth of PCa. This study exploited 
a potent synthetic androgen, methyltestosterone (MeT), to investigate the mechanism of action of 
high dose androgen therapy. MeT strongly inhibited the growth of PCa cells expressing AR, but not 
AR-negative models. By integrating ChIP-seq and RNA-seq data, we found that the genes and 
pathways regulated by MeT were highly analogous to those regulated by DHT, although MeT educed 
a quantitatively greater androgenic response. The transcriptomic analysis also revealed that MeT 
caused dysregulation of transposable element expression, with long-term treatment resulting in 
upregulation of endogenous retroviruses (ERVs). Mechanistically, increased expression of ERVs was 
linked to MeT-mediated down-regulation of DNA methyltransferases and global DNA 
hypomethylation. Increased ERV expression was associated with accumulation of double-stranded 
RNA and a “viral mimicry” response that resulted in activation of interferon signalling, upregulation of 
MHC Class I molecules and enhanced tumor cell immunogenicity as measured by enhanced 
recognition by tumour-specific CD8+ T cells. Importantly, we identified positive associations between 
AR activity and ERVs/anti-viral pathways in clinical datasets. Collectively, our study reveals that the 
potent androgen MeT can activate innate immune responses in PCa cells, a finding that has potential 
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INTRODUCTION 
Prostate cancer (PCa) cells are exquisitely dependent on androgens and the androgen 
receptor (AR) for growth and survival, which explains the efficacy of androgen deprivation 
therapy (ADT) as a treatment for advanced PCa. ADT is comprised of hormonal manipulations 
that reduce circulating androgen levels and/or directly block AR activity. While almost all men 
initially respond to ADT, the development of a therapy resistant disease state, referred to as 
castration-resistant prostate cancer (CRPC), is inevitable. In the vast majority of cases, 
resistance to ADT is mediated by adaptive alterations to the AR signalling axis, highlighting 
addiction to this pathway as a hallmark of PCa (Coutinho, Day et al. 2016).   
 
AR is a transcription factor that, upon binding to androgen, translocates from the cytoplasm 
to the nucleus and interacts with specific cis-regulatory elements (termed androgen response 
elements) on chromatin to regulate a gene expression program that promotes growth, 
survival and metabolism of PCa cells. The transcriptional output of AR can be influenced by a 
multitude of parameters, including hundreds of co-regulators (Liu, Kumari et al. 2017), 
epigenetic factors (Gao and Alumkal 2010) and the concentration and composition of the 
androgenic milieu (Auchus and Sharifi 2020). Additional complexity arises from the evolution 
of AR signalling axis components during progression to CRPC. For example, direct changes to 
the AR gene (mutation, amplification and rearrangements that result in AR splicing 
alterations) alter cellular responses to androgens, alternative ligands and anti-androgens, 
collectively enabling high AR activity despite ongoing ADT (Coutinho, Day et al. 2016). 
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Not surprisingly, most work on AR to date has focussed on its oncogenic functions. However, 
it is important to consider that in normal adult prostate epithelial cells AR promotes cellular 
quiescence by preserving luminal differentiation and protein-secretory activity. This 
understanding may explain the decades-old observation that administration of high doses of 
testosterone can result in clinical responses in men with CRPC (Huggins 1965). This apparent 
paradox is supported by pre-clinical studies demonstrating that low androgen levels promote 
growth of PCa whereas high androgen concentrations are growth-inhibitory (Langeler, van 
Uffelen et al. 1993, Kokontis, Hay et al. 1998, Mohammad, Nyquist et al. 2017). The concept 
of therapeutic application of androgens in PCa has culminated in recent clinical trials testing 
supraphysiological levels of testosterone (SupraT), which have yielded promising results in a 
subset of patients (Schweizer, Antonarakis et al. 2015, Teply, Wang et al. 2018, Denmeade, 
Wang et al. 2021, Markowski, Wang et al. 2021, Sena, Wang et al. 2021). In the clinic, SupraT 
is often combined with ADT such that patients are cycled between near-castrate and very 
high serum T levels, a treatment strategy referred to as bipolar androgen therapy (BAT) 
(Schweizer, Antonarakis et al. 2015, Teply, Wang et al. 2018, Denmeade, Wang et al. 2021, 
Markowski, Wang et al. 2021, Sena, Wang et al. 2021). 
 
A detailed understanding of the mechanism(s) by which androgens can inhibit PCa growth is 
important to optimise clinical benefit of SupraT/BTA. Numerous processes have been 
purported to explain the activity of SupraT, including AR transcriptional reprogramming (Gao, 
Gao et al. 2016, Nyquist, Corella et al. 2019) and AR’s effects on the DNA damage response 
(Chatterjee, Schweizer et al. 2019), DNA replication (D'Antonio, Vander Griend et al. 2009) 
and oxidative stress (Bui, Huang et al. 2017), but the relative importance of each and whether 
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or not other anti-cancer effects exist are poorly understood. In this study, we investigated the 
mode of action of a synthetic androgen, 17α-methyl-testosterone (MeT), which can potently 
inhibit PCa growth. By dissecting the transcriptome of MeT-activated AR, we uncovered a 
novel response of PCa cells to potent androgen action. Specifically, we demonstrate that MeT 
down-regulated DNA methyltransferases and hence reduced DNA methylation throughout 
the genome, an effect that was associated with increased expression of endogenous 
retrovirus transcripts, activation of interferon (IFN) signalling and enhanced immunogenicity 
of PCa cells. Thus, our findings demonstrate that potent androgenic action can cause viral 
mimicry in PCa cells, which may provide a basis for new targeted investigations into combining 
androgen therapies with immunotherapies.  
 
RESULTS 
Methyl-testosterone is a potent activator of AR activity and suppressor of prostate cancer cell 
growth 
In studies interrogating the therapeutic potential of AR ligands in PCa, we noted that MeT has strong 
growth-inhibitory activity in LNCaP cells grown in full serum (i.e. androgen replete conditions) at doses 
as low as 1 nM (Fig. 1A). Conversely, DHT only suppressed cell growth only at doses greater than 1 nM 
(Fig. 1A). Growth of the CRPC cell lines C42B, MR49F, and 22Rv1 was also inhibited by MeT at doses 
ranging from 1-100 nM (Fig. 1B). DHT also suppressed the growth of C42B and MR49F cells but had no 
effect on 22Rv1 cells (Supplementary Fig. 1A).  Importantly, neither the AR-negative model PC3 nor 
the R1-D567 model, which expresses an AR variant that lacks the ligand-binding domain (ARv567es), 
were affected by MeT (Supplementary Fig. 1B), indicating that growth suppression was a consequence 
of binding of MeT to AR.  
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To better understand the activity of MeT in PCa cells, we undertook a series of molecular assays.  First, 
we compared MeT and DHT in a classic transcriptional activation assay using a probasin 
promoter:luciferase reporter construct (PB3-luc; (Jia, Kim et al. 2003)).  At lower doses (0.1 nM and 
0.5 nM), MeT more potently activated endogenous AR in LNCaP cells and exogenously-supplied AR in 
PC3 cells AR (Fig. 1C). No difference in transcriptional activity was observed between the 1 nM MeT 
and DHT treatments (Fig. 1C), possibly because of signal saturation, which is known to occur with these 
types of luciferase assays (Rakotondrafara and Miller 2008, Heise, Oppermann et al. 2013, Meliani, 
Leborgne et al. 2015). This experiment provided evidence that MeT could more potently induce the 
transcriptional activity of AR compared to the physiological ligand DHT.   
 
Subsequently, to evaluate MeT regulation of AR at a global level and in a more physiological setting, 
we conducted AR ChIP-seq and RNA-seq in LNCaP cells. The AR-MeT cistrome was ~3-fold larger than 
the equivalent AR-DHT cistrome (Fig. 1D). However, heat maps and density plots of sequencing tags 
(Fig. 1E) revealed that the majority of MeT-induced AR binding sites were also targeted, albeit more 
weakly, by DHT-activated AR; hence, we refer to these as “MeT-enriched” (Fig. 1E). For both ligands, 
AR cistromes were mainly comprised of binding sites distal from gene promoters (Supplementary 
Table 1), which mirrors what has been reported previously (Tewari, Yardimci et al. 2012, Stelloo, 
Bergman et al. 2019). Although we cannot rule out the possibility that MeT creates additional AR 
binding sites in the LNCaP genome, our findings suggest that, in general, MeT did not lead to new AR 
binding events but rather enhanced its interaction with canonical regulatory elements. This concept 
was supported by transcriptomic analysis, which revealed that genes differentially expressed in 
response to MeT (n = 1212, FDR ≤ 0.05) were also altered by DHT in a directionally-consistent manner 
albeit to a lesser degree (Fig. 1F; Supplementary Data 1). This effect was most striking when assessing 
the 285 genes that were differentially expressed by DHT compared to vehicle (FDR ≤ 0.05): 99% 
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(282/285) of these genes were also regulated by MeT, all of those 282 genes were regulated in the 
same direction by both hormones, and 99% (280/282) were more strongly regulated by MeT than by 
DHT (average 1.6-fold stronger downregulated and 1.1-fold stronger upregulated (Supplementary 
Data 1). The majority of genes altered by either hormone were downregulated (Fig. 1F and 
Supplementary Data 1). Collectively, these findings suggest that MeT is a potent activator of canonical 
AR functions that largely exhibits quantitative, rather than qualitative, differences to the endogenous 
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Fig. 1. Methyl-testosterone has potent androgenic and growth suppressive activity in prostate 
cancer cells. (A) MeT potently suppresses the growth of LNCaP cells (left graph), as determined by 
Trypan blue growth assay. The response of cells to DHT is shown on the right. Error bars are ± SEM. P 
values (day 7) were determined using ANOVA and Dunnett’s multiple comparisons tests (*, p < 0.05; 
**, p < 0.01; ***, p < 0.001; ****, p < 0.0001). NS, not significant. (B) MeT inhibits the growth of CRPC 
models of PCa (C42B, MR49F and 22Rv1), as determined by Trypan blue growth assay. Statistical 
analysis was as for (A). (C) Activation of AR transcriptional activity by MeT in PC3 cells (top) and LNCaP 
cells (bottom). PC-3 cells were transfected with plasmids expressing or AR and a probasin-luciferase 
reporter for 4 h prior to a 20 h treatment with 1 nM DHT; LNCaP cells were transfected only with the 
probasin-luciferase reporter. Transcriptional activity values represent the mean of six biological 
replicates; results are representative of three independent experiments. Error bars are SEM. Unpaired 
t tests were used to compare MeT and DHT (***, p < 0.001; ****, p < 0.0001). (D) Venn diagram 
showing the overlap of AR cistromes in LNCaP cells treated with DHT or MeT (1 nM each). (E) Read 
density plots (top panels) and heatmaps (bottom panels) representing AR ChIP-seq peak sets from (D). 
(F) Heatmap of RNA-seq data for genes differentially expressed by 24 hours of MeT treatment 
(compared to Vehicle; FDR < 0.05). The heatmap was generated using ClustVis (Metsalu and Vilo 2015) 










































Supplementary Fig. 1. Anti-proliferative effects of MeT and DHT in prostate cancer models. (A) DHT 
inhibits the growth of C42B and MR49F, but not 22RV1, as determined by Trypan blue growth assays. 
Error bars are +SEM. P values were determined using ANOVA and Dunnett’s multiple comparisons 
tests (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). NS, not significant. (B) Methyl-
testosterone does not affect the growth of PC3 or R1-D567 prostate cancer cells, as determined by 
























Supplementary Table 1. Genomic distribution of AR cistromes 
 
 MeT-AR peaks DHT-AR peaks MeT and DHT 
Shared AR binding sites 
Total Peak number (FDR < 0.05)  6491 1993 4123 
Intergenic (%)  51.13 51.33 51.30 
Intragenic (%)  48.87 48.67 48.70 
Exon (%)  2.67 2.91 2.67 
Intron (%)  46.50 45.96 46.35 
CDS (%)  0.94 0.75 0.82 
UTR (%)  1.74 2.16 1.89 
5'UTR (%)  0.18 0.25 0.15 
3'UTR (%)  1.57 1.96 1.77 
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Methyl-testosterone suppresses DNA replication and repair pathways in prostate cancer cells 
Given its potent growth-inhibitory activity, we hypothesised that further dissecting the 
transcriptomic readouts of MeT-bound AR could yield new insights into mechanisms 
underlying the activity of high-dose androgen therapy in PCa. Gene set enrichment analysis 
(GSEA) (Subramanian, Tamayo et al. 2005) was used to identify ‘Hallmark’ gene sets (Liberzon, 
Birger et al. 2015) altered by treatment with this potent androgen. Providing further evidence 
that MeT regulates a transcriptional program that is highly similar to endogenous androgens, 
the most upregulated hallmarks for both MeT and DHT were ‘androgen response’, ‘protein 
secretion’ and ‘apical junction (Fig. 2A). Hallmarks that were robustly repressed by MeT/DHT 
were related to DNA replication and repair (i.e. E2F targets, MYC targets, G2M checkpoint, 
mitotic spindle, DNA repair; Fig. 2A), analogous to what has been reported for high-dose 
androgen treatment previously (Gao, Gao et al. 2016, Chatterjee, Schweizer et al. 2019, 
Nyquist, Corella et al. 2019). When we examined curated DNA repair (Chatterjee, Schweizer 
et al. 2019) and DNA replication (Gao, Gao et al. 2016) gene sets that were reported to be 
repressed by high-dose androgen treatment, we observed that MeT down-regulated these to 
a considerably greater extent than DHT (Fig. 2B-C). Many of these genes have been purported 
to be directly regulated by AR on the basis of its binding to proximal regulatory elements (Gao, 
Gao et al. 2016). Indeed, we found that AR binding near these genes was strongly stimulated 
by MeT and, to a lesser extent, DHT (Fig. 2D and Supplementary Fig. 2).  
 
A reported consequence of suppression of DNA repair and replication pathways by high-dose 
androgen treatment is cell cycle arrest (Tsihlias, Zhang et al. 2000, Chatterjee, Schweizer et 
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al. 2019). Flow cytometry revealed that MeT caused accumulation of cells in G1 phase and 
consequent reduction of cells in S and G2/M phases (Fig. 2E). The same dose of DHT did not 
have a significant effect on cell cycle (Fig. 2E), providing additional evidence that MeT is a 
more potent, yet canonical, androgen than DHT in terms of PCa cell growth suppression. One 
proposed mediator of G1 arrest by high-dose androgen treatment is increased DNA damage, 
occurring via a combination of AR-mediated double-stranded breaks (DSBs) (Haffner, De 
Marzo et al. 2011) and down-regulation of DNA repair genes (Chatterjee, Schweizer et al. 
2019). However, MeT did not significantly increase the number of γH2AX foci (Fig. 2F), a 
marker of DSBs, suggesting that DNA damage is not a major mechanism underlying its growth-
suppressive activity in PCa cells. Low dose, but not high dose, DHT caused a minor increase in 
the number of γH2AX foci (Fig. 2F), potentially representing a differential mode of action 
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Fig. 2. DNA replication and repair pathways are repressed by potent androgenic stimulation 
of prostate cancer cells. (A) Normalized enrichment scores (NES) for top-ranked Hallmark 
gene sets (Liberzon, Birger et al. 2015) representing RNA-seq data from LNCaP cells treated 
with 1 nM MeT for 24 hours. (B-C) Heatmap of RNA-seq data for androgen-regulated genes 
associated with DNA repair (Chatterjee, Schweizer et al. 2019) and DNA replication (Gao, Gao 
et al. 2016) in LNCaP cells treated with 1 nM MeT or 1 nM DHT for 24 hours. Heatmaps were 
generated using ClustVis (Metsalu and Vilo 2015) after applying unit variance scaling to each 
gene. (D) Average read density plots for AR chromatin binding proximal (<100 kb) to DNA 
repair/replication genes in LNCaP cells treated with 1 nM MeT or 1 nM DHT for 4 hours. (E) 
Cell cycle analysis by DAPI labelling and flow cytometry after 72 hours of treatment with 1 nM 
MeT or 1 nM DHT. Unpaired t tests were used to compare data at different cell cycle phases 
(i.e. G1, S and G2/M) between treatment groups (**, p < 0.01; ****, p < 0.0001). (F) 
Assessment of DNA double-strand breaks after potent androgen treatments. γH2AX foci were 
quantitated in LNCaP cells 6 hours after treatment with MeT, DHT or a positive control (H2O2). 
Error bars are SEM. P values (day 7) were determined using ANOVA and Dunnett’s multiple 



































































Supplementary Fig 2. Androgen treatments mediates AR binding to genes involved in DNA 
replication andrepair. Genome browser images showing AR ChIP-seq signals at binding sites 
associated with BARD1, MCM6, LNMB1 and ATM in LNCaP cells treated with Vehicle, 1 nM MeT or 1 
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Methyl-testosterone causes DNA hypomethylation in prostate cancer cells  
AR has a major role in regulating the epigenome via interplay with and transcriptional 
regulation of chromatin remodelling factors (Cai, Yuan et al. 2013), although little is known 
about how these mechanisms are altered in the context of high-dose androgen treatment. 
Our RNA-seq data revealed that MeT strongly down-regulated the DNA methyltransferases 
DNMT1 and DNMT3b in LNCaP cells (Fig. 3A), which we validated by qRT-PCR (Fig. 3B) and 
Western blotting (Fig. 3C and Supplementary Fig. 3). Gene signatures of response to DNMT 
inhibitors (Missiaglia, Donadelli et al. 2005, Kim, Zhong et al. 2006) were altered by MeT (Fig. 
3D), suggesting that DNA hypomethylation and subsequent effects on transcription were 
occurring downstream of DNMT down-regulation. To directly test this idea, we assayed for 5-
Methylcytosine at long interspersed nuclear elements (LINEs), a proxy for global DNA 
methylation. In support of our expression profiling data, a decrease in global DNA methylation 
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Fig. 3. Methyl-testosterone down-regulates DNA methyltransferases and causes DNA 
hypomethylation. (A) Expression of DNMT1, DNTM3A and DNMT3B, as determined by RNA-seq, of 
LNCaP cells following 24 hours of treatment with MeT or DHT (1 nM each) or a vehicle control. CPM, 
counts per million reads. Middle line, mean; above and below, ± SEM. P values (treatment compared 
to vehicle) were determined using ANOVA and Dunnett’s multiple comparisons tests (*, p < 0.05; **, 
p < 0.01; ***, p < 0.001; ****, p < 0.0001). (B) Expression of DNMT1 (top) and DNMT3B (bottom), as 
determined by qRT-PCR, following 24 hours of treatment with MeT or DHT (1 nM each) or a vehicle 
control. Gene expression was normalized to GAPDH; expression for Vehicle was set to 1. Error bars 
are SEM; P values (treatment compared to vehicle) were determined using ANOVA and Dunnett’s 
multiple comparisons tests (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). (C) 
Representative Western blot showing DNMT1 protein levels following treatment of LNCaP cells with 
the indicated doses of MeT or DHT or vehicle control for 24 and 48 hours. GAPDH is shown as a loading 
control; each sample was pooled from two replicates. Quantification of DNMT1 protein (normalised 
to GAPDH) is shown on right. (D) Association between MeT-induced genes and a gene set upregulated 
by TSA and Decitabine (left) (Kim, Zhong et al. 2006) and between MeT-repressed genes and a set of 
genes downregulated following treatment with Decitabine (Missiaglia, Donadelli et al. 2005), as 
demonstrated by GSEA. NES, normalised enrichment score. (E) Global DNA methylation (5 mC; % 
methylation of LINE-I elements) in LNCaP cells treated with indicated doses of MeT or DHT for 6 days. 
Decitabine (1 µM) was used as a positive control. P values (treatment compared to vehicle) were 
determined using ANOVA and Dunnett’s multiple comparisons tests (*, p < 0.05; **, p < 0.01; ***, p < 























Supplementary Fig. 3. Methyl-testosterone down-regulates DNMT1. Western blots showing DNMT1 
protein levels following treatment of C4-2B (top) and V16D (bottom) cells with the indicated doses of 
MeT or DHT or vehicle control for 24 and 48 hours; each sample was pooled from two replicates. 
GAPDH is shown as a loading control. Quantification of DNMT1 protein (normalised to GAPDH) is 
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Methyl-testosterone induces transcription of transposable elements and causes accumulation 
of dsRNA 
The transcription of transposable elements (TEs), which constitute ~45% of the human 
genome (Criscione, Zhang et al. 2014) and are comprised of distinct families including 
endogenous retroviruses (ERVs), LINEs and Short Interspersed Nuclear Elements (SINEs), is 
heavily influenced by DNA methylation (Reik 2007). Thus, we hypothesised that loss of DNA 
methylation in response to MeT could lead to altered TE expression. To test this hypothesis, 
we first interrogated levels of different TE classes within the ERV/LINE/SINE families in our 
short-term (24 hour) RNA-seq data. Similar to our analyses of the coding transcriptome, MeT 
caused substantial changes to expression of TEs whereas DHT had a less pronounced effect 
(Fig. 4A).  
 
Having established that potent androgen treatment could alter the expression of TEs in 24 
hours, we measured specific transcripts after 3-6 days of treatment, based on the earlier 
observation that loss of DNA methylation occurred over an equivalent period (Fig. 3E). We 
initially focussed our attention on LINEs, since these elements were specifically evaluated in 
the DNA methylation assays. LINE-I was weakly induced by MeT after 6 days of treatment, but 
its expression was not altered by DHT treatment (Supplementary Fig. 4A), a finding that was 
recapitulated in the CRPC cell line C4-2B (Supplementary Fig. 4B). Subsequently, we measured 
the expression of the major family members of ERVs, since these sequences of viral origin are 
known to influence various biological processes in cancer cells, including innate immune 
responses (Bannert, Hofmann et al. 2018). MeT induced ERV3-1 and HERV-K transcripts in 
LNCaP cells (Fig. 4B); HERV-E and HERV-W were not significantly altered but exhibited a trend 
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towards upregulation (Supplementary Fig. 4C). Analogous results – significant induction of 
ERV3-1 and HERV-K but not HERV-E or HERV-W – were observed in the C4-2B model, 
suggesting this is a general response of PCa cells to MeT (Fig. 4C, Supplementary Fig. 4D). As 
for protein-coding transcripts, equivalent doses of DHT caused similar qualitative changes to 
LINE/ERV expression but quantitatively weaker effects (Figs. 4B-C, Supplementary Fig. 4). 
Collectively, these findings demonstrate that the potent synthetic androgen MeT can induce 
expression of transposable elements, including ERVs, in a context-dependent manner in PCa 
cells.   
 
Expression of some ERVs occurs bi-directionally and can thereby result in generation of dsRNA 
(Chiappinelli, Strissel et al. 2015). Since potent androgen treatment led to increased levels of 
the major classes of ERVs over a period of 3-6 days, we speculated that this could cause 
accumulation of dsRNA. Using an immunofluorescent approach with a dsRNA-specific 
antibody (J2), we found that MeT treatment elicited a profound increase in the level of cellular 
dsRNA (Fig. 4D). Indeed, 1 nM MeT resulted in more detectable dsRNA than 100 nM DHT and 
1 µM of Decitabine, a DNMT inhibitor (DNMTi) previously reported to induce dsRNA in other 
cancer cell types (Chiappinelli, Strissel et al. 2015, Roulois, Loo Yau et al. 2015, Topper, Vaz et 
al. 2017) (Fig. 4D). Collectively, these findings reveal that potent androgenic stimulation of 
PCa cells leads to dysregulation of TE transcription that is associated with accumulation of 
ERV transcripts and dsRNA.   
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Fig. 4. Induction of transposable element expression by methyl-testosterone is associated with 
production of dsRNA. (A) Principal component analysis (PCA) of transposable element expression 
(long terminal repeats, LINE and SINE elements) from RNA-seq data following treatment of LNCaP cells 
with MeT or DHT (1 nM each) for 24 hours. The plot was generated using ClustVis (Metsalu and Vilo 
2015) after applying unit variance scaling to each element. (B) Expression of ERV3-1 and HERV-K, as 
determined by qRT-PCR, following 3 or 6 days of treatment with MeT or DHT (1 nM each) or a vehicle 
control. Expression of ERVs was normalized to GAPDH. Error bars are SEM; P values (treatment 
compared to vehicle) were determined using ANOVA and Dunnett’s multiple comparisons tests (*, p 
< 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). (C) Expression of ERV3-1 and HERV-K, as 
determined by qRT-PCR, following 3 days of treatment with MeT or DHT (1 nM each) or a vehicle 
control. Expression of ERVs was normalized to GAPDH. Error bars are SEM; statistical testing was as in 
(B). (D) Quantitation of cellular dsRNA by immunofluorescent staining with J2 monoclonal antibody 
following 72 hours of treatment with MeT, DHT or a DNMT inhibitor (DNMTi), Decitabine. Error bars 
are SEM; P values (treatment compared to vehicle) were determined using ANOVA and Dunnett’s 
multiple comparisons tests (****, p < 0.0001). (E) Representative images of J2 immunofluorescence. 
J2 signal, representing cellular dsRNA, is in green. Nuclei were counterstained with DAPI (blue).  
 
 




Supplementary Fig. 4. Induction of transposable element expression by methyl-testosterone. (A-B) 
Expression of LINE-I, as determined by qRT-PCR, following treatment with MeT or DHT in LNCaP (A) 
and C4-2B (B) cells. Expression of LINE-I was normalized to GAPDH. Error bars are SEM; P values 
(treatment compared to vehicle) were determined using ANOVA and Dunnett’s multiple comparisons 
tests (*, p < 0.05; **, p < 0.01). (C) Expression of HERV-E and HERV-W, as determined by qRT-PCR, 
following treatment with MeT or DHT in LNCaP cells. Expression of ERVs was normalized to GAPDH. 
Error bars are SEM; significance (treatment compared to vehicle) was determined using ANOVA and 
Dunnett’s multiple comparisons tests. (D) Expression of HERV-E and HERV-W, as determined by qRT-
PCR, following treatment with MeT or DHT in C4-2B cells. Expression of ERVs was normalized to 
GAPDH. Error bars are SEM; significance (treatment compared to vehicle) was determined using 
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Methyl-testosterone activates interferon signalling  
Induction of ERV transcription and accumulation of dsRNA can activate cellular responses 
similar to those elicited by infection with an exogenous virus, a phenomenon termed “viral 
mimicry” (Bannert, Hofmann et al. 2018). Given the ability of MeT to modulate ERV 
transcription and induce dsRNA, we speculated that it could cause a viral mimicry response. 
To test this hypothesis, we first measured mRNA levels of the cytosolic pattern recognition 
receptor (PRR) RIG-I (encoded by the DDX58 gene), which is a major sensor of dsRNA 
produced during viral infection. We observed induction of RIG-I in response to MeT and, to a 
lesser extent, DHT (Fig. 5A), which was confirmed by Western blotting (Fig. 5B). Another PRR 
involved in antiviral responses, STING, is best known for its role in sensing of cytosolic DNA 
but also serves as a detector of RNA viruses and can interact with RIG-I (Ni, Ma et al. 2018): 
similarly to RIG-I, STING was strongly upregulated by MeT in PCa cells (Fig. 5C). Downstream 
of PRRs, the mitochondrial antiviral signalling protein (MAVS) and TANK Binding Kinase 1 (TBK-
1) are required to activate innate immune anti-viral responses (Sun, Sun et al. 2006). As 
expected, MeT treatment increased the levels of MAVS mRNA and phosphorylated (active) 
TBK-1; DHT again caused analogous but blunted responses (Figs. 5C-D). Sensing of dsRNA by 
PRRs leads to activation of Type I IFN signalling (Gonzalez-Cao, Karachaliou et al. 2018). MeT 
treatment caused induction of IFN-β (encoded by IFNB1) as well as IRF3 and IRF7, 
transcription factors that can activate IFN expression (Fig. 5E). Upregulation of IFN signalling 
by MeT was also observed in an independent cell line model, C4-2B (Supplementary Fig. 5). 
Collectively, these findings reveal that MeT activates an anti-viral response, likely due to its 
ability to increase cellular levels of dsRNA. 
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Fig. 5. Methyl-testosterone activates an interferon-mediated anti-viral response. (A) Expression of 
RIG-I as determined by qRT-PCR following 3 or 6 days of treatment with the indicated doses of MeT 
or DHT or a vehicle control. Gene expression was normalized to GAPDH. Error bars are SEM; P values 
(treatment compared to vehicle at each time-point) were determined using ANOVA and Dunnett’s 
multiple comparisons tests (**, p < 0.01; ***, p < 0.001; ****, p < 0.0001). (B) Western blot showing 
RIG-I protein levels following treatment of LNCaP cells with the indicated doses of MeT or DHT or 
vehicle control for 3 or 6 days. GAPDH is shown as a loading control. (C) Expression of STING as 
determined by qRT-PCR following 3 or 6 days of treatment with the indicated doses of MeT or DHT or 
a vehicle control. Gene expression was normalized to GAPDH. Error bars are SEM. Statistical analysis 
was as for (A) (***, p < 0.001; ****, p < 0.0001). (D) Expression of MAVS as determined by qRT-PCR 
following 3 or 6 days of treatment with the indicated doses of MeT or DHT or a vehicle control. Gene 
expression was normalized to GAPDH. Error bars are SEM. Statistical analysis was as for (A) (*, p < 
0.05). (E) Western blot showing levels of total and phosphorylated TBK1 following treatment of C4-2B 
cells with the indicated doses of MeT or DHT or vehicle control for 3 or 6 days. GAPDH is shown as a 
loading control. (F) Expression of IFNβ and IRF7 as determined by qRT-PCR following 3 or 6 days of 
treatment with the indicated doses of MeT or DHT or a vehicle control. Gene expression was 
normalized to GAPDH. Error bars are SEM. Statistical analysis was as for (A) (*, p < 0.05; **, p < 0.01; 









































Supplementary Fig. 5. Induction of IFN signalling by methyl-testosterone in C4-2B cells. Expression 
of IFNβ (encoded by IFNB1), ISG15, IRF3 and IRF7, as determined by qRT-PCR, following treatment 
with MeT or DHT in C4-2B cells. Expression of genes was normalized to GAPDH. Error bars are SEM; P 
values (treatment compared to vehicle) were determined using ANOVA and Dunnett’s multiple 
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Association between AR activity and anti-viral responses in clinical prostate cancer  
Our mechanistic investigations using PCa cell lines suggested that high AR activity could 
activate a viral mimicry response involving IFN signalling. To gain evidence for this concept in 
a more clinically-relevant setting, we analysed large transcriptomic datasets from patients 
with primary prostate cancer (TCGA) and metastatic CRPC (SU2C). Supporting our pre-clinical 
mechanistic work, we found a significant correlation between AR activity and Reactome’s 
“antiviral mechanism by IFN-stimulated genes” gene set (Fig. 6A). Moreover, by exploiting a 
study in which ERVs were quantitated in TCGA samples (Rooney, Shukla et al. 2015), we 
discovered a strong positive correlation between AR activity and the expression of ERVs in the 
ERV3-1 and HERV-K classes (Fig. 6B). No association between AR signalling and HERV-E (r = 
0.079, p = 0.30) or HERV-W (r = -0.047, p = 0.54) classes was observed, corroborating our 
earlier findings that these classes of ERVs were not robustly induced by high dose androgen 










Fig. 6. Positive association between AR signalling and anti-viral responses in patient tumours. (A) AR 
activity, based on a 267-gene signature (Sowalsky, Ye et al. 2018), is associated with the Reactome 
“antiviral mechanism by IFN-stimulated genes” gene set in the TCGA (left) and SU2C (right) datasets. 
Activity scores were calculated using ssGSEA. P and r values were determined using Pearson’s 
correlation tests. (B) AR activity is associated with the levels of ERV3-1 (left) and HERVK in the TCGA 
dataset. AR activity scores were calculated using ssGSEA. Counts per million (CPM) reads for ERV3-1 
and HERVK (sum of all HERVK transcripts) were obtained from a published study (Rooney, Shukla et 
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Methyl-testosterone can enhance the interaction between prostate cancer cells and T cells 
IFN-mediated anti-viral defense signalling is associated with increased immunogenicity of 
solid tumours and improved responses to immune checkpoint therapy (Chiappinelli, Strissel 
et al. 2015, Stone, Chiappinelli et al. 2017, Topper, Vaz et al. 2017, Sheng, LaFleur et al. 2018, 
Morel, Sheahan et al. 2021). Indeed, we found that MeT treatment caused increased 
expression of MHC class I antigen processing and presentation genes over a period of 3-6 days 
(Fig. 7A). Moreover, AR activity was positively correlated with Class I (but not Class II: r = 0.003 
and p = 0.96 for TCGA; r = 0.174 and p = 0.06 for SU2C) MHC-mediated antigen processing 
and presentation in the TCGA and SU2C cohorts (Fig. 7B). 
 
To determine whether type I IFN-driven modulation of immune signalling in PCa in response 
to MeT influences T cell function, we utilised the murine RM1 model of CRPC (Owen, Gearing 
et al. 2020). We first confirmed that RM1 cells expressed AR (Fig. 7C) and were growth-
inhibited by MeT/DHT (Fig. 7D, Supplementary Fig. 6A), which collectively highlight the 
suitability of this model as a tool to understand the impact of high dose androgens on PCa 
biology. Mirroring the findings from human PCa cell lines, MeT increased expression of ERVs 
(murine ERV-L, MTA, RLTR1B and RLTR45), LINE-I elements, Rig-I and Irf7 in RM1 cells (Fig. 
7E). Despite DHT having equivalent growth-suppressive effects, it did not influence the 
expression of transposable elements, Rig-I or interferon pathway genes (Supplementary Fig. 
6B). We next used an ex vivo co-culture system to assess whether viral mimicry induced by 
MeT could lead to T cell activation. Whilst DHT-treatment had no effect on T cell response, 
MeT-treatment of RM1 cells increased the immunogenicity of RM1 cells, resulting in 
enhanced CD8+ T cell recognition and functional cytokine production (Fig. 7F). 
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Fig. 7. Methyl-testosterone elicits viral mimicry and enhances interferon-γ (IFN-γ) expression in T 
cells in a   mouse model of prostate cancer. (A) Expression of HLA genes and B2M as determined by 
qRT-PCR following 3 or 6 days of treatment with the indicated doses of MeT or DHT or a vehicle 
control. Gene expression was normalized to GAPDH. Error bars are SEM; P values (treatment 
compared to vehicle at each time-point) were determined using ANOVA and Dunnett’s multiple 
comparisons tests (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). (B) AR activity is 
associated with the Reactome “Class I MHC-mediated antigen processing and presentation” gene set 
in the TCGA (left) and SU2C (right) datasets. Activity scores were calculated using ssGSEA. P and r 
values were determined using Pearson’s correlation tests. (C) Western blot showing AR protein 
expression in RM1 cells following treatment with the indicated doses of MeT or vehicle control (in 
both full and charcoal-stripped media). GAPDH is shown as a loading control. (D) MeT suppresses the 
growth of RM1 cells, as determined by Sulforhodamine B colorimetric assay mean absorbance 
(550 nm) is shown at the indicated time-points; error bars are ± SEM. P values were determined using 
unpaired t tests at day 5 (***, p < 0.001; ****, p < 0.0001). (E) Expression of ERVs (Rltr1B, Rltr45, Erv-
L, Erv3 Mta), LINE-I, RIG-I IRF7 and ISG15 in RM1 cells as determined by qRT-PCR following 3 of 
treatment with the indicated doses of MeT. Gene expression was normalized to Hprt. Vehicle for each 
gene was set to 1. Error bars are SEM; P values (treatment compared to vehicle at each time-point) 
were determined using ANOVA and Dunnett’s multiple comparisons tests (*, p < 0.05; **, p < 0.01; 
***, p < 0.001; ****, p < 0.0001). (F) Intracellular cytokine staining (ICS) assay demonstrating IFN‐γ+ in 
CD8+ following activation by RM1 cells treated with indicated doses of MeT or DHT for 3 days. Vehicle 
control for each AR ligand was set to 1. Error bars are SEM; P values (treatment compared to vehicle 
at each time-point) were determined using ANOVA and Dunnett’s multiple comparisons tests (*, p < 




















Supplementary Fig. 6. Effects of DHT on RM1 murine model of prostate cancer. (A) DHT suppresses 
the growth of RM1 cells, as determined by Sulforhodamine B colorimetric assay Mean absorbance 
(550 nm) is shown at the indicated time-points; error bars are ± SEM. P values were determined using 
unpaired t tests at day 5 (***, p < 0.001). (B) Expression of ERVs (Rltr1B, Rltr45, Erv-L, Erv3 Mta), LINE-
I, RIG-I IRF7 and ISG15 in RM1 cells as determined by qRT-PCR following 3 of treatment with the 
indicated doses of MeT. Gene expression was normalized to Hprt. Vehicle for each gene was set to 1. 
Error bars are SEM; P values (treatment compared to vehicle at each time-point) were determined 
using ANOVA and Dunnett’s multiple comparisons tests (no significant differences for any transcripts 
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DISCUSSION 
Although the mainstay treatment for advanced prostate cancer relies on suppression of AR 
activity, there is accumulating evidence that potent activation of AR by treating CRPC patients 
with high doses of testosterone can also be of therapeutic benefit. The molecular mechanisms 
underlying this apparent paradox remain to be fully elucidated. Here, by using a synthetic and 
highly potent androgen, MeT, we provide new insights into the consequences of hyper-
activation of AR in PCa.   
 
Molecular dissection of AR activity revealed that MeT elicits remarkably similar activity to DHT 
in terms of qualitative effects on the transcriptome and AR cistrome. Strikingly, however, 
MeT’s effect on transcription was considerably stronger than DHT’s for almost every AR-
regulated gene and when evaluated by transcriptional activation assays using a synthetic 
androgen-responsive reporter gene, the latter observation being consistent with previous 
work (Wolf, Diel et al. 2011). The potency of MeT was manifested by robust regulation of DNA 
damage/repair and replication pathways and gene sets that are known to respond to high 
doses of T and DHT and have been purported to (at least partly) underpin growth suppression 
and cell death caused by high dose androgen treatment (Gao, Gao et al. 2016, Chatterjee, 
Schweizer et al. 2019, Nyquist, Corella et al. 2019). Interestingly, despite strong down-
regulation of DNA repair genes, we did not observe increased staining of the DNA damage 
marker γH2AX in response to MeT. Increased DNA damage has been purported to be a 
mechanism by which high dose androgens cause cell death (Chatterjee, Schweizer et al. 
2019), synergise with agents that inhibit DNA repair (Chatterjee, Schweizer et al. 2019) and 
elicit therapeutic responses in PDXs (Lam, Nguyen et al. 2020) or patients with defective 
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homology-directed repair (HDR) (Teply, Kachhap et al. 2017, Markowski, Shenderov et al. 
2020). This concept has led to a prevailing belief that HDR gene defects could be useful 
predictive biomarkers of BAT (Chatterjee, Schweizer et al. 2019) and that combining BAT with 
DNA damaging therapies, such as radiotherapy (e.g. NCT04704505), is a rational therapeutic 
strategy. By contrast, other studies failed to detect heightened DNA damage in response to 
high doses of physiological or synthetic (i.e. R1881) androgens (Polkinghorn, Parker et al. 
2013), and a recent analysis of BAT clinical trials failed to demonstrate improved progression-
free survival in patients with HDR gene defects (Schweizer, Antonarakis et al. 2019). We 
propose that definitively establishing the relevance of DNA damage, as a mediator of 
therapeutic response to androgen therapies (including MeT) is imperative to maximise clinical 
impact. Interestingly, in our experiments low dose (1 nM) but not high dose (100 nM) DHT 
resulted in a significant increase in DNA damage. Since 1 nM DHT did not substantially impact 
on PCa cell proliferation, this also argues against DNA damage being important in androgen-
mediated growth suppression.      
 
In addition to its effects on DNA replication and repair pathways, our data revealed that MeT 
caused a major shift in the expression profile of TEs, including ERVs such as ERV3-1 and HERV-
K. This occurred concomitantly with down-regulation of DNMT enzymes, including DNMT and 
DNMT3b, and loss of DNA methylation at LINE-I elements. Given the well-established role of 
DNA methylation is suppressing the expression (and mobility) of ERVs and other TEs (Reik 
2007), we propose that inhibition of DNMTs is a key mechanism underlying our observation. 
A negative association between the expression/activity of AR and DNMTs has been reported 
previously (e.g. (Chu, Chang et al. 2014)), but the molecular underpinnings of this 
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phenomenon are not known. One plausible explanation is that hyper-active AR decreases 
DNMT expression via its interplay with Rb and E2F. More specifically, it has been reported 
that high dose androgen treatment leads to AR and Rb binding to, and transcriptionally 
repressing, a series of E2F-regulated genes involved in DNA replication (Gao, Gao et al. 2016), 
a finding that we recapitulated with MeT. Since DNMT1 is a well-established target of E2F 
(Kimura, Nakamura et al. 2003, McCabe, Davis et al. 2005), it is reasonable to expect that it 
would be down-regulated by AR-mediated perturbation of the Rb/E2F1 axis. Such a 
mechanism is reminiscent of an earlier study demonstrating that the CDK4/6 inhibitor 
abemaciclib reduces E2F activity and thereby decreases DNMT1 expression (Goel, DeCristo et 
al. 2017). 
 
Upregulation of ERVs can result in accumulation of cellular dsRNA (Chiappinelli, Strissel et al. 
2015), which is sensed by PRRs (i.e. RIG-I, STING) that signal via MAVS/TBK-1 to activate IFN 
signalling. We propose that this “viral mimicry” response is a key mechanism by which MeT 
activates IFN, although we cannot rule out the possibility that host lncRNAs and/or microRNAs 
induced by MeT play a role in RIG-I activation, as has been described recently (Rehwinkel and 
Gack 2020). Viral mimicry is thought to be an important mediator of tumour innate immunity 
in response to epigenetic therapies such as DNMT inhibitors, histone deacetylate inhibitors, 
CDK4/6 inhibitors and EZH2 inhibitors (Chiappinelli, Strissel et al. 2015, Roulois, Loo Yau et al. 
2015, Goel, DeCristo et al. 2017, Krug, De Jay et al. 2019, Morel, Sheahan et al. 2021). In 
support of this, we demonstrated that MeT enhanced the immunogenicity of murine PCa cells 
leading to increased T cell responses in a co-culture system, providing in vitro evidence that a 
viral mimicry response induced by this androgen could modulate the tumour immune 
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microenvironment. A limitation of this experiment is that we only measured IFN‐γ in T cells, 
and hence it is unknown whether the viral mimicry response induced by MeT leads to cancer 
cell killing by T-cells. We propose to test whether MeT leads to increased cytotoxic T cell 
mediate cancer cell killing using IncuCyte immune cell killing assays in co-culture condition 
(Cichocki, Bjordahl et al. 2020, Granger and Appledorn 2021). 
 
PCa is recognised as an immunologically “cold” cancer type based on its tumour 
microenvironment (i.e. few infiltrating cytotoxic T cells and a predominance of 
immunosuppressive cells, such as regulatory T cells and M2 macrophages), low 
immunogenicity and down-regulation of MHC Class I antigen processing/presenting 
machinery in tumour cells (de Almeida, Fong et al. 2020). These characteristics likely explain 
the limited impact of immunotherapies in this disease to date (de Almeida, Fong et al. 2020). 
A cellular immunotherapy, Sipuleucel-T, is approved for men with mCRPC but only confers a 
survival benefit of ~4 months (Kantoff, Higano et al. 2010). Similarly, multiple trials of immune 
checkpoint inhibitors (ICIs) have failed to demonstrate overall survival benefits (de Almeida, 
Fong et al. 2020), although some patients have experienced extraordinary responses to this 
treatment strategy (Graff, Alumkal et al. 2016, Markowski, Shenderov et al. 2020). With this 
background in mind, there is considerable interest in developing combinatorial treatment 
strategies that would sensitize CRPC tumours to immunotherapy. Our study found that MeT 
enhanced expression of MHC Class I genes and increased T cell cytotoxicity, suggesting that 
this regulator of viral mimicry could increase tumour cell immunogenicity, which is critical to 
improve response to ICIs. In support of this concept, a recent study found that inhibition of 
EZH2 activated a dsRNA–STING–IFN stress response that increased intratumoral trafficking of 
 
126 | P a g e  
 
activated CD8+ T cells and sensitized PCa cells to PD-1 checkpoint blockade (Morel, Sheahan 
et al. 2021). Moreover, there is evidence that both AR activation (i.e. BAT) and AR inhibition 
(i.e. Enzalutamide) could sensitize tumours to PD-1 inhibitors, albeit in very small studies 
(Graff, Alumkal et al. 2016, Markowski, Shenderov et al. 2020). Whether response to ICIs in 
patients previously treated with BAT is a result of viral mimicry is an enticing possibility that 
warrants further investigation, either using pre-clinical models and/or by molecular analysis 
of samples from patients being treated by BAT/ICI in ongoing clinical trials (e.g. COMBAT-
CRPC, NCT03554317). 
 
Immunological priming by BAT has been hypothesised to be a consequence of androgen-
mediated DNA damage, which can be sensed by the dsDNA sensor protein cGAS that can in 
turn activate IFN signalling (Markowski, Shenderov et al. 2020). At least 2 lines from our study 
of evidence suggest that this hypothesis should be modified to consider dsRNA as an 
alternative trigger of IFN signalling. First, MeT (and to a lesser extent DHT) induced ERVs, RIG-
I and MAVS and caused accumulation of dsRNA. Second, we did not observe increased DNA 
damage – using γH2AX as a molecular marker of DNA damage - in response to MeT or high-
dose DHT (100 nM) in LNCaP cells. However, it must be noted that the absence of γH2AX foci 
does not preclude MeT-mediated DNA damage, nor did we specifically measure cytoplasmic 
DNA. Additionally, STING, which is traditionally thought of as a sensor of cytoplasmic DNA, 
was strongly induced by MeT, although it must be noted that emerging evidence suggests 
that this factor also plays a key role in dsRNA-based immune responses (Ni, Ma et al. 2018, 
Morel, Sheahan et al. 2021). In short, it is plausible that the multifactorial impact on 
transcription and genome organisation caused by MeT (or high doses of DHT/T) would result 
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in both dsRNA accumulation and DNA damage, both of which could elicit viral mimicry and 
IFN signalling.  
 
An important question that still needs to be addressed is whether, and to what extent, 
activation of IFN signalling contributes to MeT-mediated suppression of PCa cell growth. Type 
I IFNs can elicit cell cycle arrest and apoptosis in malignant cells (Kotredes and Gamero 2013), 
therefore it is possible that induction of this pathway at least partly explains the efficacy of 
MeT. However, MeT (and high doses of T/DHT) cause growth suppression within 1-2 days, 
whereas we observed induction of IFNβ and IRF7 3-6 days after treatment, an observation 
that is consistent with a stepwise activation of IFN involving epigenomic remodelling, ERV 
transcription and sensing of dsRNA. Moreover, growth suppression of RM1 cells by MeT and 
DHT was equivalent, even though the latter hormone did not induce ERVs or the IFN pathway. 
These observations argue against viral mimicry and IFN pathway activation playing a major 
role in the growth-inhibitory effects of MeT, at least when PCa cells are grown in vitro. Future 
in vivo studies carried out in the context of antagonism or ablation of viral mimicry effectors 
(e.g. RIG-I, IFNβ) could resolve this outstanding question. 
 
A consistent finding throughout our study was that MeT exhibited greater potency – in terms 
of PCa cell growth inhibition, AR DNA binding and transcriptional activity, and viral mimicry 
responses – than DHT. MeT has been reported to have reduced affinity, when compared to 
DHT, for both the rat AR ligand-binding domain (Fang, Tong et al. 2003, Attardi, Hild et al. 
2006) and cytosolic fractions from rat prostate (Saartok, Dahlberg et al. 1984). However, the 
main pathway for metabolism of testosterone and its derivatives in PCa cells is via 
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glucuronidation (Smith, Ballard et al. 1994), and MeT is very poorly glucuronidated by human 
glucuronyl-transferases (Kuuranne, Kurkela et al. 2003). With these early biochemical studies 
in mind, we propose that the stronger androgenic effects elicited by MeT relate to its 
increased stability compared to DHT. Moreover, we hypothesise that the increased potency 
of MeT, as opposed to a differential mode of action, explains why activation of IFN has not 
been observed in previous studies aimed at dissecting the mode of action of high dose DHT 
and other androgens (i.e. R1881) (Chatterjee, Schweizer et al. 2019, Nyquist, Corella et al. 
2019). This hypothesis is supported by the observation that DHT elicited effects on ERVs, 
dsRNA production and IFN signalling that were qualitatively analogous to those mediated by 
MeT but were in almost all cases weaker. In short, we postulate that a certain threshold of AR 
activation, in terms of both strength and duration, is required to activate a viral mimicry 
response and that such a threshold can be more readily reached with stable synthetic 
androgens such as MeT.   
 
Whether MeT could be harnessed as a therapeutic for advanced PCa, either as a monotherapy 
or in combination with immunotherapy, is an intriguing question. PCa is an immunologically 
“cold” cancer but it is possible that a MeT-induced viral mimicry response could increase 
tumour cell immunogenicity, which is critical to improve response to ICIs. In support of this 
concept, it has been shown that a small subset of patients treated with BAT showed an 
extreme response to immune checkpoint blockade (Markowski, Shenderov et al. 2020). 
Further evidence for this concept comes from our observation of a positive association 
between AR activity and anti-viral responses in patients with primary or metastatic tumours. 
As shown in Figure 6A, the correlation between AR activity and IFN response is stronger in 
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localised disease compared to CRPC, which we propose simply reflects the more homogenous 
nature of localised PCa in comparison with CRPC tumours.  
 
Current medical recommendations suggest that MeT should be explicitly avoided in men with 
PCa but these are based on the viewpoint that androgens promote tumour progression, which 
is overly simplistic in the era of SupraT/BAT as a rational, valid treatment for CRPC. As an 
anabolic-androgenic steroid, MeT has a range of medical uses, including to treat delayed 
puberty in males (Bertelloni, Baroncelli et al. 2010), as a component of post-menopausal 
hormone replacement therapy in women (Chiuve, Martin et al. 2004) and, historically, as a 
treatment for breast cancer (Nevinny-Stickel, Dederick et al. 1964); as such, its 
pharmacodynamic, pharmacokinetic and safety profiles are relatively well understood. 
Drawbacks of MeT include high estrogenicity, due to its efficient aromatization into the 
potent and stable estrogen 17α-methylestradiol (El-Desoky el, Reyad et al. 2016) and 
hepatotoxicity (Sanchez-Osorio, Duarte-Rojo et al. 2008). Of course, other AR ligands may be 
even more effective than MeT in terms of growth suppression and modulation of immune 
responses. In this respect, selective AR modulators (SARMs) are of interest (Christiansen, 
Lipshultz et al. 2020) since it is conceivable that some may possess the requisite androgenic 
anti-growth and immunomodulatory activities in prostate cancer cells and favourable 
anabolic properties in other tissues. In short, we propose that investigation beyond the 
physiological androgens testosterone and DHT is required to maximise the therapeutic 
potential of AR activation in PCa.  
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In summary, our investigations have revealed a novel consequence of potent activation of AR 
in PCa cells. We propose that this work will expose new avenues of research aimed at 
elucidating interplay between androgenic and immune responses in the prostate and 
facilitate the development of new hormonal strategies to sensitize PCa to immunotherapies. 
 
MATERIALS AND METHODS 
Cell lines and cell culture 
The human prostate carcinoma cell lines LNCaP, VCaP, PC3, 22Rv1 and C4-2B were obtained 
from the American Type Culture Collection (ATCC). LNCaP-V16D, LNCaP-MR49F and CWR-R1-
D567 have been described previously (Nyquist, Li et al. 2013, Bishop, Thaper et al. 2017). C4-
2B, 22Rv1, LNCaP, and LNCaP-V16D cells were maintained in RPMI-1640 (Sigma Aldrich) 
containing 10% fetal bovine serum (FBS) and 2 mM L-Glutamine. PC3 cells were cultured in 
RPMI-1640 containing 5% FBS and 2 mM L-Glutamine. LNCaP-MR42D and LNCaP-MR49F were 
maintained in RPMI-1640 containing 10% FBS, 10 µM Enzalutamide and 2 mM L-Glutamine. 
CWR-R1-D567 cells were maintained in RPMI-1640 containing 10% charcoal-stripped serum 
(CSS) and 2 mM L-Glutamine. VCaP cells were maintained in DMEM (high glucose) containing 
10% FBS, 2 mM L-Glutamine, 2 mM Sodium Pyruvate, and 2 mM of non-essential amino acids 
solution (Sigma Aldrich). All cell lines were authenticated by short tandem repeat profiling by 
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Cell viability assays 
Cells were seeded at varying densities (depending on the doubling time of cell lines and length 
of the proliferation assay) in 6-well plates and incubated at 37 °C and 5% CO2 for at least 24 
hours to allow cells to be attached to the plate surface before treatment. At the appropriate 
timepoints, cells were treated with freshly prepared drugs (as indicated in Fig. legends), 
followed by incubation at 37 °C and 5% CO2 until next time-point. Treatments were refreshed 
every 2–3 days. At the end of each time-point, cell viability was assessed using Trypan blue 
exclusion assays. The impact on MeT (1 nM and 100 nM) on the proliferation of RM1 cells was 
assessed in a 96-well format using the sulforhodamine B-binding assay over 5 days with a 
seeding density of 500 cells per well, as described previously (Houghton, Fang et al. 2007). 




AR transactivation assays were performed in 96-well plates essentially as previously described 
(Buchanan, Yang et al. 2004). LNCaP cells were used to test the transactivation of endogenous 
AR, whereas PC-3 cells were used to test the transactivation of exogenous AR. Cells were 
transfected with 1 ng of pcDNA-AR (PC3 only) and 100 ng of a reporter construct containing 
3 copies of the Probasin enhancer (pGL4.14-PB3-luc) using LipofectAMINE 2000 (GIBCO-BRL), 
according to the manufacturer's instructions. Following transfection, cells were treated for 24 
h in phenol-red free medium supplemented with the different doses of MeT and DHT, and 
luciferase activity was determined in cell lysates using the Luciferase™ Reporter Gene Assay 
Kit (Promega) and a plate reading luminometer (Top Count). 
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Chromatin immunoprecipitation (ChIP)-sequencing 
LNCaP cells were seeded at 5 × 106 cells/plate in 15 cm plates phenol-red-free medium 
supplemented with 5% DCC-stripped FBS and allowed to grow for 2 days prior to treatment 
with Vehicle (Ethanol), MeT 1nM, and DHT 1nM on 3 biological replicates each for 4 hours. 
Subsequently, cells were fixed with formaldehyde and chromatin immunoprecipitation (ChIP) 
was performed essentially as described previously (Paltoglou, Das et al. 2017) using an Abcam 
AR antibody (ab108341). For each treatment condition, 2 biological replicates were 
generated. After DNA quantification with Qubit dsDNA HS assay (Thermo-Fisher Scientific), 5 
ng of ChIP DNA (ChIP-enriched or input) was used for library preparation using a TruSeq ChIP 
Library Prep kit (Illumina). Sequencing was performed on an Illumina Nextseq 500 platform 
(single-end protocol, 75 bp read length) at the South Australian Genomics Centre (SAGC). 
Mapping and processing of fastq files were performed as described previously (Chan, Selth et 
al. 2015). Deeptools (Ramírez, Ryan et al. 2016) was used to convert BAM files to bigwig and 
for visualizing ChIP-seq data as heatmaps. Peak annotations were performed using Cisgenome 
v2.0 (Ji, Jiang et al. 2008). HOMER (Heinz, Benner et al. 2010) was used to generate histograms 
of tag density at specific sets of peaks. Alignments were visualised and interrogated using the 
Integrative Genomics Viewer v2.3.80 (Thorvaldsdóttir et al., 2013). 
 
RNA sequencing 
LNCaP were seeded at the 2x105 cells/well in 6-well plates and treated with vehicle, 1 nM 
MeT or 1 nM DHT. Total RNA was extracted at 6 hours and 24 hours after treatment using 
Trizol. For each treatment condition, 3 biological replicates were generated. The integrity of 
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RNA was first assessed using a 2100 Bioanalyzer system (Agilent). RNA concentration were 
quantified by Nanodrop 2000 (Thermo Fisher Scientific) and total RNA (2 µg) was supplied to 
the South Australian Genomics Centre (SAGC). RNA sequencing libraries were constructed 
using a TruSeq Total RNA HT kit (Illumina) and libraries were sequenced on the Illumina 
NextSeq 500 platform (stranded, paired-end 75 bp reads).  
 
The quality of raw data was initially assessed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Raw FASTQ files were then 
filtered for short sequences using Cutadapt v1.16.6 (Martin 2011) with the following settings:  
minimum overlap length in Adaptor options: 3, Minimum length in filter options: 20, 
maximum error rate: 0.1, quality cut-off: 20.  
 
To evaluate expression of protein-coding genes, reads were mapped against the human 
reference genome (hg19) using STAR version 2.6.0b-2 (Dobin, Davis et al. 2013) with default 
parameters. FeatureCounts was used to count and assign the mapped reads to genomic 
features (Liao, Smyth et al. 2014). Count tables generated by featureCounts were used for 
differential expression analysis using R version 3.2.3 and edgeR version 3.3 (Robinson, 
McCarthy et al. 2010) as described previously (Lun, Chen et al. 2016). Heatmaps summarising 
RNA-seq data were generated  using ClustVis (Metsalu and Vilo 2015).  
 
To evaluate expression of transposable elements (TEs), reads were re-mapped against the 
human reference genome (hg19) using STAR version 2.6.0b-2 (Dobin, Davis et al. 2013) with  
parameters that retained multiply mapped reads (--runThreadN 4 --outSAMtype BAM 
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SortedByCoordinate --runMode alignReads --outFilterMultimapNmax 1000 --
outFilterMismatchNmax 3 -- outMultimapperOrder Random --winAnchorMultimapNmax 
1000 --alignEndsType EndToEnd --alignIntronMax 1 --alignMatesGapMax 350). HOMER was 
used to count and assign the mapped reads to different families of TEs (LTR, LINE and SINE). 
Count tables generated by HOMER were used to make a PCA plot with ClustVis.  
 
Gene set enrichment analysis 
Genes were ranked according to expression using the Signal2Noise metric. Gene Set 
Enrichment Analysis (Preranked analysis) (Subramanian, Tamayo et al. 2005) was 
implemented using the Broad Institute’s public GenePattern server with default parameters.  
 
Flow cytometry for cell cycle analysis 
LNCaP cells were seeded in 6-well plates and incubated overnight at 37°C and 5% CO2. Three 
days after treatment, cells were washed with a freshly prepared wash buffer containing PBS 
with 2% FBS, followed by trypsinization. The cell suspension was added to a 5 ml FACS tube 
containing cell culture media that had been collected earlier. Tubes were centrifuged at 700 
g for 5 min and cell pellets were re-suspended and washed with 1ml PBS, followed by 
centrifugation at 700 g for 5 minutes. After removing supernatants, cell pellets were 
resuspended in residual liquid by flicking the tubes. Subsequently, 1ml ice-cold 70% EtOH in 
PBS was added into tubes containing the cell suspensions and fixed overnight at 4°C. 
Following cell fixation, cells were centrifuged at 700 g for 5 minutes and the cell pellets were 
washed twice with 1 ml Hanks' Balanced Salt Solution + 2% FBS. Cell were then stained with 
1 ml of DAPI (10 µg/mL). The prepared cell suspension was used for cell cycle analysis based 
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on DNA content using a BD FACSCanto II flow cytometer (Analyser); analysis was carried out 
using FlowJo software. 
 
Quantitative RT-PCR (qRT-PCR) analysis of mRNA from human cells 
Total RNA from human cell lines was extracted using TRI Reagent (Sigma), as described 
previously (Das, Gregory et al. 2017). Total RNA was treated with Turbo DNA-free kit 
(Invitrogen), and reverse transcribed using iScript Reverse Transcriptase Supermix kit (Bio-
Rad). PCR was done in triplicate using a CFX384TM Real-Time System, as described previously 
(Moore, Buchanan et al. 2012). Levels of GAPDH were used for normalization of qRT-PCR data. 
Primer sequences are listed in Table S1. 
 
Quantitative RT-PCR (qRT-PCR) analysis of mRNA from mouse cells 
mRNA was extracted using the Qiagen Rneasy Plus Mini Kit (Qiagen) according to the 
manufacturer’s instructions and reverse transcribed using iScript Reverse Transcriptase 
Supermix cDNA for qRT-PCR kit (Bio-Rad). qRT-PCR was performed using PowerUp SYBR 
Green Master Mix (applied biosystems) to quantify gene expression on the CFX384TM Real-
Time System (Bio-Rad) as described previously (Owen, Gearing et al. 2020). Gene expression 
(arbitrary units) was calculated as mean relative transcript abundance (RTA) by methods 
outlined previously (Bidwell, Slaney et al. 2012) and expressed relative to a housekeeping 
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Western blotting  
Protein extraction from cells using RIPA buffer (human cell lines) or hypotonic lysis buffer (RM1) and 
Western blotting was done essentially as described previously (Moore, Buchanan et al. 2012). Primary 
antibodies used in human Western blotting were: TBK1 Antibody (Cell Signalling; 3013); phospho-
Ser172-TBK1 (Cell Signalling; D52C2); RIG-I (Santa Cruz; SC-376845); and GAPDH (Millipore, MAB374). 
Primary antibodies used in murine Western blotting were: AR (N-20; Santa Cruz; SC-816) and GAPDH 
XP (Cell Signaling; D16h11). HRP conjugated anti-rabbit and anti-mouse IgG secondary antibodies 
(Dako) were used and immunoreactive bands visualized using Clarity Western ECL Substrate (Bio-Rad). 
 
Immunofluorescence  
LNCaP cells were seeded on glass coverslips in 6-well plates. To improve cell adhesion, glass 
coverslips were coated with 1:8 diluted L-Poly-Lysine. After treatment, cells were fixed in 4% 
paraformaldehyde for 10 minutes, permeabilized in 0.1% Triton X-100 for 15 minutes, and 
blocked in 2.5% BSA (for phospho-Histone H2A.X) or 5% BSA (for J2) solution for 1 hour. The 
coverslips then were incubated with anti-γH2AX primary antibody (Millipore; 05-636) or J2 
antibody (both used at 1:1000) overnight at 4 °C, followed by washing (twice with 5 min 
intervals) and then incubation with a fluorescent-tagged secondary antibody for 1 hour at 
room temperature. Cell nuclei were visualised by co-staining the cells with 4´-6-Diamidino-2-
phenylindole (DAPI; Invitrogen) for 1 min. Imaging was carried out using a confocal 
microscope (Olympus FV3000 Confocal Microscope). To quantify the number of γH2AX foci 
per nucleus, images were analysed using Image J software: i) the number of cells (i.e. DAPI-
stained nuclei) were counted in each image by Analyze Particles tool; ii) the number of γH2AX 
foci in each image was quantified using the Find Maxima tool, which was performed using the 
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noise tolerance parameter adjusted for positive control; iii) the average number of foci per 
nucleus for each treatment was calculated by counting γH2AX foci from 70-150 cells per 
treatment across multiple microscope fields.  To quantify J2 signal, Image J (Schneider, 
Rasband et al. 2012) was used to measure signal intensity at regions of interest (ROI); total 
signal intensity was normalised to cell counts at each ROI.  
Quantification of LINE-I DNA Methylation  
Cells were grown and treated in 6-well plates and genomic DNA was isolated using QIAamp 
DNA Mini kits, according to the manufacturer's instructions. To quantify the DNA methylation 
in DNA samples, Global DNA Methylation-LINE-I Kits (Active Motif) were used to assess the 
methylation of 5-mC status at Long Interspersed Nucleotide Element 1 (LINE-I) elements, as 
specified by the manufacturer. 
 
Intracellular cytokine staining for T‐cell specificity 
For assessment of androgen effects on antigen presentation in cancer cells, RM1 cells were 
treated with MeT, DHT or vehicle control as previously described. Following 72 hrs, RM1 cells 
(5×104) were co-cultured with in vitro expanded RM1‐specific CD8+ T cells for 5 hrs in the 
presence of 10 µg/mL Brefeldin A. Intracellular cytokine staining assays for production of IFN‐
γ were carried out as previously described (Owen, Gearing et al. 2020). 
 
 
Analysis of prostate cancer clinical transcriptomic data 
Clinical transcriptomic datasets (TCGA (Abeshouse, Ahn et al. 2015) and SU2C (Robinson, Van 
Allen et al. 2015)) were downloaded from cBioportal (Gao, Aksoy et al. 2013). The activity of 
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AR signalling and other pathways (i.e. antiviral mechanism by IFN-stimulated genes, MHC 
class I antigen processing and presentation) in these datasets was estimated by single sample 
GSEA (ssGSEA) (Barbie, Tamayo et al. 2009); ssGSEA was implemented using the Broad 
Institute’s public GenePattern server, using rank normalisation and default parameters.  
 
Statistical analysis 
Statistical analyses for grouped quantitative data were carried out using two-tailed unpaired 
t-test or ANOVA (GraphPad Prism 9). The relationships between activity scores were 
determined using Pearson’s correlation coefficient (Graphpad Prism 9). Further details of 
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Supplementary Data1.  
A) MeT vs Vehicle 
 
No gene_id logFC logCPM LR PValue FDR 
1 KLK3 1.102505 12.20737 308.6007 4.41E-69 1.87E-67 
2 DHCR24 1.013861 11.28665 246.4704 1.53E-55 4.95E-54 
3 TUBB -1.14484 11.22334 344.2626 7.53E-77 3.77E-75 




5 TUBA1B -1.02658 10.47486 150.4516 1.38E-34 2.46E-33 
6 KRT18 1.933156 10.33859 567.1592 2.33E-125 2.39E-
123 
7 ABHD2 1.056565 10.32729 165.8682 5.91E-38 1.16E-36 
8 SORD 1.524395 10.12226 722.6912 3.48E-159 5.81E-
157 
9 TMPRSS2 1.9133 10.07856 889.5421 1.84E-195 5.66E-
193 
10 ODC1 1.919991 9.933507 959.7237 1.02E-210 3.52E-
208 
11 BRP44 1.025034 9.9108 132.7389 1.03E-30 1.61E-29 
12 ATP1A1 1.083749 9.856039 378.8471 2.22E-84 1.34E-82 
13 FKBP5 2.826146 9.752285 1374.943 5.85E-301 9.50E-
298 
14 SLC45A3 1.794352 9.685641 692.9592 1.02E-152 1.44E-
150 
15 ACSL3 2.530338 9.582629 990.3053 2.30E-217 9.01E-
215 
16 SPDEF 1.81474 9.384326 542.9447 4.31E-120 4.15E-
118 
17 CENPN 1.577379 9.320023 686.6329 2.41E-151 3.30E-
149 
18 ELOVL5 1.175085 9.248209 224.8435 7.94E-51 2.31E-49 
19 KLK2 1.68128 9.239738 551.3755 6.32E-122 6.25E-
120 
20 ABCC4 1.138322 9.135198 170.3646 6.16E-39 1.27E-37 
21 UAP1 1.075357 9.142776 369.5943 2.29E-82 1.32E-80 
22 COPG1 1.079653 9.135934 351.0871 2.46E-78 1.28E-76 
23 DBI 1.346483 9.101579 226.7449 3.06E-51 9.05E-50 
24 PEX10 1.45545 9.027251 442.5256 3.05E-98 2.21E-96 
25 SSR2 1.130174 9.028995 167.2236 2.99E-38 5.99E-37 
26 GDF15 1.246685 8.914849 279.276 1.08E-62 3.96E-61 
27 PPAP2A 1.767033 8.874552 822.3957 7.29E-181 1.97E-
178 
28 HM13 1.006956 8.816252 257.3113 6.62E-58 2.24E-56 
29 MIA3 1.093211 8.716466 242.8354 9.47E-55 3.02E-53 
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30 SLC41A1 2.693377 8.666302 1377.688 1.48E-301 2.81E-
298 
31 NDRG1 3.390736 8.62771 2448.34 0 0 
32 RRBP1 1.016748 8.673835 219.8926 9.55E-50 2.68E-48 
33 C17orf28 1.257265 8.646756 316.6161 7.91E-71 3.48E-69 
34 APP 1.034228 8.639645 174.5952 7.34E-40 1.54E-38 
35 TRPM4 1.215836 8.641616 243.4252 7.04E-55 2.26E-53 
36 SLC39A7 1.04882 8.640004 305.2606 2.35E-68 9.76E-67 
37 MAP7D1 1.082256 8.637467 229.6355 7.16E-52 2.14E-50 
38 SMS 2.166353 8.558071 1116.133 1.03E-244 6.50E-
242 
39 NCAPD3 2.267871 8.563809 785.0907 9.41E-173 2.15E-
170 
40 ABCC1 1.147796 8.538649 182.54 1.35E-41 2.99E-40 
41 PMEPA1 1.11535 8.391103 342.0117 2.33E-76 1.14E-74 
42 CORO1B 1.425981 8.376904 447.3255 2.76E-99 2.01E-97 
43 H2AFX -2.20271 8.459112 653.4829 3.91E-144 4.99E-
142 
44 SCAP 1.273117 8.345523 332.9503 2.19E-74 1.03E-72 
45 SLC9A3R2 1.002723 8.347771 192.8273 7.68E-44 1.82E-42 
46 ARF4 1.032718 8.209469 223.9967 1.22E-50 3.49E-49 
47 CREB3L4 1.261963 8.198118 334.1976 1.17E-74 5.57E-73 
48 PACS1 1.984219 8.161179 785.0768 9.48E-173 2.15E-
170 
49 TBRG1 1.002711 8.188979 329.6456 1.15E-73 5.30E-72 
50 CAPZB 1.40817 8.153803 400.5794 4.12E-89 2.72E-87 
51 MLPH 1.392538 8.15998 431.327 8.36E-96 5.97E-94 
52 TPD52 1.212396 8.161516 161.0796 6.57E-37 1.25E-35 
53 SERP1 1.173807 8.131943 203.6154 3.40E-46 8.59E-45 
54 MCM7 -2.19755 8.226906 1113.188 4.49E-244 2.69E-
241 
55 MBOAT2 1.139948 8.12853 357.0327 1.25E-79 6.71E-78 
56 SLC50A1 1.091445 8.081225 197.1609 8.70E-45 2.11E-43 
57 BAIAP2 1.104676 8.073449 281.5848 3.39E-63 1.26E-61 
58 ECI2 1.115146 8.068436 275.6245 6.75E-62 2.42E-60 
59 PRKDC -1.1474 8.09885 125.4546 4.05E-29 5.94E-28 
60 MICAL1 3.059149 8.011749 1554.8 0 0 
61 SAT1 2.303927 7.935712 1025.171 6.07E-225 2.55E-
222 
62 SSR3 1.011443 7.960082 177.1866 1.99E-40 4.26E-39 
63 GLUD1 1.262113 7.952331 417.6326 7.99E-93 5.51E-91 
64 B2M 1.47189 7.95434 233.8719 8.53E-53 2.64E-51 
65 HMGXB3 1.139274 7.964506 299.9471 3.38E-67 1.36E-65 
66 TMED9 1.202777 7.943769 335.741 5.40E-75 2.58E-73 
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67 SERINC2 1.072148 7.951807 202.9951 4.64E-46 1.17E-44 
68 NANS 1.015961 7.925586 215.8399 7.31E-49 1.99E-47 
69 ANKH 1.285997 7.921012 535.9416 1.44E-118 1.38E-
116 
70 TACC3 -1.35228 7.958916 356.1131 1.98E-79 1.05E-77 
71 VPS26B 1.615397 7.865412 616.6265 4.05E-136 4.47E-
134 
72 CHPF 1.246516 7.86973 230.7004 4.19E-52 1.26E-50 
73 HERC3 1.180985 7.824053 150.1779 1.59E-34 2.82E-33 
74 KPNA2 -1.66235 7.896057 632.5545 1.39E-139 1.68E-
137 
75 TNFRSF10B 1.020375 7.780281 233.4449 1.06E-52 3.26E-51 
76 HEBP2 1.10033 7.754269 227.2638 2.36E-51 7.01E-50 
77 MYC -1.56335 7.759253 519.0624 6.77E-115 6.11E-
113 
78 TPM1 1.073725 7.72101 302.3249 1.03E-67 4.20E-66 
79 MKI67 -2.67576 7.768959 714.567 2.03E-157 3.16E-
155 
80 MTOR 1.122382 7.6254 138.3406 6.14E-32 1.01E-30 
81 FN1 -1.19125 7.680013 156.4909 6.61E-36 1.23E-34 
82 SEC11C 1.23395 7.613902 153.3484 3.21E-35 5.85E-34 
83 RHOU 2.167109 7.623098 804.5011 5.67E-177 1.43E-
174 
84 NCAPD2 -1.80916 7.689602 606.4034 6.78E-134 7.34E-
132 
85 GFM1 1.338574 7.593172 256.3054 1.10E-57 3.69E-56 
86 PAK1IP1 2.387798 7.594383 1117.176 6.11E-245 4.08E-
242 
87 FOXM1 -1.63477 7.674485 716.9346 6.21E-158 9.94E-
156 
88 SYVN1 1.000653 7.593092 203.8742 2.98E-46 7.58E-45 
89 CSE1L -1.35737 7.623052 365.7079 1.61E-81 9.06E-80 
90 AIDA -1.10573 7.598071 140.4468 2.13E-32 3.55E-31 
91 RBMX -1.0122 7.594585 288.9231 8.53E-65 3.23E-63 
92 PPAPDC1B 1.110143 7.50677 233.6865 9.36E-53 2.89E-51 
93 CBWD1 1.778387 7.492296 510.5037 4.93E-113 4.34E-
111 
94 TBC1D1 1.357368 7.505586 486.5281 8.11E-108 6.40E-
106 
95 HMGB2 -1.92992 7.56376 551.252 6.72E-122 6.59E-
120 
96 SAPCD2 -1.20272 7.481292 303.6156 5.37E-68 2.21E-66 
97 MYBL2 -2.2685 7.505904 777.8938 3.45E-171 7.55E-
169 
98 C1orf21 1.443016 7.405648 450.1608 6.65E-100 4.88E-98 
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99 HIST2H2BE 1.478518 7.37175 488.6229 2.84E-108 2.26E-
106 
100 NASP -1.54286 7.471485 513.7376 9.75E-114 8.66E-
112 
101 MDC1 -1.96038 7.471565 527.8025 8.49E-117 7.98E-
115 
102 RANBP1 -1.13948 7.46558 148.3011 4.08E-34 7.17E-33 
103 LMNB2 -1.38575 7.447536 328.1175 2.47E-73 1.13E-71 
104 DNMT1 -1.84248 7.449779 530.912 1.79E-117 1.69E-
115 
105 SEC61B 1.012905 7.358126 128.9505 6.95E-30 1.05E-28 
106 RRM1 -1.70327 7.388294 592.5655 6.93E-131 7.29E-
129 
107 TPX2 -2.55077 7.409799 1190.686 6.45E-261 5.23E-
258 
108 ELL2 1.290407 7.311118 217.7268 2.83E-49 7.78E-48 
109 ARRDC1 1.224093 7.306428 191.5759 1.44E-43 3.38E-42 
110 TSC22D1 1.504501 7.305186 624.1406 9.40E-138 1.08E-
135 
111 SPAG5 -1.96586 7.378592 1009.157 1.84E-221 7.45E-
219 
112 MCM2 -3.25425 7.370048 1314.99 6.25E-288 7.10E-
285 
113 CTBP1 -1.73532 7.339669 691.7332 1.88E-152 2.63E-
150 
114 LRIG1 1.541028 7.277218 281.3816 3.75E-63 1.39E-61 
115 AZGP1 1.55445 7.246189 294.3881 5.50E-66 2.15E-64 
116 HERPUD1 1.178085 7.267212 376.2176 8.29E-84 4.93E-82 
117 RPA1 -1.00348 7.292358 257.4977 6.03E-58 2.05E-56 
118 PCNA -2.29076 7.316584 775.344 1.24E-170 2.66E-
168 
119 TK1 -2.40243 7.319267 690.508 3.47E-152 4.80E-
150 
120 CHRNA2 1.634173 7.192927 371.8103 7.55E-83 4.40E-81 
121 C1orf85 1.194064 7.180633 307.9533 6.10E-69 2.58E-67 
122 C1orf122 1.067236 7.18229 95.62431 1.39E-22 1.54E-21 
123 PRKD1 -1.05385 7.215452 233.2838 1.15E-52 3.52E-51 
124 CCNB1 -1.73838 7.235568 454.2172 8.72E-101 6.47E-99 
125 ATAD2 -1.20414 7.210836 233.0338 1.30E-52 3.96E-51 
126 SEPP1 1.597374 7.116772 412.4631 1.07E-91 7.26E-90 
127 SMC1A -1.02717 7.173127 116.4915 3.71E-27 5.06E-26 
128 ZG16B 1.157092 7.107736 169.2795 1.06E-38 2.16E-37 
129 BIRC5 -1.81075 7.177067 346.1707 2.89E-77 1.45E-75 
130 ELOVL7 1.139251 7.068933 170.6596 5.31E-39 1.10E-37 
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131 PLK1 -2.34233 7.175124 981.4612 1.92E-215 6.83E-
213 
132 PPFIBP2 1.405403 7.071177 421.265 1.29E-93 8.97E-92 
133 CENPF -2.65802 7.146804 669.8106 1.10E-147 1.45E-
145 
134 PSAT1 -1.31278 7.101152 233.2423 1.17E-52 3.58E-51 
135 IGF1R 1.227603 7.023089 154.2994 1.99E-35 3.64E-34 
136 WFS1 1.091063 6.993063 148.7446 3.26E-34 5.76E-33 
137 MCM4 -3.26059 7.062613 1688.681 0 0 
138 CBX5 -1.05325 7.02122 196.7588 1.06E-44 2.57E-43 
139 RABEP2 1.136575 6.971847 210.3371 1.16E-47 3.08E-46 
140 LMNB1 -2.84859 7.04996 1317.988 1.39E-288 1.76E-
285 
141 CDC20 -2.513 7.066853 1110.524 1.70E-243 9.68E-
241 
142 MEAF6 1.205925 6.967128 272.7044 2.92E-61 1.04E-59 
143 SLC35F2 1.672322 6.930858 492.3402 4.41E-109 3.58E-
107 
144 TIMELESS -1.19271 7.011181 207.5162 4.78E-47 1.24E-45 
145 MCM3 -2.56895 7.015346 1027.143 2.26E-225 9.89E-
223 




147 F5 2.045852 6.905314 503.1163 1.99E-111 1.69E-
109 
148 PGM3 1.560865 6.89683 450.1969 6.54E-100 4.82E-98 
149 DAPK3 1.178791 6.929353 233.1573 1.22E-52 3.73E-51 
150 WHSC1 -1.47703 6.966715 324.6563 1.40E-72 6.37E-71 
151 RAB4A 1.049846 6.913361 200.7618 1.42E-45 3.53E-44 
152 NUSAP1 -2.61455 6.984579 1181.569 6.18E-259 4.68E-
256 
153 SRP19 1.161849 6.897063 190.4124 2.58E-43 6.04E-42 
154 ZWINT -1.73203 6.975172 708.0898 5.21E-156 7.89E-
154 
155 MYO19 -1.31371 6.942265 382.666 3.27E-85 2.02E-83 
156 GTF2E2 1.04861 6.859239 183.7858 7.23E-42 1.62E-40 
157 LRRFIP2 1.137049 6.884022 201.6501 9.11E-46 2.28E-44 
158 TCOF1 -2.34301 6.936038 735.5391 5.59E-162 9.93E-
160 
159 RAD21 -1.11169 6.892567 165.618 6.70E-38 1.31E-36 
160 RCC2 -1.34572 6.904302 348.6003 8.55E-78 4.38E-76 
161 SLC22A23 1.021756 6.835524 193.8476 4.60E-44 1.10E-42 
162 NAMPT 1.123835 6.822034 207.5622 4.67E-47 1.22E-45 
163 TP53 -1.60033 6.865286 381.0834 7.23E-85 4.44E-83 
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164 PRC1 -2.3849 6.878806 865.6275 2.91E-190 8.48E-
188 
165 TYMS -2.70844 6.875414 1343.805 3.42E-294 4.86E-
291 
166 MKLN1 1.048939 6.782135 202.5771 5.72E-46 1.44E-44 
167 FEN1 -2.36599 6.856174 1088.94 8.37E-239 4.32E-
236 
168 OTUD7B 1.258978 6.767622 203.7774 3.13E-46 7.94E-45 
169 RCC1 -1.78013 6.813997 618.4277 1.64E-136 1.85E-
134 
170 HMGCS1 1.447633 6.7105 321.2542 7.72E-72 3.46E-70 
171 HMGCS2 2.068509 6.651636 700.2602 2.62E-154 3.87E-
152 
172 ATP1B1 -1.13926 6.753034 200.1631 1.92E-45 4.74E-44 
173 CDK1 -2.71822 6.77637 913.291 1.27E-200 4.00E-
198 
174 HES6 1.384235 6.654255 133.4881 7.07E-31 1.11E-29 
175 NUP205 -1.23592 6.725211 152.3077 5.43E-35 9.77E-34 
176 ZYX 1.042066 6.690777 145.4572 1.71E-33 2.91E-32 
177 PPM1A 1.279608 6.66174 331.077 5.60E-74 2.61E-72 
178 GFPT1 1.01855 6.660885 189.0691 5.08E-43 1.17E-41 
179 MCM5 -2.67709 6.75905 789.0616 1.29E-173 3.12E-
171 
180 NUCB2 1.701794 6.625689 350.1536 3.92E-78 2.03E-76 
181 SEC24D 1.449741 6.633217 232.7447 1.50E-52 4.57E-51 
182 PPAPDC2 1.37501 6.634727 397.833 1.63E-88 1.07E-86 
183 POLE3 -1.299 6.692208 307.3153 8.40E-69 3.52E-67 
184 APPBP2 1.575724 6.61907 392.7653 2.07E-87 1.34E-85 
185 ACP2 1.066957 6.624005 213.283 2.64E-48 7.11E-47 
186 FAM177A1 1.03761 6.615524 185.9647 2.42E-42 5.48E-41 
187 DNAJC10 1.078406 6.596172 175.0401 5.87E-40 1.24E-38 
188 TMPO -2.52112 6.683045 726.7627 4.53E-160 7.80E-
158 
189 ALDH1A3 1.523543 6.573224 338.8383 1.14E-75 5.53E-74 
190 SELM 1.054759 6.605823 77.05903 1.66E-18 1.49E-17 
191 TMEM97 -1.46271 6.653461 472.8102 7.84E-105 5.98E-
103 
192 TSKU 1.551399 6.582456 385.3147 8.67E-86 5.50E-84 
193 TMEM125 1.5613 6.532456 339.3559 8.81E-76 4.28E-74 
194 FANCI -2.15162 6.62416 787.3054 3.11E-173 7.35E-
171 
195 DNAJC3 1.097632 6.536444 181.2118 2.64E-41 5.77E-40 
196 DHFR -1.08106 6.583575 180.1067 4.59E-41 1.00E-39 
197 CAD -1.19815 6.577752 148.4543 3.77E-34 6.66E-33 
198 RHBDF1 1.231231 6.520357 215.7936 7.48E-49 2.03E-47 
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199 H1F0 1.184458 6.514215 315.3405 1.50E-70 6.55E-69 
200 CHTF18 -1.10213 6.5864 203.456 3.68E-46 9.29E-45 
201 TP53I11 1.001571 6.524923 166.8999 3.52E-38 7.00E-37 
202 NUDT9 1.297071 6.493919 357.4887 9.92E-80 5.37E-78 
203 ARFGAP3 1.03879 6.483907 218.693 1.74E-49 4.85E-48 
204 ST6GALNAC1 1.778908 6.465627 545.0317 1.52E-120 1.47E-
118 
205 FXYD3 1.594635 6.456788 166.4964 4.31E-38 8.49E-37 
206 TONSL -2.7993 6.54392 761.4106 1.33E-167 2.69E-
165 
207 ERRFI1 2.396972 6.449845 625.5226 4.71E-138 5.46E-
136 
208 CYP2U1 2.382067 6.438611 752.9833 9.01E-166 1.74E-
163 
209 STARD10 1.065298 6.46205 90.23963 2.11E-21 2.24E-20 
210 LPAR3 1.164568 6.392414 171.2806 3.89E-39 8.04E-38 
211 CHAF1A -2.07606 6.47708 564.767 7.72E-125 7.83E-
123 
212 KIF20A -2.47709 6.495192 989.6868 3.13E-217 1.19E-
214 
213 FAM105A 2.156335 6.395164 636.382 2.05E-140 2.53E-
138 
214 CREB3 1.330188 6.382446 238.3737 8.90E-54 2.80E-52 
215 GMPPA 1.192689 6.389208 240.3809 3.25E-54 1.03E-52 
216 ST7 -1.25679 6.434559 243.1134 8.24E-55 2.63E-53 
217 RNASEH2A -1.92643 6.46065 362.4873 8.09E-81 4.46E-79 
218 CDC25B -1.71029 6.455418 414.9696 3.04E-92 2.08E-90 
219 C12orf44 1.112789 6.378276 183.236 9.53E-42 2.13E-40 
220 SEC61G 1.028399 6.360787 69.52986 7.53E-17 6.10E-16 
221 Mar-02 1.094852 6.346342 185.3067 3.36E-42 7.60E-41 
222 SMC4 -2.10645 6.403634 425.6532 1.44E-94 1.02E-92 
223 MT2A -1.12949 6.412637 100.5581 1.15E-23 1.35E-22 
224 TFDP1 -1.04138 6.384332 209.8179 1.51E-47 3.98E-46 
225 REEP4 -1.40724 6.402221 236.9455 1.82E-53 5.72E-52 
226 SHMT1 -1.02091 6.384896 219.8868 9.57E-50 2.68E-48 
227 POLD4 1.483001 6.301807 234.5942 5.94E-53 1.85E-51 
228 CYTH1 1.114964 6.307986 189.9782 3.21E-43 7.49E-42 
229 CKS2 -1.83259 6.377009 321.9099 5.56E-72 2.50E-70 
230 WDR90 -1.10826 6.328975 160.1325 1.06E-36 1.99E-35 
231 ERBB2IP 1.010267 6.249908 62.56129 2.58E-15 1.90E-14 
232 TMEM79 1.537379 6.25542 499.5023 1.22E-110 1.02E-
108 
233 WNT7B 1.149858 6.280866 276.8787 3.60E-62 1.31E-60 
234 CNN2 1.05879 6.259797 224.2268 1.08E-50 3.11E-49 
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235 PCDH1 1.607217 6.239676 248.7152 4.95E-56 1.63E-54 
236 TSPYL2 1.123337 6.260646 153.1687 3.52E-35 6.39E-34 
237 TELO2 -1.01961 6.287891 131.3721 2.05E-30 3.17E-29 
238 UBE2T -2.08563 6.302109 509.9576 6.48E-113 5.66E-
111 
239 CBX2 -1.35803 6.268047 300.6352 2.40E-67 9.69E-66 
240 MCM6 -1.95161 6.277195 721.3881 6.68E-159 1.10E-
156 
241 GNMT 2.439455 6.163692 664.9697 1.24E-146 1.60E-
144 
242 SLC16A6 1.925227 6.220973 366.6904 9.84E-82 5.59E-80 
243 UGT2B11 3.381715 6.119025 878.6553 4.29E-193 1.28E-
190 
244 PTTG1 -1.13815 6.281529 82.99068 8.24E-20 7.97E-19 
245 PIK3R3 -1.00472 6.23804 165.9614 5.64E-38 1.11E-36 
246 IGBP1 1.009105 6.187094 211.8651 5.38E-48 1.44E-46 
247 RECQL4 -2.44567 6.257349 735.0075 7.30E-162 1.28E-
159 
248 YIPF1 1.350027 6.149532 289.4761 6.47E-65 2.46E-63 
249 TCF19 -3.17297 6.252116 1086.997 2.21E-238 1.09E-
235 
250 ZCCHC6 1.274969 6.147848 222.7858 2.23E-50 6.34E-49 
251 GEMIN4 -1.61516 6.20047 372.4269 5.54E-83 3.28E-81 
252 CDCA5 -3.10287 6.238124 1261.541 2.58E-276 2.66E-
273 
253 GADD45G 2.928615 6.156119 1031.987 2.00E-226 9.48E-
224 
254 MTMR9 1.228813 6.139286 201.2752 1.10E-45 2.74E-44 
255 RFC2 -1.66704 6.199762 305.9512 1.66E-68 6.93E-67 
256 GREB1 1.294012 6.120287 198.2542 5.02E-45 1.23E-43 
257 SMPD2 1.172216 6.124848 167.983 2.04E-38 4.13E-37 
258 DEK -1.93842 6.168683 409.6557 4.36E-91 2.93E-89 
259 NEU1 1.000617 6.103164 208.6205 2.75E-47 7.18E-46 
260 HLTF -1.06762 6.134986 100.1209 1.43E-23 1.67E-22 
261 SELS 1.197415 6.093093 230.9763 3.65E-52 1.10E-50 
262 CRLS1 1.012555 6.076245 129.3629 5.65E-30 8.54E-29 
263 DERL2 1.100616 6.086523 93.39008 4.29E-22 4.66E-21 
264 TOP2A -3.27268 6.159168 710.8513 1.31E-156 2.01E-
154 
265 DDAH2 1.075739 6.082459 185.7827 2.65E-42 6.00E-41 
266 DSEL -1.17527 6.103658 218.1113 2.34E-49 6.47E-48 
267 UBE2C -2.70921 6.167261 695.3527 3.06E-153 4.46E-
151 
268 Mar-05 1.037374 6.063772 179.1387 7.47E-41 1.61E-39 
269 CORO2A 1.020624 6.027818 151.8501 6.83E-35 1.23E-33 
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270 SASH1 1.207238 6.020806 91.74808 9.84E-22 1.06E-20 
271 POLD1 -1.70165 6.096017 268.312 2.65E-60 9.37E-59 
272 LONRF1 1.681935 5.992754 378.0212 3.36E-84 2.01E-82 
273 EFCAB4A 1.17597 6.025514 167.7012 2.35E-38 4.74E-37 
274 PTPRM 1.231821 6.012084 161.7762 4.63E-37 8.80E-36 
275 FAM214B 1.221125 6.022107 189.8395 3.45E-43 8.01E-42 
276 CCNB2 -2.3793 6.098181 742.9113 1.40E-163 2.52E-
161 
277 TROAP -1.69885 6.095553 383.1854 2.52E-85 1.57E-83 
278 ACAD8 1.607501 5.987761 323.4961 2.51E-72 1.14E-70 
279 PKP4 -1.31 6.026131 206.9198 6.46E-47 1.66E-45 
280 EXOSC2 -1.03818 6.02918 209.0109 2.26E-47 5.91E-46 
281 RACGAP1 -2.25328 6.047303 631.398 2.48E-139 2.94E-
137 
282 LRRC45 -1.54626 6.026365 262.478 4.95E-59 1.73E-57 
283 SNHG3 -1.12506 6.010091 176.4108 2.95E-40 6.26E-39 
284 LSM2 -1.12572 6.01861 97.2629 6.07E-23 6.86E-22 
285 MTHFD2 -1.04098 5.985797 131.1138 2.34E-30 3.61E-29 
286 CCNF -2.25008 6.00093 639.0337 5.42E-141 6.77E-
139 
287 KIFC1 -2.9716 6.000929 1098.194 8.16E-241 4.41E-
238 
288 XRCC3 -1.43163 5.971976 295.0115 4.02E-66 1.58E-64 
289 E2F1 -3.03618 5.996343 1132.469 2.90E-248 2.06E-
245 
290 RNF185 1.015195 5.888818 145.5135 1.66E-33 2.83E-32 
291 KIF2C -2.92428 5.981083 1030.185 4.93E-226 2.24E-
223 
292 DTYMK -1.087 5.963959 86.3344 1.52E-20 1.53E-19 
293 CCDC53 1.220078 5.883705 119.2415 9.27E-28 1.30E-26 
294 PKMYT1 -3.17892 5.970537 724.0308 1.78E-159 3.02E-
157 
295 CDC6 -2.71456 5.945206 956.275 5.74E-210 1.92E-
207 
296 KANK2 -1.39431 5.903333 195.9566 1.59E-44 3.84E-43 
297 HMMR -2.1397 5.923096 390.2568 7.28E-87 4.67E-85 
298 NCAPG -2.75675 5.917118 851.3649 3.67E-187 1.04E-
184 
299 SNHG1 -1.66199 5.894013 337.8273 1.90E-75 9.13E-74 
300 KCNMA1 1.048287 5.817175 92.86631 5.59E-22 6.06E-21 
301 NCAPH2 -1.04697 5.901586 146.5628 9.78E-34 1.68E-32 
302 KIF4A -2.00257 5.899307 514.496 6.67E-114 5.97E-
112 
303 NDFIP2 1.28736 5.815608 166.6536 3.98E-38 7.87E-37 
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304 CDCA3 -2.43805 5.893867 508.1527 1.60E-112 1.39E-
110 
305 MLF1IP -2.59502 5.883664 774.1869 2.21E-170 4.65E-
168 
306 PARP2 -1.536 5.878172 297.0701 1.43E-66 5.69E-65 
307 HJURP -2.82867 5.888758 816.9411 1.12E-179 2.89E-
177 
308 IQGAP3 -2.15928 5.881633 558.399 1.87E-123 1.89E-
121 
309 RWDD2A 1.144425 5.800116 183.9652 6.60E-42 1.48E-40 
310 RPA2 -1.20334 5.852203 173.6675 1.17E-39 2.45E-38 
311 POLA2 -2.16493 5.857153 617.5233 2.58E-136 2.88E-
134 
312 C15orf23 -1.11599 5.854737 204.6946 1.97E-46 5.04E-45 
313 MCMBP -1.2245 5.828437 265.1596 1.29E-59 4.53E-58 
314 CDK2 -1.50778 5.841479 299.9445 3.39E-67 1.36E-65 
315 MESP1 1.055936 5.748554 78.99119 6.24E-19 5.74E-18 
316 INCENP -2.03569 5.835241 378.6788 2.41E-84 1.45E-82 
317 DNAJC9 -1.31581 5.825465 206.7788 6.93E-47 1.78E-45 
318 FAM83D -2.45341 5.838418 720.8671 8.67E-159 1.41E-
156 
319 FOXD4 1.583442 5.745258 364.0671 3.66E-81 2.05E-79 
320 FZD5 1.203639 5.723739 129.8697 4.38E-30 6.65E-29 
321 AURKA -2.26681 5.788678 499.3343 1.33E-110 1.10E-
108 
322 PSIP1 -1.20329 5.755688 162.085 3.96E-37 7.56E-36 
323 SNX25 1.518669 5.693395 280.8462 4.91E-63 1.81E-61 
324 ASRGL1 1.333319 5.700826 296.8215 1.62E-66 6.43E-65 
325 LRRC20 -1.07583 5.746568 178.1508 1.23E-40 2.63E-39 
326 MSH6 -1.34492 5.735659 222.0121 3.29E-50 9.31E-49 
327 TOPBP1 -1.2495 5.727987 166.7894 3.72E-38 7.38E-37 
328 ZNF350 1.54278 5.671632 314.3957 2.41E-70 1.05E-68 
329 CBLL1 1.436619 5.675176 221.5112 4.23E-50 1.19E-48 
330 C9orf152 1.30564 5.658872 176.9403 2.26E-40 4.81E-39 
331 BUB1B -3.03646 5.738795 753.0286 8.81E-166 1.73E-
163 
332 CADPS2 2.250906 5.627089 423.0305 5.34E-94 3.73E-92 
333 DLGAP5 -2.21023 5.726486 329.2605 1.39E-73 6.41E-72 
334 NCAPG2 -1.90439 5.713099 350.935 2.65E-78 1.38E-76 
335 C14orf80 -1.35272 5.711237 247.3248 9.95E-56 3.24E-54 
336 ASF1B -3.8302 5.735445 1225.607 1.66E-268 1.45E-
265 
337 UNG -1.42818 5.672245 277.2868 2.93E-62 1.07E-60 
338 NUP85 -1.46517 5.692248 291.8036 2.01E-65 7.78E-64 
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339 TMEM201 -1.33915 5.678676 172.2282 2.41E-39 5.01E-38 
340 SLC29A1 -2.77261 5.661481 778.4889 2.56E-171 5.72E-
169 
341 MAF 2.932162 5.575168 507.8834 1.83E-112 1.58E-
110 
342 LIFR 2.752187 5.555242 489.2013 2.13E-108 1.70E-
106 
343 FANCD2 -2.13342 5.646963 494.3288 1.63E-109 1.33E-
107 
344 PNMA1 1.241846 5.553088 265.5523 1.06E-59 3.73E-58 
345 CCNA2 -2.98941 5.643516 695.3065 3.14E-153 4.51E-
151 
346 CAMK2N1 -2.14393 5.616474 459.8053 5.30E-102 3.99E-
100 
347 CAP2 1.783524 5.53728 276.5103 4.33E-62 1.56E-60 
348 MAP9 1.153307 5.546306 115.2109 7.08E-27 9.58E-26 
349 ANLN -2.7275 5.608306 472.6704 8.41E-105 6.37E-
103 
350 CDT1 -2.6894 5.617058 592.6203 6.74E-131 7.16E-
129 
351 TFPT 1.03312 5.547885 99.8895 1.61E-23 1.87E-22 
352 CHAF1B -1.83884 5.603972 347.9958 1.16E-77 5.90E-76 
353 GALK2 1.006977 5.504204 102.635 4.03E-24 4.83E-23 
354 RAD51C -1.15301 5.562171 138.3002 6.27E-32 1.03E-30 
355 WDR62 -2.89153 5.586252 525.3029 2.97E-116 2.77E-
114 
356 UGT2B17 -1.49002 5.547899 224.8046 8.10E-51 2.35E-49 
357 ACPP 1.065064 5.482185 182.4516 1.41E-41 3.12E-40 
358 PRR11 -1.93725 5.569425 386.2358 5.46E-86 3.49E-84 
359 MELK -2.7595 5.576693 666.8211 4.91E-147 6.41E-
145 
360 STC2 -1.45317 5.527638 194.9093 2.70E-44 6.45E-43 
361 TTC39A 1.531964 5.457682 308.8245 3.94E-69 1.68E-67 
362 CKAP2 -1.2193 5.532953 141.2153 1.44E-32 2.43E-31 
363 DDC -1.59046 5.532478 148.0825 4.55E-34 7.97E-33 
364 NDC80 -2.66059 5.558103 634.4423 5.40E-140 6.60E-
138 
365 PRPF4 -1.12161 5.51558 140.7936 1.79E-32 3.00E-31 
366 LRRC16A 1.282402 5.462036 166.5632 4.17E-38 8.22E-37 
367 TCEAL3 1.027348 5.460493 126.2593 2.70E-29 4.00E-28 
368 TMEM48 -1.79609 5.505487 320.863 9.40E-72 4.19E-70 
369 ERLEC1 1.236214 5.424797 154.3849 1.91E-35 3.50E-34 
370 AURKB -2.99083 5.525203 569.7318 6.42E-126 6.63E-
124 
371 SLC2A12 1.710115 5.413684 343.7637 9.67E-77 4.80E-75 
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372 HAUS5 -1.60938 5.507433 236.6324 2.13E-53 6.68E-52 
373 SNAPC4 -1.04952 5.472485 112.4805 2.80E-26 3.69E-25 
374 POLR1E -1.49621 5.46638 245.2165 2.87E-55 9.23E-54 
375 NR4A1 1.671129 5.435144 289.9536 5.09E-65 1.94E-63 
376 PFAS -1.32278 5.45572 113.5676 1.62E-26 2.16E-25 
377 ESPL1 -3.35512 5.494887 823.629 3.93E-181 1.09E-
178 
378 NUP155 -1.28387 5.441691 134.8934 3.48E-31 5.55E-30 
379 FANCG -1.86435 5.473524 361.5053 1.32E-80 7.23E-79 
380 PRKCA 2.027003 5.384767 343.0186 1.40E-76 6.94E-75 
381 NRARP -1.16411 5.441732 162.6872 2.93E-37 5.62E-36 
382 KIAA0513 1.392395 5.380875 211.8561 5.41E-48 1.45E-46 
383 PLXNA3 1.091541 5.397839 66.45759 3.58E-16 2.78E-15 
384 TRIP13 -1.96282 5.45135 479.7892 2.37E-106 1.86E-
104 
385 RRAS 1.256704 5.388401 126.1676 2.83E-29 4.18E-28 
386 CDKN3 -1.23991 5.455793 106.8736 4.74E-25 5.97E-24 
387 GMNN -1.74604 5.450182 366.4446 1.11E-81 6.29E-80 
388 DDX11 -1.61283 5.438654 192.4068 9.48E-44 2.24E-42 
389 C5orf4 1.226262 5.38173 93.28493 4.53E-22 4.91E-21 
390 ITPKC 1.012044 5.381158 125.0619 4.93E-29 7.23E-28 
391 BCAP29 1.127326 5.365335 111.3899 4.86E-26 6.32E-25 
392 RABAC1 1.299533 5.358938 90.53673 1.82E-21 1.93E-20 
393 WIPI1 3.085675 5.320718 715.7274 1.14E-157 1.79E-
155 
394 CENPE -2.55539 5.416865 398.9942 9.12E-89 5.99E-87 
395 SMAP1 1.128774 5.354387 180.4406 3.88E-41 8.47E-40 
396 OAZ3 1.101403 5.338351 70.90724 3.74E-17 3.09E-16 
397 RAP1GAP 1.973047 5.301951 290.4567 3.95E-65 1.52E-63 
398 EZH2 -1.82731 5.393788 342.9186 1.48E-76 7.26E-75 
399 CDCA8 -2.75916 5.409472 817.8243 7.19E-180 1.90E-
177 
400 SMC2 -1.93674 5.364923 247.6822 8.31E-56 2.71E-54 
401 ZBTB24 1.112941 5.319554 155.8564 9.10E-36 1.68E-34 
402 NETO2 -1.08871 5.353325 181.9619 1.81E-41 3.98E-40 
403 EMP2 -1.2952 5.364514 157.3889 4.21E-36 7.82E-35 
404 CENPO -1.63327 5.363486 303.6638 5.24E-68 2.17E-66 
405 YWHAH -1.00771 5.334659 129.9422 4.22E-30 6.43E-29 
406 EDEM2 1.234739 5.287493 149.0135 2.85E-34 5.04E-33 
407 TECPR1 1.002065 5.270997 95.51449 1.47E-22 1.63E-21 
408 PBK -2.07243 5.352495 361.7017 1.20E-80 6.59E-79 
409 NCAPH -3.25505 5.350564 989.5939 3.28E-217 1.20E-
214 
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410 RFC4 -1.93463 5.343251 371.91 7.18E-83 4.21E-81 
411 LOC150776 -1.07254 5.331821 92.46693 6.85E-22 7.39E-21 
412 NUP160 -1.42056 5.301647 134.1115 5.17E-31 8.21E-30 
413 ADAM7 1.202614 5.265882 222.1598 3.06E-50 8.66E-49 
414 NOTCH1 -1.23504 5.292124 74.77103 5.29E-18 4.57E-17 
415 CDC45 -3.02432 5.344925 626.7053 2.60E-138 3.05E-
136 
416 RGS3 -1.12618 5.30241 166.0001 5.53E-38 1.09E-36 
417 BUB1 -2.40453 5.320551 457.2626 1.89E-101 1.42E-99 
418 PHF1 1.034168 5.262987 87.6755 7.71E-21 7.94E-20 
419 PIAS1 1.229291 5.251054 129.4538 5.40E-30 8.17E-29 
420 SLC7A5 -1.38152 5.277115 164.1857 1.38E-37 2.67E-36 
421 GTSE1 -2.46696 5.299098 672.4993 2.86E-148 3.82E-
146 
422 SLC25A20 1.181722 5.2054 195.5404 1.96E-44 4.72E-43 
423 MDN1 -1.04446 5.224759 57.79713 2.91E-14 1.98E-13 
424 BHLHA15 1.509403 5.167879 142.853 6.33E-33 1.07E-31 
425 POC1A -1.59785 5.245995 225.6205 5.38E-51 1.57E-49 
426 CKS1B -1.54118 5.228513 135.1903 3.00E-31 4.81E-30 
427 BRCA1 -3.09521 5.210567 524.7953 3.83E-116 3.54E-
114 
428 HLA-DMA 1.88914 5.125523 210.2816 1.19E-47 3.16E-46 
429 PTPN21 2.308262 5.107155 294.9429 4.16E-66 1.63E-64 
430 SLC39A8 -1.38282 5.177939 211.3398 7.01E-48 1.87E-46 
431 PODXL -1.29161 5.175001 152.7887 4.26E-35 7.72E-34 
432 AFF3 1.782135 5.101864 226.5547 3.36E-51 9.93E-50 
433 KIF11 -2.75344 5.181224 380.6875 8.82E-85 5.39E-83 
434 BTG2 -1.39522 5.161335 189.0626 5.09E-43 1.17E-41 
435 ARID5B 1.397515 5.090399 133.0787 8.69E-31 1.36E-29 
436 PGC 2.199557 5.097379 383.2945 2.39E-85 1.49E-83 
437 FAM64A -2.30997 5.174444 407.6541 1.19E-90 7.94E-89 
438 MAD2L1 -2.46985 5.137843 307.9156 6.21E-69 2.62E-67 
439 TBC1D8 1.127747 5.102788 104.3703 1.68E-24 2.05E-23 
440 C4orf34 1.345178 5.04361 139.8938 2.81E-32 4.67E-31 
441 PPP2R5B 1.027742 5.075568 107.2249 3.97E-25 5.02E-24 
442 CENPM -1.42535 5.135223 112.4281 2.88E-26 3.78E-25 
443 EAF2 2.160754 5.067209 286.3176 3.15E-64 1.18E-62 
444 TFAP4 -1.15115 5.088297 159.2153 1.68E-36 3.14E-35 
445 PSRC1 -2.30736 5.139266 497.618 3.14E-110 2.58E-
108 
446 CDC25A -1.00609 5.098526 101.1647 8.46E-24 9.98E-23 
447 BCL2L12 -1.34974 5.126352 129.9842 4.13E-30 6.30E-29 
448 ECT2 -1.9274 5.101833 273.0659 2.44E-61 8.68E-60 
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449 FANCA -2.6372 5.118483 522.419 1.26E-115 1.15E-
113 
450 WRAP53 -1.46638 5.10507 223.492 1.57E-50 4.47E-49 
451 CXCR7 -2.41898 5.08734 473.6052 5.26E-105 4.04E-
103 
452 FN3KRP -1.12619 5.078632 117.5823 2.14E-27 2.95E-26 
453 KIAA1731 -1.00206 5.066189 86.95609 1.11E-20 1.13E-19 
454 SLC10A7 1.739501 5.006378 230.9897 3.63E-52 1.10E-50 
455 UGT2B15 -1.58315 5.06843 205.6687 1.21E-46 3.10E-45 
456 ARHGAP19 -1.43039 5.083822 169.5721 9.18E-39 1.88E-37 
457 EXOSC8 -1.59109 5.079829 251.7733 1.07E-56 3.55E-55 
458 MCM8 -1.40254 5.061522 170.138 6.90E-39 1.42E-37 
459 SLC44A1 -1.12636 5.041781 103.331 2.84E-24 3.43E-23 
460 KIAA0101 -1.34067 5.069066 124.7198 5.86E-29 8.56E-28 
461 EML1 1.08568 5.004544 122.2279 2.06E-28 2.96E-27 
462 TFAM -1.0786 5.03236 98.67487 2.98E-23 3.41E-22 
463 DEPDC1 -2.58639 5.061649 323.2672 2.81E-72 1.27E-70 
464 METTL7A -1.13267 5.040264 114.7384 8.98E-27 1.21E-25 
465 NET1 -1.0463 5.030003 83.96344 5.04E-20 4.93E-19 
466 ARHGAP11A -2.7988 5.052337 337.3679 2.39E-75 1.15E-73 
467 CIT -3.02174 5.062757 791.295 4.21E-174 1.04E-
171 
468 NUP107 -1.49223 5.022358 183.0315 1.06E-41 2.35E-40 
469 GINS1 -2.84708 5.043659 771.3359 9.21E-170 1.90E-
167 
470 ZWILCH -1.62127 5.026318 281.7203 3.17E-63 1.18E-61 
471 LIG1 -1.91338 5.034235 286.6422 2.68E-64 1.01E-62 
472 RAD54L -3.46275 5.045544 704.0766 3.88E-155 5.81E-
153 
473 TYMP 1.257953 4.937592 138.6267 5.32E-32 8.74E-31 
474 C20orf72 -1.84753 5.008939 287.6562 1.61E-64 6.08E-63 
475 DDB2 -2.00279 5.021673 351.6334 1.87E-78 9.78E-77 
476 CDKN2C -1.84896 5.018923 262.1932 5.71E-59 1.99E-57 
477 CEP55 -2.71222 4.997699 490.714 9.96E-109 8.03E-
107 
478 LBR -1.38069 4.970888 127.4202 1.50E-29 2.24E-28 
479 CCDC14 -1.51614 4.983164 163.7695 1.70E-37 3.29E-36 
480 ZNF395 -1.03166 4.954544 106.0548 7.17E-25 8.92E-24 
481 C2orf76 1.034981 4.903542 57.65162 3.13E-14 2.12E-13 
482 C10orf47 1.017365 4.910119 95.87337 1.22E-22 1.37E-21 
483 CLSPN -3.80621 4.974504 746.4599 2.36E-164 4.47E-
162 
484 KNTC1 -2.78784 4.965225 618.9634 1.26E-136 1.43E-
134 
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485 DNAJB9 1.724768 4.8996 247.8891 7.49E-56 2.45E-54 
486 HIST1H2AC 1.196452 4.885308 91.65938 1.03E-21 1.10E-20 
487 PRKCH 1.275291 4.868928 132.4279 1.21E-30 1.88E-29 
488 RFC5 -2.38398 4.949173 368.6632 3.66E-82 2.09E-80 
489 BCHE -2.25651 4.92801 361.2371 1.51E-80 8.23E-79 
490 USP1 -1.47739 4.921063 167.0937 3.19E-38 6.37E-37 
491 LYAR -1.50544 4.932251 181.5964 2.17E-41 4.77E-40 
492 CDCA7L -2.18438 4.924996 521.7968 1.72E-115 1.56E-
113 
493 C9orf100 -2.58737 4.944562 502.9781 2.14E-111 1.80E-
109 
494 DSN1 -1.64178 4.924662 228.1293 1.53E-51 4.55E-50 
495 HIST1H2BD 1.566302 4.834448 146.6505 9.36E-34 1.61E-32 
496 GINS2 -2.26059 4.922295 331.6574 4.19E-74 1.97E-72 
497 SYNJ1 1.018524 4.845336 60.85368 6.15E-15 4.40E-14 
498 ATP11A -1.44176 4.870624 102.0676 5.37E-24 6.39E-23 
499 STEAP4 6.927834 4.757507 1233.643 2.98E-270 2.82E-
267 
500 LUZP2 -1.56074 4.866457 188.7955 5.82E-43 1.34E-41 
501 SOCS2 2.464368 4.823498 333.6941 1.51E-74 7.14E-73 
502 POLH -1.43982 4.871978 146.7418 8.94E-34 1.54E-32 
503 TNFRSF19 1.533254 4.816737 209.0766 2.18E-47 5.73E-46 
504 CDYL2 1.046766 4.821179 70.01139 5.90E-17 4.81E-16 
505 MVP 1.144575 4.810926 133.6722 6.44E-31 1.02E-29 
506 MYNN -1.19668 4.842375 120.8719 4.08E-28 5.78E-27 
507 NR2C2AP -1.3963 4.865353 155.1469 1.30E-35 2.39E-34 
508 CCDC99 -1.96585 4.875761 290.7999 3.33E-65 1.28E-63 
509 ELOVL6 -1.48167 4.847384 200.1887 1.90E-45 4.70E-44 
510 E2F3 -1.01918 4.843824 87.62695 7.90E-21 8.12E-20 
511 UGT2B28 3.893655 4.738447 744.1228 7.61E-164 1.39E-
161 
512 FAM101B -1.3925 4.84779 201.9817 7.72E-46 1.93E-44 
513 ZNF18 1.154333 4.817943 146.4863 1.02E-33 1.74E-32 
514 MCM10 -4.32466 4.855 744.3193 6.90E-164 1.28E-
161 
515 FAM198B -1.66277 4.815321 146.1116 1.23E-33 2.10E-32 
516 TRADD 1.31002 4.778269 105.8736 7.86E-25 9.71E-24 
517 RAI14 -1.22035 4.817695 105.8037 8.14E-25 1.00E-23 
518 UHRF1 -3.61134 4.827836 758.5996 5.41E-167 1.08E-
164 
519 INPP4B 1.779542 4.737244 206.9816 6.26E-47 1.62E-45 
520 C16orf59 -1.75965 4.835931 290.2952 4.29E-65 1.64E-63 
521 RAD1 -1.02587 4.794676 98.62368 3.05E-23 3.49E-22 
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522 KIF18B -3.75678 4.830277 596.9025 7.90E-132 8.47E-
130 
523 CDCA2 -2.75471 4.817123 439.4649 1.42E-97 1.02E-95 
524 NAT1 2.105876 4.757416 251.384 1.30E-56 4.30E-55 
525 LIN7B 1.602485 4.752415 181.8536 1.91E-41 4.20E-40 
526 C17orf96 -1.26239 4.767808 111.6182 4.33E-26 5.64E-25 
527 MANEA -1.21951 4.745592 111.0307 5.83E-26 7.56E-25 
528 TTF2 -1.38898 4.759101 162.1472 3.84E-37 7.34E-36 
529 C21orf58 -2.35905 4.785925 507.6473 2.06E-112 1.76E-
110 
530 WDHD1 -2.5941 4.763399 611.5602 5.12E-135 5.60E-
133 
531 ACOX3 1.074054 4.689627 61.81209 3.78E-15 2.75E-14 
532 ZNF812 2.544403 4.648766 584.373 4.20E-129 4.38E-
127 
533 MTHFD1L -1.11124 4.7318 97.74967 4.75E-23 5.42E-22 
534 PUS7 -1.00813 4.693314 68.98917 9.90E-17 7.97E-16 
535 MEX3D -1.08268 4.704777 98.24086 3.70E-23 4.24E-22 
536 MEX3A -1.35255 4.700962 101.3829 7.58E-24 8.95E-23 
537 SHCBP1 -2.76888 4.72046 423.2217 4.86E-94 3.41E-92 
538 NAT8L -1.28146 4.682233 73.65812 9.29E-18 7.92E-17 
539 MXD3 -1.73475 4.718974 215.1305 1.04E-48 2.82E-47 
540 HAUS6 -1.36579 4.67344 131.8728 1.60E-30 2.47E-29 
541 BAHCC1 -1.01076 4.676828 61.13839 5.32E-15 3.83E-14 
542 POLA1 -1.59616 4.684699 200.1805 1.91E-45 4.71E-44 
543 TUBGCP3 -1.17059 4.680888 117.0667 2.78E-27 3.81E-26 
544 SUV39H1 -1.65967 4.690893 231.6669 2.58E-52 7.82E-51 
545 RFWD3 -2.07941 4.677295 226.5095 3.44E-51 1.01E-49 
546 KIF23 -2.97371 4.685966 651.689 9.59E-144 1.21E-
141 
547 BMPR1A 1.150621 4.60637 92.87615 5.57E-22 6.03E-21 
548 ORC6 -3.34711 4.683425 674.5864 1.01E-148 1.36E-
146 
549 PIGW -1.24672 4.638507 130.511 3.17E-30 4.87E-29 
550 PLK2 -1.41448 4.671327 128.4041 9.16E-30 1.37E-28 
551 POLQ -3.26326 4.655492 385.0002 1.01E-85 6.41E-84 
552 RBBP8 -1.76981 4.640005 216.371 5.60E-49 1.53E-47 
553 NUF2 -2.40672 4.651253 301.1723 1.83E-67 7.45E-66 
554 NEK2 -2.46444 4.648609 341.503 3.00E-76 1.46E-74 
555 PRIM2 -1.14901 4.629397 81.60635 1.66E-19 1.58E-18 
556 PSMC3IP -2.44706 4.631968 347.0801 1.83E-77 9.30E-76 
557 DTL -4.49669 4.61236 954.0361 1.76E-209 5.71E-
207 
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558 CDCA4 -2.9533 4.610723 479.5007 2.74E-106 2.12E-
104 
559 CDC7 -2.0867 4.595561 309.8759 2.32E-69 9.97E-68 
560 MRE11A -1.08835 4.584518 75.07879 4.52E-18 3.92E-17 
561 TUBA3D 2.335066 4.537442 380.21 1.12E-84 6.81E-83 
562 SKA3 -2.30676 4.585329 330.5552 7.28E-74 3.37E-72 
563 STIL -2.05411 4.582942 248.6831 5.03E-56 1.65E-54 
564 LAMA1 2.261857 4.505519 404.8368 4.88E-90 3.24E-88 
565 VRK1 -1.63239 4.572572 256.6143 9.39E-58 3.17E-56 
566 TARBP1 -1.0655 4.544414 89.33701 3.33E-21 3.50E-20 
567 CABLES2 -1.25456 4.561123 133.9291 5.66E-31 8.98E-30 
568 OAS3 -2.25464 4.56786 240.3174 3.35E-54 1.06E-52 
569 PCTP 1.26239 4.519361 134.8077 3.64E-31 5.79E-30 
570 TMEM194A -2.42661 4.547988 352.4024 1.27E-78 6.72E-77 
571 UACA -1.14131 4.536448 68.28635 1.41E-16 1.13E-15 
572 CCDC34 -1.26032 4.551422 70.07553 5.71E-17 4.66E-16 
573 PVT1 -1.13798 4.528861 86.51544 1.39E-20 1.40E-19 
574 MAPK11 1.126087 4.475094 84.29218 4.27E-20 4.19E-19 
575 PRKX -1.16917 4.511738 68.34921 1.37E-16 1.09E-15 
576 SEC14L2 2.358778 4.44341 309.6495 2.60E-69 1.11E-67 
577 PAQR6 1.064693 4.495225 64.28098 1.08E-15 8.16E-15 
578 NDE1 -1.15307 4.505692 91.76889 9.74E-22 1.05E-20 
579 DUSP1 1.116623 4.459056 81.90146 1.43E-19 1.36E-18 
580 SLC25A19 -1.84023 4.490555 291.9924 1.83E-65 7.10E-64 
581 RIF1 -1.18942 4.470228 77.44654 1.36E-18 1.23E-17 
582 ANP32E -1.16421 4.482062 68.30151 1.40E-16 1.12E-15 
583 SKP2 -2.16685 4.483818 276.831 3.68E-62 1.33E-60 
584 ACD -1.00083 4.491429 57.18785 3.96E-14 2.67E-13 
585 KRT19 1.52064 4.433102 106.5317 5.64E-25 7.06E-24 
586 CD3EAP -1.20903 4.461233 106.5053 5.71E-25 7.14E-24 
587 ID2 1.114766 4.451093 86.96935 1.10E-20 1.12E-19 
588 DCK -1.36039 4.467973 79.68538 4.39E-19 4.07E-18 
589 ADCY3 -1.26148 4.462304 71.77503 2.41E-17 2.02E-16 
590 CEP57 -1.02447 4.45679 63.1173 1.95E-15 1.45E-14 
591 CHEK1 -2.67607 4.48128 307.0872 9.41E-69 3.93E-67 
592 HAUS1 -1.45359 4.484391 152.0858 6.07E-35 1.09E-33 
593 TARP 2.0082 4.394865 293.1411 1.03E-65 4.00E-64 
594 BTG3 -1.44741 4.458835 139.2849 3.82E-32 6.29E-31 
595 ORAI3 1.406972 4.385888 129.0624 6.57E-30 9.92E-29 
596 GUSBP1 -1.70377 4.420452 204.5126 2.16E-46 5.51E-45 
597 RCCD1 -1.22891 4.442964 125.0822 4.88E-29 7.16E-28 
598 FAM107B -1.1013 4.418613 72.64276 1.55E-17 1.31E-16 
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599 YEATS4 -1.37125 4.4016 89.13679 3.68E-21 3.87E-20 
600 GINS4 -2.83117 4.410119 370.9958 1.14E-82 6.59E-81 
601 LOC100132247 -1.22548 4.371449 5.883853 0.01528 0.027177 
602 FANCC -1.8619 4.390391 189.7382 3.63E-43 8.41E-42 
603 DBF4B -2.06223 4.401455 256.8599 8.30E-58 2.81E-56 
604 CCDC141 2.787908 4.324552 174.0387 9.71E-40 2.04E-38 
605 SH2D3A 1.225514 4.317489 91.76856 9.74E-22 1.05E-20 
606 DBF4 -1.85695 4.362105 207.1958 5.62E-47 1.45E-45 
607 RAD18 -1.16233 4.356835 86.0776 1.73E-20 1.73E-19 
608 CSPG5 -1.06289 4.354519 90.54889 1.80E-21 1.92E-20 
609 SH3BP1 -1.06124 4.359435 70.7006 4.16E-17 3.42E-16 
610 MIR22HG 1.593397 4.321499 179.503 6.22E-41 1.34E-39 
611 DEPDC1B -2.69309 4.373182 344.0621 8.32E-77 4.15E-75 
612 PRSS16 1.029776 4.309015 57.0447 4.26E-14 2.86E-13 
613 BMPR1B 1.288273 4.299067 90.54056 1.81E-21 1.93E-20 
614 GCNT2 1.101548 4.295841 61.31621 4.86E-15 3.50E-14 
615 HAUS7 -1.16574 4.337564 42.28691 7.88E-11 4.11E-10 
616 FGD4 1.577784 4.287323 111.3836 4.88E-26 6.33E-25 
617 TEAD4 -1.08412 4.32635 68.56459 1.23E-16 9.84E-16 
618 ORC1 -2.92149 4.352869 384.9004 1.07E-85 6.70E-84 
619 TRIM52 1.313995 4.273618 112.1945 3.24E-26 4.24E-25 
620 RMI1 -1.514 4.316916 102.4814 4.35E-24 5.21E-23 
621 SPC24 -2.63448 4.336883 372.2121 6.17E-83 3.64E-81 
622 ZFAND2A 1.068566 4.277248 72.57435 1.61E-17 1.36E-16 
623 POLD3 -1.93025 4.315872 212.8788 3.23E-48 8.69E-47 
624 WEE1 -2.12736 4.312252 174.0315 9.74E-40 2.04E-38 
625 IL10RB 1.10843 4.257556 97.425 5.59E-23 6.33E-22 
626 DST -1.04814 4.306202 32.04447 1.51E-08 6.38E-08 
627 NRM -1.93358 4.31834 198.1546 5.28E-45 1.29E-43 
628 EME1 -3.06517 4.314727 346.9957 1.91E-77 9.66E-76 
629 RFC3 -2.85784 4.302175 320.0803 1.39E-71 6.18E-70 
630 TMEM237 -1.63188 4.288242 191.3249 1.63E-43 3.83E-42 
631 TRERF1 -1.22385 4.251048 74.02023 7.73E-18 6.64E-17 
632 FIGNL1 -2.51617 4.277732 225.5112 5.68E-51 1.66E-49 
633 ASPM -3.05577 4.279402 223.4129 1.63E-50 4.64E-49 
634 CCNE1 -1.48767 4.267012 166.8232 3.66E-38 7.26E-37 
635 ZNF43 -1.08378 4.256483 75.80417 3.13E-18 2.76E-17 
636 ZNF385B 1.068493 4.22953 69.82443 6.48E-17 5.28E-16 
637 CDC25C -2.27893 4.290442 264.1282 2.16E-59 7.58E-58 
638 URB2 -1.11889 4.236503 38.19154 6.41E-10 3.10E-09 
639 ANKRD37 2.81022 4.170971 283.5484 1.27E-63 4.73E-62 
640 DIAPH3 -2.22925 4.25633 369.7869 2.08E-82 1.20E-80 
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641 TTK -2.90284 4.256631 311.6591 9.50E-70 4.11E-68 
642 ANO7 1.582033 4.185993 108.8021 1.79E-25 2.30E-24 
643 ERN1 1.068375 4.156414 25.92961 3.54E-07 1.29E-06 
644 G2E3 -1.24851 4.193824 60.09737 9.03E-15 6.40E-14 
645 CHEK2 -2.14126 4.214408 301.1367 1.86E-67 7.56E-66 
646 AJUBA -1.16244 4.188373 94.40761 2.57E-22 2.81E-21 
647 TNFRSF21 -1.02892 4.174664 66.25842 3.96E-16 3.06E-15 
648 FICD 1.800882 4.140731 199.2631 3.02E-45 7.41E-44 
649 APLN -1.2229 4.181197 96.93863 7.15E-23 8.06E-22 
650 ISG20 1.287618 4.128919 78.58197 7.67E-19 7.03E-18 
651 MFHAS1 -1.02568 4.160037 58.37976 2.16E-14 1.49E-13 
652 HNRNPU-AS1 -1.19214 4.163327 101.998 5.56E-24 6.61E-23 
653 C1orf112 -1.62682 4.174699 153.3047 3.29E-35 5.98E-34 
654 LRR1 -1.19925 4.168088 114.8618 8.44E-27 1.14E-25 
655 RAB27A 1.065875 4.133523 59.69147 1.11E-14 7.81E-14 
656 AGR2 1.385475 4.086989 87.89266 6.91E-21 7.15E-20 
657 MIS18A -1.9019 4.160942 175.9537 3.71E-40 7.84E-39 
658 GPSM2 -2.34426 4.158148 244.1555 4.88E-55 1.57E-53 
659 PARVA 1.101712 4.083544 73.80191 8.64E-18 7.37E-17 
660 SGK1 2.090041 4.126749 152.5369 4.84E-35 8.72E-34 
661 ERCC6L -2.15891 4.124497 131.4457 1.98E-30 3.06E-29 
662 SGOL2 -2.27281 4.126562 258.6919 3.31E-58 1.14E-56 
663 KDM5B-AS1 1.06292 4.077932 57.56826 3.26E-14 2.21E-13 
664 CEP78 -1.87971 4.117113 172.2264 2.41E-39 5.01E-38 
665 PHTF2 -1.2045 4.090515 59.43018 1.27E-14 8.87E-14 
666 PDSS1 -1.36548 4.099026 128.4645 8.88E-30 1.33E-28 
667 MERTK 2.4027 4.034444 217.7853 2.75E-49 7.57E-48 
668 PSCA 1.005194 4.080927 60.38523 7.80E-15 5.54E-14 
669 KIF20B -2.91237 4.10426 356.1447 1.95E-79 1.04E-77 
670 CENPH -1.60544 4.09512 154.3255 1.97E-35 3.60E-34 
671 EXO1 -4.22236 4.094591 631.448 2.42E-139 2.90E-
137 
672 NEDD1 -1.27383 4.062327 68.38542 1.34E-16 1.07E-15 
673 MASTL -1.77061 4.07329 161.707 4.79E-37 9.10E-36 
674 TMEM150A 1.039055 4.032263 77.84202 1.12E-18 1.01E-17 
675 A1BG 1.398434 4.026405 41.66666 1.08E-10 5.57E-10 
676 HSPG2 -1.09465 4.046511 77.21183 1.54E-18 1.38E-17 
677 ACACB -1.32703 4.04808 62.16556 3.16E-15 2.31E-14 
678 SLC5A3 -1.34694 4.027646 47.76811 4.80E-12 2.78E-11 
679 NEURL1B -1.66536 4.042715 126.2141 2.76E-29 4.08E-28 
680 SKA1 -2.95702 4.036338 348.6993 8.14E-78 4.18E-76 
681 C1orf96 -1.62557 4.011396 118.7362 1.20E-27 1.67E-26 
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682 QSER1 -1.19693 3.992907 76.32404 2.41E-18 2.15E-17 
683 C11orf82 -2.4944 4.00667 188.4001 7.11E-43 1.63E-41 
684 TIPARP 2.133877 3.963071 165.3256 7.77E-38 1.51E-36 
685 PIF1 -2.52455 4.027417 217.1512 3.78E-49 1.04E-47 
686 C15orf42 -3.64515 4.010447 410.3408 3.09E-91 2.09E-89 
687 SLITRK3 -2.73803 3.984061 351.9018 1.63E-78 8.59E-77 
688 RELL2 1.165997 3.956934 56.75353 4.94E-14 3.30E-13 
689 CEP85 -1.24208 3.990531 54.28541 1.73E-13 1.11E-12 
690 C9orf40 -1.6649 3.979057 142.6632 6.96E-33 1.18E-31 
691 FAM123B -1.16898 3.947375 50.20149 1.39E-12 8.42E-12 
692 PLK4 -2.60187 3.956852 219.7499 1.03E-49 2.86E-48 
693 KIF15 -3.3208 3.955213 424.9456 2.05E-94 1.44E-92 
694 HERC5 1.284517 3.886767 130.0925 3.91E-30 5.97E-29 
695 DCLRE1B -2.14993 3.928038 234.2715 6.98E-53 2.17E-51 
696 RASD1 2.236472 3.863466 169.5251 9.40E-39 1.92E-37 
697 PLEKHA7 -1.03048 3.912357 43.92 3.42E-11 1.85E-10 
698 FBXO5 -2.25191 3.919201 200.8726 1.35E-45 3.35E-44 
699 DFFB -1.03534 3.895758 42.13086 8.54E-11 4.44E-10 
700 DEFB132 1.299497 3.856532 81.5667 1.69E-19 1.61E-18 
701 SERTAD1 1.155962 3.876137 62.81318 2.27E-15 1.68E-14 
702 C17orf107 1.615546 3.823275 156.3913 6.95E-36 1.29E-34 
703 CDH26 -1.22118 3.859626 70.65852 4.25E-17 3.49E-16 
704 MYCL1 1.088066 3.837652 56.65464 5.19E-14 3.46E-13 
705 CCP110 -1.34822 3.860193 80.912 2.36E-19 2.22E-18 
706 HIST1H2BC 1.438715 3.811325 76.83254 1.86E-18 1.67E-17 
707 SDC4 -1.41598 3.854239 124.185 7.67E-29 1.12E-27 
708 STXBP5L -1.379 3.84011 118.6546 1.25E-27 1.73E-26 
709 NCOA7 -1.06508 3.840618 52.72481 3.84E-13 2.42E-12 
710 PRIM1 -2.7987 3.862068 274.9707 9.37E-62 3.35E-60 
711 FANCE -1.44336 3.857833 118.6963 1.22E-27 1.70E-26 
712 RAD51AP1 -3.10514 3.858318 311.8686 8.55E-70 3.71E-68 
713 TIPIN -1.37836 3.843579 73.74915 8.87E-18 7.57E-17 
714 SLC7A2 -1.75815 3.830496 86.37052 1.49E-20 1.50E-19 
715 KIF24 -2.95619 3.858929 303.4058 5.97E-68 2.45E-66 
716 OIP5 -2.26235 3.853208 230.1571 5.51E-52 1.65E-50 
717 FAM176B 1.516353 3.800912 89.7365 2.72E-21 2.87E-20 
718 DUSP9 -1.16083 3.809888 58.29823 2.25E-14 1.55E-13 
719 HAUS8 -2.79464 3.827204 310.7765 1.48E-69 6.37E-68 
720 TRAIP -2.20067 3.817425 180.5902 3.60E-41 7.87E-40 
721 TTN 2.614608 3.775705 258.7871 3.15E-58 1.09E-56 
722 WNT10B -1.14977 3.778618 90.63025 1.73E-21 1.84E-20 
723 SUV39H2 -1.60642 3.784435 135.8789 2.12E-31 3.42E-30 
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724 B3GALT4 2.832441 3.720288 328.9995 1.59E-73 7.27E-72 
725 SMC6 -1.5804 3.776707 82.32832 1.15E-19 1.10E-18 
726 DPYSL2 -1.26224 3.758385 59.14969 1.46E-14 1.02E-13 
727 IQCC -1.51402 3.759863 116.9337 2.97E-27 4.07E-26 
728 FLJ41484 -1.5235 3.741278 84.19088 4.49E-20 4.40E-19 
729 GINS3 -1.73824 3.756026 119.3809 8.64E-28 1.21E-26 
730 RAD51 -2.98367 3.756982 395.1846 6.15E-88 4.00E-86 
731 MNS1 -2.44062 3.749475 184.9116 4.10E-42 9.25E-41 
732 LOC728554 -1.30577 3.73998 107.1871 4.05E-25 5.11E-24 
733 LOC219347 -1.01781 3.749536 48.77995 2.86E-12 1.69E-11 
734 E2F2 -3.57466 3.755456 479.6686 2.52E-106 1.96E-
104 
735 CTDSPL2 -1.27314 3.720102 44.89663 2.08E-11 1.14E-10 
736 SLC27A2 -1.61449 3.725654 128.8359 7.37E-30 1.11E-28 
737 SH3D21 2.647745 3.671158 234.1186 7.54E-53 2.34E-51 
738 KIAA1524 -2.11234 3.73011 165.4529 7.28E-38 1.42E-36 
739 SPC25 -2.5445 3.737694 215.2429 9.86E-49 2.67E-47 
740 GSTCD -1.99654 3.706872 143.8889 3.76E-33 6.39E-32 
741 LRCH1 1.206261 3.675248 44.32163 2.79E-11 1.51E-10 
742 SYBU -1.16677 3.678905 66.81248 2.99E-16 2.33E-15 
743 HIST1H4H 1.486856 3.628909 48.00753 4.25E-12 2.47E-11 
744 KIF14 -2.71377 3.700978 226.7791 3.00E-51 8.92E-50 
745 PRKD3 -1.19138 3.679304 69.00198 9.84E-17 7.93E-16 
746 TBX15 2.031142 3.649352 186.9746 1.45E-42 3.31E-41 
747 ESCO2 -3.55128 3.678045 255.0783 2.03E-57 6.78E-56 
748 ORM1 4.646724 3.584169 558.3566 1.91E-123 1.91E-
121 
749 CASC5 -3.54596 3.668182 281.3416 3.83E-63 1.41E-61 
750 ZFP36L2 -1.40277 3.646974 107.2857 3.85E-25 4.87E-24 
751 BRI3BP -1.04553 3.644973 38.75384 4.81E-10 2.35E-09 
752 CA12 -1.41513 3.646291 119.7792 7.07E-28 9.95E-27 
753 CCNE2 -3.26585 3.647541 258.1389 4.37E-58 1.49E-56 
754 NRGN -1.17895 3.657298 49.72338 1.77E-12 1.07E-11 
755 JDP2 -1.15876 3.63517 58.98903 1.59E-14 1.10E-13 
756 CSGALNACT1 3.40068 3.570962 363.437 5.03E-81 2.80E-79 
757 KHK -1.37881 3.631483 61.99874 3.44E-15 2.51E-14 
758 ERI1 -1.72734 3.606816 160.2264 1.01E-36 1.91E-35 
759 MMP16 -2.2333 3.620427 137.2339 1.07E-31 1.75E-30 
760 CHML -1.2323 3.599155 44.99648 1.97E-11 1.09E-10 
761 HPGD 2.109722 3.546501 143.4881 4.60E-33 7.81E-32 
762 WDR67 -1.25399 3.621995 55.63943 8.71E-14 5.72E-13 
763 PARPBP -2.4475 3.618575 156.3664 7.04E-36 1.30E-34 
764 NUP35 -1.19488 3.598997 66.57558 3.37E-16 2.62E-15 
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765 DSCC1 -2.13346 3.614539 182.6449 1.28E-41 2.85E-40 
766 SLC15A2 1.385816 3.573008 87.0846 1.04E-20 1.06E-19 
767 KLF5 1.288376 3.562063 62.57721 2.56E-15 1.89E-14 
768 IL17RB -1.99178 3.581358 160.1375 1.06E-36 1.99E-35 
769 ENPP1 -1.21258 3.559328 62.39313 2.81E-15 2.06E-14 
770 SPTBN4 1.395943 3.522144 108.7891 1.81E-25 2.31E-24 
771 LAT2 2.427611 3.494342 149.5321 2.19E-34 3.90E-33 
772 ORM2 4.097867 3.458973 353.356 7.88E-79 4.18E-77 
773 SNHG12 -1.30454 3.53138 75.89123 3.00E-18 2.65E-17 
774 CENPL -1.79845 3.539967 99.88182 1.62E-23 1.88E-22 
775 HSPA4L -1.67534 3.524468 59.37183 1.31E-14 9.13E-14 
776 LRRN1 -1.61001 3.495236 76.19264 2.57E-18 2.29E-17 
777 BARD1 -2.55148 3.507466 129.8716 4.37E-30 6.65E-29 
778 KCNQ4 -1.01167 3.498545 33.61509 6.72E-09 2.94E-08 
779 CAMK2B -1.14934 3.51744 58.65534 1.88E-14 1.30E-13 
780 CKAP2L -2.74072 3.497197 218.0685 2.39E-49 6.58E-48 
781 EXPH5 -1.15146 3.457627 52.61518 4.06E-13 2.55E-12 
782 CECR6 2.186917 3.43316 78.76437 7.00E-19 6.42E-18 
783 LOC100128191 -2.64894 3.508863 224.3989 9.93E-51 2.86E-49 
784 HS3ST1 1.066131 3.47225 54.76213 1.36E-13 8.81E-13 
785 NT5C3 -1.00783 3.470744 34.14562 5.11E-09 2.27E-08 
786 OSGEPL1 -1.16074 3.469654 51.25061 8.13E-13 5.03E-12 
787 C14orf132 -1.01481 3.467186 35.43416 2.64E-09 1.20E-08 
788 HAUS3 -1.43001 3.459513 101.3935 7.54E-24 8.91E-23 
789 CDC14B 1.323304 3.421135 65.15301 6.93E-16 5.31E-15 
790 TAF5 -1.16492 3.458455 55.89393 7.65E-14 5.05E-13 
791 SGOL1 -2.76634 3.475341 261.1823 9.48E-59 3.29E-57 
792 KLF10 -1.1361 3.443025 62.58935 2.55E-15 1.88E-14 
793 ADCY1 -1.64174 3.444643 130.4402 3.28E-30 5.03E-29 
794 ZNF107 -1.66983 3.428667 96.52452 8.81E-23 9.90E-22 
795 RNF43 -1.28268 3.445817 63.50381 1.60E-15 1.19E-14 
796 RMI2 -3.02067 3.453655 276.6049 4.13E-62 1.49E-60 
797 ZAK -1.94421 3.440323 118.3677 1.44E-27 1.99E-26 
798 CENPA -2.92953 3.460974 297.4671 1.17E-66 4.68E-65 
799 APOBEC3B -1.35257 3.444421 85.66577 2.13E-20 2.13E-19 
800 DDX12P -2.2256 3.44998 158.0284 3.05E-36 5.68E-35 
801 KLF4 1.189636 3.388472 52.24152 4.91E-13 3.07E-12 
802 TRIM59 -1.45269 3.408551 122.5707 1.73E-28 2.50E-27 
803 VLDLR 1.481824 3.381713 115.8754 5.06E-27 6.88E-26 
804 DONSON -2.00066 3.413257 158.1582 2.86E-36 5.33E-35 
805 SWT1 1.644071 3.366704 73.42668 1.04E-17 8.88E-17 
806 DNA2 -2.76689 3.405734 150.8371 1.14E-34 2.03E-33 
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807 LIN54 -1.04281 3.402325 31.36063 2.14E-08 8.94E-08 
808 GEN1 -1.9078 3.395221 136.0877 1.91E-31 3.08E-30 
809 EPB41L2 -1.04174 3.39408 52.91812 3.48E-13 2.19E-12 
810 FAM134B -1.29243 3.367858 58.6655 1.87E-14 1.29E-13 
811 E2F8 -3.81998 3.392733 317.5903 4.85E-71 2.15E-69 
812 ZNF367 -4.32813 3.380485 299.4173 4.41E-67 1.77E-65 
813 NNMT 1.047581 3.347602 41.63383 1.10E-10 5.66E-10 
814 ZNF100 -1.04783 3.352851 24.02709 9.50E-07 3.32E-06 
815 ABCG1 1.105241 3.311829 28.89807 7.63E-08 3.02E-07 
816 BLM -3.41356 3.366816 279.0465 1.21E-62 4.43E-61 
817 SPATA5 -1.32015 3.348486 71.99 2.16E-17 1.81E-16 
818 GSG2 -3.4629 3.364504 362.7189 7.20E-81 3.99E-79 
819 SNHG4 -1.14853 3.330395 57.11487 4.11E-14 2.77E-13 
820 SLC6A6 -1.40983 3.336926 52.14168 5.16E-13 3.23E-12 
821 PRKY -1.60872 3.323492 99.28248 2.19E-23 2.53E-22 
822 CENPJ -1.85117 3.341224 63.57473 1.54E-15 1.15E-14 
823 NKPD1 1.02814 3.292974 34.08192 5.28E-09 2.34E-08 
824 ANKRD32 -1.16676 3.32541 38.79946 4.70E-10 2.29E-09 
825 ZIK1 -1.29188 3.317349 87.37181 8.99E-21 9.22E-20 
826 SCLT1 -1.33599 3.308964 73.59365 9.60E-18 8.18E-17 
827 CRISPLD2 2.077797 3.259313 107.2989 3.83E-25 4.85E-24 
828 C17orf48 1.018594 3.271453 37.04864 1.15E-09 5.42E-09 
829 SASS6 -1.95293 3.282375 115.6829 5.58E-27 7.56E-26 
830 LRRCC1 -1.39311 3.277272 51.58085 6.87E-13 4.26E-12 
831 COLEC12 -1.32371 3.262694 86.10465 1.71E-20 1.71E-19 
832 MND1 -3.12209 3.307658 199.8417 2.26E-45 5.55E-44 
833 DNMT3B -1.44814 3.284436 76.21404 2.55E-18 2.27E-17 
834 PKIB -1.07747 3.267757 49.06057 2.48E-12 1.48E-11 
835 C18orf56 -1.22464 3.292778 39.3162 3.60E-10 1.78E-09 
836 CDH24 -1.19277 3.281354 44.90404 2.07E-11 1.14E-10 
837 ADAT2 -1.02294 3.251893 37.47591 9.25E-10 4.41E-09 
838 TRNP1 -1.25211 3.254968 44.57074 2.45E-11 1.34E-10 
839 CCDC15 -1.00268 3.260078 33.55018 6.94E-09 3.04E-08 
840 SLC2A3 4.014408 3.21207 331.2792 5.06E-74 2.37E-72 
841 KIAA1656 1.186426 3.234862 50.09021 1.47E-12 8.89E-12 
842 NEIL3 -3.04605 3.264715 255.398 1.73E-57 5.80E-56 
843 MAPRE2 -1.00429 3.23097 49.70027 1.79E-12 1.08E-11 
844 LRRC37A4 -1.16917 3.225988 40.99446 1.53E-10 7.78E-10 
845 LOC401431 -1.08407 3.196361 38.23166 6.28E-10 3.04E-09 
846 C4orf46 -3.12073 3.184868 187.1242 1.35E-42 3.07E-41 
847 WDR76 -2.68684 3.182243 224.8671 7.85E-51 2.29E-49 
848 ANG 1.814142 3.110239 102.8918 3.54E-24 4.26E-23 
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849 OPTN 1.691043 3.098588 105.9395 7.60E-25 9.41E-24 
850 CEP152 -2.1307 3.15379 94.95323 1.95E-22 2.15E-21 
851 RBL1 -2.58173 3.150147 110.088 9.37E-26 1.21E-24 
852 TMEM107 -1.16554 3.156484 43.78547 3.66E-11 1.97E-10 
853 TRPV1 -1.04874 3.148863 34.01874 5.46E-09 2.41E-08 
854 NOC3L -1.00389 3.126805 58.27829 2.28E-14 1.56E-13 
855 ARMC12 2.123023 3.118034 143.9772 3.59E-33 6.12E-32 
856 RELL1 -1.27884 3.118836 50.25672 1.35E-12 8.23E-12 
857 SNAI2 2.481717 3.122005 204.8473 1.83E-46 4.68E-45 
858 TEX30 -1.4719 3.122972 64.3744 1.03E-15 7.80E-15 
859 XRCC2 -3.57366 3.10956 315.5248 1.37E-70 6.00E-69 
860 BEND3 -1.3985 3.096632 64.15968 1.15E-15 8.66E-15 
861 PTPRN2 2.082654 3.083282 176.1122 3.42E-40 7.26E-39 
862 BRCA2 -3.54997 3.112857 295.2399 3.59E-66 1.42E-64 
863 POLR3G -1.45319 3.092283 70.21691 5.31E-17 4.35E-16 
864 HELLS -3.3891 3.100935 162.3502 3.47E-37 6.64E-36 
865 PART1 1.712935 3.060102 77.45019 1.36E-18 1.23E-17 
866 CDCA7 -3.07772 3.091576 202.5467 5.81E-46 1.46E-44 
867 SLC45A1 1.032657 3.046409 39.69559 2.97E-10 1.48E-09 
868 KIAA1211 -1.41924 3.092965 57.84276 2.84E-14 1.93E-13 
869 LOC642846 -2.5479 3.100182 114.2246 1.16E-26 1.57E-25 
870 NR1D1 -1.21055 3.063159 49.29168 2.21E-12 1.32E-11 
871 SLC31A2 1.143838 3.039866 39.33853 3.56E-10 1.76E-09 
872 PER2 -1.27893 3.059703 42.4396 7.29E-11 3.82E-10 
873 CASP8AP2 -1.132 3.045985 34.18097 5.02E-09 2.23E-08 
874 FAM178A -1.261 3.030438 44.4955 2.55E-11 1.39E-10 
875 CLDN8 1.161157 3.026854 59.4506 1.25E-14 8.79E-14 
876 ODF3B 1.054682 3.018693 45.6125 1.44E-11 8.00E-11 
877 LOC100129480 1.568523 2.993878 57.22885 3.88E-14 2.62E-13 
878 CEP128 -2.23337 3.035504 123.0141 1.38E-28 2.00E-27 
879 C16orf55 -1.27736 3.024729 51.41188 7.49E-13 4.64E-12 
880 CHRNA5 -1.24955 3.008231 57.56419 3.27E-14 2.22E-13 
881 CEP68 -1.2034 2.994158 46.65497 8.47E-12 4.79E-11 
882 ABTB1 1.586115 2.970268 107.5077 3.45E-25 4.38E-24 
883 RNASE4 1.730216 2.948282 60.43789 7.59E-15 5.40E-14 
884 S100P 2.105736 2.925508 96.50694 8.89E-23 9.98E-22 
885 MMS22L -2.38191 3.000201 117.5078 2.22E-27 3.06E-26 
886 FANCM -1.23901 2.987179 49.32213 2.17E-12 1.30E-11 
887 NHSL1 -1.06838 2.98745 34.67221 3.90E-09 1.75E-08 
888 SPATA18 -1.43826 2.974484 69.01939 9.75E-17 7.86E-16 
889 ZNF704 -1.00002 2.96406 28.36926 1.00E-07 3.90E-07 
890 PTGER4 1.524584 2.933251 54.94859 1.24E-13 8.03E-13 
 




2.154137 2.922719 113.8169 1.43E-26 1.92E-25 
892 CCDC18 -1.80017 2.956273 63.77814 1.39E-15 1.04E-14 
893 MTMR11 1.026313 2.937255 21.65315 3.27E-06 1.06E-05 
894 E2F7 -4.91385 2.942007 247.2552 1.03E-55 3.34E-54 
895 AKAP12 2.532329 2.863866 121.4501 3.05E-28 4.36E-27 
896 CENPI -3.01173 2.932829 251.4544 1.25E-56 4.16E-55 
897 ALOXE3 -1.08352 2.913425 36.00663 1.97E-09 9.07E-09 
898 CAMK2D -1.55716 2.911014 80.60872 2.75E-19 2.58E-18 
899 ZNF551 -1.54863 2.898383 62.83916 2.24E-15 1.66E-14 
900 CENPK -3.0927 2.918185 154.9931 1.41E-35 2.58E-34 
901 ALG10B -1.09698 2.904789 31.75831 1.75E-08 7.35E-08 
902 SORL1 -1.73064 2.907479 82.575 1.02E-19 9.78E-19 
903 AZGP1P1 1.403957 2.87277 58.04092 2.57E-14 1.75E-13 
904 DOK3 -1.19857 2.904108 26.44425 2.71E-07 1.01E-06 
905 ZNF850 -1.43981 2.877071 58.69405 1.84E-14 1.27E-13 
906 HIST1H2BG 1.137454 2.850955 14.86339 0.000116 0.000304 
907 PAG1 -1.88583 2.895752 81.31123 1.93E-19 1.82E-18 
908 FAM40B -1.56009 2.899425 66.90838 2.84E-16 2.23E-15 
909 POLE2 -2.15642 2.88688 67.75599 1.85E-16 1.46E-15 
910 C16orf7 1.233663 2.858755 45.09093 1.88E-11 1.04E-10 
911 SCML2 -2.04179 2.881585 117.5708 2.15E-27 2.97E-26 
912 ADAM22 -1.36209 2.873116 45.25893 1.73E-11 9.55E-11 
913 CEP57L1 -1.37994 2.870672 46.51872 9.07E-12 5.11E-11 
914 TMCC3 2.885206 2.843765 167.1876 3.04E-38 6.09E-37 
915 LIN9 -2.98293 2.863285 172.5152 2.09E-39 4.35E-38 
916 AUTS2 -1.69129 2.864932 86.86803 1.16E-20 1.18E-19 
917 SORBS2 -1.56091 2.85289 78.51926 7.92E-19 7.25E-18 
918 LOC730101 -1.37135 2.832468 75.19295 4.27E-18 3.72E-17 
919 SNX16 1.058401 2.809404 25.65605 4.08E-07 1.48E-06 
920 SOX8 -1.52318 2.821924 63.5696 1.55E-15 1.16E-14 
921 CENPQ -2.06973 2.832032 102.4547 4.41E-24 5.27E-23 
922 PLXDC2 1.159774 2.807117 47.19046 6.44E-12 3.68E-11 
923 KIF18A -2.58675 2.830089 132.4496 1.19E-30 1.86E-29 
924 BRIP1 -3.62238 2.817232 209.6381 1.65E-47 4.34E-46 
925 KDELC1 -1.19361 2.78665 47.68966 4.99E-12 2.89E-11 
926 HSD17B11 1.36911 2.747794 53.85517 2.16E-13 1.38E-12 
927 PTPRCAP 1.180093 2.765529 15.88675 6.72E-05 0.000183 
928 ZMYM1 -1.20525 2.77071 26.19817 3.08E-07 1.13E-06 
929 SERPINI1 -1.30872 2.778014 44.85772 2.12E-11 1.16E-10 
930 LOC100288637 -2.51647 2.787301 95.18491 1.73E-22 1.92E-21 
931 FAM86B1 -1.08404 2.747808 39.62318 3.08E-10 1.53E-09 
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932 DPYSL5 -1.27905 2.748075 30.95906 2.64E-08 1.09E-07 
933 NANP -1.35702 2.750439 40.8687 1.63E-10 8.28E-10 
934 ZNF530 -1.69082 2.748085 75.36687 3.91E-18 3.42E-17 
935 FAM69A 1.22512 2.717053 32.20534 1.39E-08 5.89E-08 
936 KLF11 -1.54491 2.741484 46.76429 8.01E-12 4.55E-11 
937 AMACR 2.005658 2.704537 66.28415 3.90E-16 3.03E-15 
938 SRCIN1 -1.58181 2.725143 84.74002 3.40E-20 3.37E-19 
939 ZNF124 -1.45314 2.735325 47.93472 4.41E-12 2.56E-11 
940 ENO2 -1.49626 2.725995 49.35197 2.14E-12 1.28E-11 
941 LOC100506469 -1.02567 2.717116 28.40661 9.83E-08 3.83E-07 
942 RELT -2.53494 2.732905 65.19319 6.79E-16 5.20E-15 
943 RTKN2 -2.06478 2.716191 94.11113 2.98E-22 3.26E-21 
944 RNF219 -1.00003 2.694821 23.15978 1.49E-06 5.07E-06 
945 DPF1 -1.24215 2.71074 47.67369 5.03E-12 2.91E-11 
946 GLDC -1.13095 2.691858 39.18088 3.86E-10 1.90E-09 
947 NUAK2 -1.70525 2.692936 62.80441 2.28E-15 1.69E-14 
948 DENND5B -1.17903 2.673064 37.88917 7.49E-10 3.60E-09 
949 PLK3 -1.45445 2.672837 73.33306 1.10E-17 9.30E-17 
950 SLMO1 -1.08521 2.67575 37.99684 7.09E-10 3.42E-09 
951 ZNF93 -1.11103 2.671161 34.28057 4.77E-09 2.12E-08 
952 KHDRBS3 -1.15034 2.672515 25.4356 4.57E-07 1.65E-06 
953 LIMD2 1.271281 2.63981 49.16096 2.36E-12 1.41E-11 
954 CEP97 -1.05388 2.653911 24.20318 8.67E-07 3.04E-06 
955 RTTN -1.63953 2.656886 71.61399 2.62E-17 2.18E-16 
956 ESPN -1.08073 2.646307 32.31347 1.31E-08 5.59E-08 
957 IER5 -1.89334 2.65326 84.15907 4.57E-20 4.47E-19 
958 TAF4B -1.32777 2.630413 39.20987 3.81E-10 1.87E-09 
959 C17orf53 -2.47448 2.658987 124.9219 5.29E-29 7.74E-28 
960 HLF -1.60576 2.636684 95.70296 1.33E-22 1.49E-21 
961 EPS8L1 2.620432 2.587459 90.74023 1.64E-21 1.75E-20 
962 CBLN2 -1.92761 2.632524 96.20168 1.04E-22 1.16E-21 
963 CPEB3 1.213971 2.58833 36.86618 1.27E-09 5.92E-09 
964 FCHSD1 1.253142 2.608096 33.80884 6.08E-09 2.67E-08 
965 ZNF136 -1.01757 2.620838 21.04429 4.49E-06 1.44E-05 
966 NPPC 2.723005 2.599821 139.9337 2.75E-32 4.58E-31 
967 THBS1 -1.83254 2.637855 52.05617 5.39E-13 3.37E-12 
968 RASSF5 -1.12099 2.597728 43.365 4.54E-11 2.41E-10 
969 EGLN3 -1.57213 2.609625 68.63082 1.19E-16 9.53E-16 
970 SFTPA2 -1.00607 2.601936 39.58828 3.14E-10 1.56E-09 
971 FERMT2 1.690235 2.570251 39.15683 3.91E-10 1.92E-09 
972 WLS -1.03426 2.598078 25.16743 5.26E-07 1.88E-06 
973 MYBPC1 1.523943 2.566469 58.62965 1.90E-14 1.31E-13 
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974 NOVA1 -1.0091 2.59571 32.33856 1.30E-08 5.53E-08 
975 IL1RN -2.1615 2.568722 102.6374 4.02E-24 4.83E-23 
976 ZNF738 -1.45842 2.59568 50.2456 1.36E-12 8.27E-12 
977 PPARGC1B -1.6331 2.565518 42.67018 6.48E-11 3.41E-10 
978 FAM72D -2.61545 2.584525 112.6984 2.51E-26 3.32E-25 
979 CDH15 1.391528 2.543718 48.69188 3.00E-12 1.77E-11 
980 KCNH2 1.106511 2.54331 23.42814 1.30E-06 4.44E-06 
981 LOC100289019 -1.28144 2.565203 39.2761 3.68E-10 1.81E-09 
982 GSN 1.332322 2.527229 59.26114 1.38E-14 9.64E-14 
983 DOK4 1.13866 2.530696 47.32529 6.01E-12 3.45E-11 
984 MYL9 2.356212 2.49094 176.7636 2.47E-40 5.25E-39 
985 PBX1 -1.37297 2.539773 32.30585 1.32E-08 5.61E-08 
986 DMBX1 -3.31864 2.55599 187.633 1.04E-42 2.38E-41 
987 C4orf21 -2.70675 2.540547 118.6437 1.25E-27 1.74E-26 
988 SFR1 -1.56724 2.538136 47.53869 5.39E-12 3.11E-11 
989 SPIN4 -1.75798 2.517004 53.11968 3.14E-13 1.98E-12 
990 PMAIP1 -2.07863 2.526016 99.02954 2.49E-23 2.87E-22 
991 PPP1R14C -1.86232 2.519561 66.34634 3.78E-16 2.94E-15 
992 SLC16A10 -1.49963 2.5063 54.31323 1.71E-13 1.10E-12 
993 PRSS53 -1.1251 2.485032 28.66805 8.59E-08 3.37E-07 
994 STON2 -2.096 2.486208 91.17675 1.31E-21 1.40E-20 
995 HES2 1.223881 2.445505 52.51301 4.27E-13 2.68E-12 
996 KAZN -1.26518 2.447172 37.58481 8.75E-10 4.18E-09 
997 MAP1A -1.09005 2.453251 23.67543 1.14E-06 3.94E-06 
998 DGKA 1.866233 2.423003 94.02393 3.12E-22 3.41E-21 
999 LPCAT4 -1.10384 2.449361 40.44437 2.02E-10 1.02E-09 
1000 EPS8 -1.72946 2.417679 74.86677 5.04E-18 4.36E-17 
1001 GCFC1-AS1 1.288144 2.399184 50.20985 1.38E-12 8.39E-12 
1002 CEP72 -1.9532 2.416237 79.32761 5.26E-19 4.85E-18 
1003 ARPM1 -1.6938 2.400956 61.32243 4.85E-15 3.49E-14 
1004 SLITRK6 1.716986 2.375405 56.18784 6.59E-14 4.36E-13 
1005 SPOCK1 1.862883 2.378154 75.15071 4.36E-18 3.79E-17 
1006 PAX1 -1.15955 2.383393 25.69356 4.00E-07 1.45E-06 
1007 LOC388588 1.114402 2.351305 22.85323 1.75E-06 5.90E-06 
1008 FLJ43663 2.383105 2.350449 103.4788 2.63E-24 3.19E-23 
1009 PCDH11Y -1.0438 2.346546 15.69972 7.42E-05 0.000201 
1010 ANK1 1.231433 2.307912 32.85622 9.92E-09 4.28E-08 
1011 KANK1 1.113171 2.305604 26.79755 2.26E-07 8.44E-07 
1012 FAM54A -2.9195 2.328249 126.3087 2.63E-29 3.90E-28 
1013 C1orf135 -3.51417 2.327583 195.0289 2.54E-44 6.09E-43 
1014 FAM72B -3.14189 2.327372 182.0249 1.75E-41 3.86E-40 
1015 NAV3 -2.87294 2.307982 173.5452 1.24E-39 2.60E-38 
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1016 RPP25 -2.247 2.319348 73.56585 9.73E-18 8.28E-17 
1017 FAM110C 1.266511 2.277315 36.74183 1.35E-09 6.30E-09 
1018 FERMT1 -1.62606 2.296089 37.68478 8.32E-10 3.98E-09 
1019 CCPG1 1.103146 2.264724 16.39262 5.15E-05 0.000143 
1020 TLN2 -1.32066 2.295772 41.96012 9.32E-11 4.83E-10 
1021 NUP62CL -1.23328 2.266863 52.39818 4.53E-13 2.84E-12 
1022 ATAD5 -3.02111 2.251379 163.2787 2.17E-37 4.20E-36 
1023 C18orf54 -3.36421 2.27838 120.4654 5.00E-28 7.07E-27 
1024 LRIG3 -1.68613 2.253936 63.85011 1.34E-15 1.01E-14 
1025 TUBA3E 1.549677 2.242307 34.19097 5.00E-09 2.22E-08 
1026 S1PR3 -2.1669 2.257376 86.43685 1.44E-20 1.46E-19 
1027 RGS16 1.144013 2.23219 22.22318 2.43E-06 8.05E-06 
1028 FLJ27352 1.440643 2.215473 43.63146 3.96E-11 2.13E-10 
1029 RDH12 1.17123 2.198395 28.03445 1.19E-07 4.58E-07 
1030 WWTR1 1.395273 2.20958 40.19173 2.30E-10 1.16E-09 
1031 SPRY1 -1.39013 2.229203 40.37813 2.09E-10 1.05E-09 
1032 HIST1H3E 1.072551 2.199202 24.40843 7.79E-07 2.75E-06 
1033 C19orf57 -1.48688 2.232643 39.45573 3.36E-10 1.66E-09 
1034 ATG16L2 -1.04803 2.229414 18.44324 1.75E-05 5.17E-05 
1035 ABCA12 -2.10961 2.211496 79.61031 4.56E-19 4.22E-18 
1036 FAM81A -2.04924 2.201616 74.27069 6.81E-18 5.86E-17 
1037 BAI2 -2.08205 2.210137 67.83247 1.78E-16 1.41E-15 
1038 SLC35G1 -1.1792 2.189683 30.6818 3.04E-08 1.25E-07 
1039 DOC2A -1.18475 2.18977 23.712 1.12E-06 3.87E-06 
1040 CEL -1.57992 2.20338 55.45546 9.56E-14 6.25E-13 
1041 TNFAIP3 1.815204 2.169242 49.47055 2.01E-12 1.21E-11 
1042 MIR210HG 1.020706 2.177146 19.53759 9.86E-06 3.02E-05 
1043 ARL6IP6 -1.51766 2.183627 40.6177 1.85E-10 9.37E-10 
1044 ACSM1 1.127692 2.158517 34.81551 3.62E-09 1.63E-08 
1045 EML5 -1.33987 2.166066 30.82732 2.82E-08 1.17E-07 
1046 SPTLC3 -1.13605 2.163615 23.00166 1.62E-06 5.48E-06 
1047 SPTB 3.032926 2.147878 135.5347 2.52E-31 4.05E-30 
1048 NTNG1 1.119156 2.142932 19.52801 9.91E-06 3.03E-05 
1049 ACTA2 2.44597 2.1205 156.0955 8.07E-36 1.49E-34 
1050 C3orf67 -1.29347 2.155856 37.66297 8.41E-10 4.03E-09 
1051 BORA -1.72587 2.176648 37.17712 1.08E-09 5.09E-09 
1052 B4GALT6 -1.2244 2.154657 25.74113 3.90E-07 1.42E-06 
1053 ALG10 -1.39232 2.136098 24.05594 9.36E-07 3.27E-06 
1054 RDM1 -1.56178 2.141119 45.98921 1.19E-11 6.63E-11 
1055 RPS6KA5 -1.07954 2.128145 21.25958 4.01E-06 1.29E-05 
1056 LOC100128361 -2.17419 2.14019 44.19524 2.97E-11 1.61E-10 
1057 MAP2K6 -1.53591 2.121205 42.30775 7.80E-11 4.07E-10 
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1058 DGKH -1.62531 2.105578 48.41111 3.46E-12 2.03E-11 
1059 TMEM198 1.231294 2.101973 25.52855 4.36E-07 1.57E-06 
1060 IL36RN -1.1089 2.081946 20.08638 7.40E-06 2.31E-05 
1061 DOCK8 1.663145 2.079418 32.76555 1.04E-08 4.48E-08 
1062 FHOD3 -1.31769 2.096363 37.30608 1.01E-09 4.79E-09 
1063 C1orf95 -1.35075 2.078048 41.48846 1.19E-10 6.08E-10 
1064 C5orf34 -2.76075 2.086564 114.4972 1.01E-26 1.37E-25 
1065 CARTPT 1.052406 2.075935 21.50327 3.53E-06 1.15E-05 
1066 OSBPL3 -2.34789 2.079187 85.02476 2.95E-20 2.92E-19 
1067 FAM83E 2.570063 2.024604 107.6969 3.13E-25 3.99E-24 
1068 CENPP -1.77688 2.063449 54.67616 1.42E-13 9.20E-13 
1069 CEP135 -1.27049 2.048791 29.50725 5.57E-08 2.24E-07 
1070 HIST1H3D 1.690032 1.974339 49.53411 1.95E-12 1.17E-11 
1071 KDELR3 1.558803 1.967166 28.79817 8.03E-08 3.17E-07 
1072 FRK 1.02276 1.974574 15.75645 7.20E-05 0.000195 
1073 SLCO5A1 -1.09875 1.979989 19.63936 9.35E-06 2.87E-05 
1074 FAM72A -2.5642 1.984398 93.7363 3.60E-22 3.93E-21 
1075 KCNRG 1.069423 1.965047 21.55398 3.44E-06 1.12E-05 
1076 NKD1 -1.47093 1.974114 37.45952 9.33E-10 4.44E-09 
1077 TERT -4.1561 1.971424 246.2368 1.72E-55 5.55E-54 
1078 NDUFA4L2 1.904308 1.937276 41.22357 1.36E-10 6.93E-10 
1079 GLS2 -1.38334 1.960414 36.6204 1.44E-09 6.68E-09 
1080 C8orf37 -1.2345 1.947375 25.65078 4.09E-07 1.48E-06 
1081 VASH2 -1.26784 1.942977 31.99667 1.54E-08 6.53E-08 
1082 FAM184A -1.31369 1.932584 23.43671 1.29E-06 4.43E-06 
1083 SPRY4 1.809711 1.907563 58.10853 2.48E-14 1.70E-13 
1084 SNORD96A -1.09602 1.933839 15.86783 6.79E-05 0.000185 
1085 FOXN4 -2.57939 1.923733 80.97104 2.29E-19 2.15E-18 
1086 LRFN2 -1.52234 1.906427 34.05736 5.35E-09 2.37E-08 
1087 FAM86HP -1.49703 1.901182 24.93247 5.94E-07 2.12E-06 
1088 ZPLD1 -1.30848 1.89286 23.56633 1.21E-06 4.16E-06 
1089 TACSTD2 1.237194 1.870662 28.80697 8.00E-08 3.16E-07 
1090 TLL1 -2.60858 1.876395 108.2262 2.40E-25 3.06E-24 
1091 SYP 1.090691 1.866526 23.87587 1.03E-06 3.57E-06 
1092 CHAC2 -1.83655 1.881431 41.94793 9.37E-11 4.86E-10 
1093 IL1RAP -1.20648 1.875948 21.87642 2.91E-06 9.55E-06 
1094 TNS4 2.242506 1.830132 62.23311 3.05E-15 2.23E-14 
1095 BMX -2.1776 1.871175 64.00359 1.24E-15 9.34E-15 
1096 CNKSR2 -1.27943 1.850409 21.95448 2.79E-06 9.20E-06 
1097 LOC399815 -1.48621 1.850908 43.12363 5.14E-11 2.72E-10 
1098 PLS1 -1.06651 1.836253 22.50702 2.09E-06 7.01E-06 
1099 CYP2E1 1.235881 1.832136 23.47648 1.26E-06 4.34E-06 
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1100 RPL36A -1.00276 1.831481 19.38397 1.07E-05 3.25E-05 
1101 GRID2IP 1.011762 1.81248 21.0586 4.45E-06 1.43E-05 
1102 ZNF670 -1.21212 1.826519 24.04651 9.40E-07 3.29E-06 
1103 PDE4A -1.3815 1.818773 31.52318 1.97E-08 8.26E-08 
1104 MREG -1.03493 1.818472 22.39408 2.22E-06 7.40E-06 
1105 ZNF273 -1.77619 1.823732 43.52925 4.18E-11 2.23E-10 
1106 RIMS4 -1.81132 1.806549 67.9084 1.71E-16 1.36E-15 
1107 SP4 -1.38909 1.795308 19.90012 8.16E-06 2.53E-05 
1108 SOBP -1.4504 1.793005 28.3486 1.01E-07 3.94E-07 
1109 SCARA3 -2.28258 1.78656 64.34631 1.04E-15 7.90E-15 
1110 SSTR5 -2.0986 1.760856 78.42893 8.29E-19 7.58E-18 
1111 LTB4R2 -1.07409 1.765178 14.40708 0.000147 0.000382 
1112 LOC100505633 -1.34983 1.774233 20.58555 5.70E-06 1.80E-05 
1113 SNCG 2.141418 1.739804 86.96288 1.11E-20 1.12E-19 
1114 FHIT 1.638182 1.726672 42.47578 7.16E-11 3.75E-10 
1115 APCDD1 -1.0052 1.741211 19.11834 1.23E-05 3.71E-05 
1116 IRX5 -1.26884 1.752793 23.92784 1.00E-06 3.48E-06 
1117 TMOD2 -1.15865 1.73486 21.77992 3.06E-06 1.00E-05 
1118 ASPHD2 1.504459 1.715996 35.25951 2.89E-09 1.31E-08 
1119 PTCRA 1.930257 1.688935 46.68008 8.36E-12 4.73E-11 
1120 CNIH2 -1.21141 1.724738 18.62461 1.59E-05 4.73E-05 
1121 BEST1 -2.16933 1.710968 46.46788 9.31E-12 5.25E-11 
1122 MTBP -2.65029 1.698324 89.12618 3.70E-21 3.88E-20 
1123 TNNT1 1.092825 1.675933 10.44822 0.001228 0.002736 
1124 ZNF695 -2.35394 1.697929 60.84913 6.16E-15 4.41E-14 
1125 TG 4.1646 1.638793 192.4292 9.38E-44 2.22E-42 
1126 CCDC75 -1.1721 1.673007 20.37489 6.37E-06 2.00E-05 
1127 SMYD2 -1.28818 1.677318 19.0658 1.26E-05 3.81E-05 
1128 LOC100335030 -1.32428 1.667135 22.52934 2.07E-06 6.93E-06 
1129 CADM2 1.0948 1.648612 21.68954 3.21E-06 1.05E-05 
1130 LINC00176 -1.03309 1.656477 9.771892 0.001772 0.003834 
1131 GJC1 -1.68402 1.651347 42.66762 6.49E-11 3.41E-10 
1132 ITIH4 -1.02405 1.640978 17.01973 3.70E-05 0.000104 
1133 FAM161A -1.11544 1.621317 20.49142 5.99E-06 1.89E-05 
1134 PLCH1 -2.49368 1.627385 79.40895 5.05E-19 4.66E-18 
1135 LOC100507424 -1.33874 1.618079 23.18715 1.47E-06 5.01E-06 
1136 C14orf28 1.065 1.604954 17.60773 2.71E-05 7.83E-05 
1137 TMEM51 -1.10643 1.60531 13.86745 0.000196 0.0005 
1138 GLI3 -1.10048 1.602994 16.66514 4.46E-05 0.000125 
1139 LRP4 1.181704 1.564273 24.0128 9.57E-07 3.34E-06 
1140 SLC38A4 1.956431 1.574071 45.79123 1.32E-11 7.32E-11 
1141 LOC100130522 -1.32239 1.573387 23.25106 1.42E-06 4.85E-06 
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1142 RIN2 -1.08761 1.548226 17.88452 2.35E-05 6.83E-05 
1143 SNORA61 -1.62578 1.560059 37.53262 8.99E-10 4.29E-09 
1144 FGD1 -1.40586 1.558773 23.68611 1.13E-06 3.91E-06 
1145 RUNX1 2.734274 1.545251 95.17885 1.74E-22 1.92E-21 
1146 CDKN1C 1.32803 1.533424 30.07559 4.16E-08 1.69E-07 
1147 SLC22A1 1.779197 1.531084 57.15464 4.03E-14 2.72E-13 
1148 SERPINB8 1.398553 1.529914 30.32696 3.65E-08 1.49E-07 
1149 CHRNB1 1.758455 1.526782 32.44972 1.22E-08 5.23E-08 
1150 SLA2 2.549826 1.518812 62.54033 2.61E-15 1.92E-14 
1151 FAS -1.18092 1.527157 12.94238 0.000321 0.000794 
1152 MIR17HG -1.13688 1.521143 17.41567 3.00E-05 8.60E-05 
1153 ZC3HAV1L -1.12874 1.515464 13.74072 0.00021 0.000532 
1154 FAM18B2 1.1073 1.510544 23.12508 1.52E-06 5.16E-06 
1155 RELB 1.22223 1.485984 32.33023 1.30E-08 5.55E-08 
1156 NINL -2.23201 1.505842 72.21464 1.93E-17 1.62E-16 
1157 KSR2 -1.78497 1.505379 53.33565 2.81E-13 1.78E-12 
1158 FMNL3 -1.70245 1.509285 46.8384 7.71E-12 4.39E-11 
1159 RUNX2 -1.42959 1.497007 26.20327 3.07E-07 1.13E-06 
1160 MAP3K8 -1.39547 1.48672 34.76635 3.72E-09 1.67E-08 
1161 LOC646862 1.650769 1.44402 33.6782 6.50E-09 2.85E-08 
1162 SYCE2 -1.60112 1.472849 29.53277 5.50E-08 2.21E-07 
1163 MYB -2.79468 1.464304 81.6063 1.66E-19 1.58E-18 
1164 TMEM92 2.267773 1.424565 72.64822 1.55E-17 1.31E-16 
1165 FAM49A -1.01656 1.446769 12.24935 0.000465 0.00112 
1166 OSMR 1.089576 1.42196 9.5673 0.001981 0.004243 
1167 KLHL11 -1.75409 1.424296 39.23119 3.76E-10 1.85E-09 
1168 CERS1 -1.31818 1.430794 18.26135 1.93E-05 5.66E-05 
1169 C1QTNF6 -1.15064 1.413993 12.90532 0.000328 0.000807 
1170 NWD1 -1.18629 1.414917 14.98437 0.000108 0.000286 
1171 HIST1H1E 2.96548 1.355928 68.5934 1.21E-16 9.71E-16 
1172 DNALI1 1.244847 1.363986 26.14563 3.17E-07 1.16E-06 
1173 ELOVL2 3.171632 1.352361 88.97125 4.01E-21 4.18E-20 
1174 LOC100505815 -1.07858 1.359125 11.0402 0.000892 0.002031 
1175 C21orf63 -1.19031 1.366243 12.63672 0.000378 0.000924 
1176 LOC728558 -1.17439 1.361073 13.9122 0.000192 0.000489 
1177 FAM189A2 2.41436 1.351339 55.57986 8.97E-14 5.88E-13 
1178 PBX4 -1.25146 1.340035 18.90357 1.37E-05 4.12E-05 
1179 KCNK5 -2.61271 1.321363 80.26566 3.27E-19 3.05E-18 
1180 CDC14A -1.28691 1.317279 17.64996 2.66E-05 7.67E-05 
1181 SCNN1G 1.762162 1.303017 45.01709 1.95E-11 1.07E-10 
1182 DSE -1.10457 1.327406 13.21516 0.000278 0.000693 
1183 LOC100507634 1.303284 1.305097 22.51538 2.08E-06 6.98E-06 
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1184 ZNF726 -1.79213 1.314377 51.1638 8.50E-13 5.25E-12 
1185 CCDC150 -2.97812 1.32368 69.58955 7.30E-17 5.92E-16 
1186 COL5A2 -1.40336 1.313311 22.99794 1.62E-06 5.49E-06 
1187 C1QL1 -1.28244 1.30253 24.14731 8.92E-07 3.13E-06 
1188 SIX1 -1.78416 1.29539 46.08767 1.13E-11 6.33E-11 
1189 STARD9 -1.82016 1.287747 33.36004 7.66E-09 3.34E-08 
1190 ODAM -1.1372 1.276016 18.70473 1.53E-05 4.55E-05 
1191 FLT4 -2.63701 1.275186 85.31737 2.54E-20 2.53E-19 
1192 GAS2L3 -2.46385 1.266427 57.97387 2.66E-14 1.81E-13 
1193 LOC144481 3.840201 1.240202 91.85196 9.34E-22 1.00E-20 
1194 FANCB -3.29328 1.266418 118.7223 1.20E-27 1.68E-26 
1195 LOC100507266 -1.69659 1.252319 26.94533 2.09E-07 7.85E-07 
1196 ZNF519 -1.76136 1.252172 46.55266 8.92E-12 5.04E-11 
1197 BRDT -2.04241 1.227013 40.47631 1.99E-10 1.00E-09 
1198 EDN2 -1.14199 1.204857 10.46637 0.001216 0.002712 
1199 REP15 3.918908 1.16051 171.0062 4.46E-39 9.22E-38 
1200 FRMPD2 -1.79538 1.173007 30.37788 3.56E-08 1.46E-07 
1201 HEY1 -1.22813 1.167951 12.96696 0.000317 0.000784 
1202 RADIL -2.09897 1.161073 56.7567 4.93E-14 3.30E-13 
1203 MYBL1 -2.58499 1.132487 53.42557 2.69E-13 1.70E-12 
1204 ANTXR1 -1.86435 1.103571 34.02184 5.45E-09 2.41E-08 
1205 BCL2 -2.22535 1.09301 36.63148 1.43E-09 6.65E-09 
1206 KCNG3 1.628505 1.072403 34.5463 4.16E-09 1.86E-08 
1207 ANGPT2 2.571655 1.058679 78.00937 1.03E-18 9.34E-18 
1208 NLRC5 -1.43576 1.079631 23.12287 1.52E-06 5.16E-06 
1209 TGM3 -3.30533 1.063226 96.72651 7.96E-23 8.97E-22 
1210 OXTR -1.74428 1.004629 27.00498 2.03E-07 7.62E-07 
1211 LGI2 -4.03209 0.985462 101.5434 6.99E-24 8.27E-23 


























B) DHT vs Vehicle 
 
No gene_id logFC logCPM LR PValue FDR 
1 KRT8 1.045876 10.91338 226.5447 3.38E-51 1.48E-48 
2 TMPRSS2 1.034806 10.07856 270.9375 7.09E-61 4.74E-58 
3 FKBP5 1.332703 9.752285 334.1801 1.18E-74 4.48E-71 
4 ACSL3 1.3599 9.582629 306.3878 1.34E-68 1.69E-65 
5 SLC41A1 1.300349 8.666302 342.749 1.61E-76 9.14E-73 
6 NDRG1 1.023857 8.62771 244.7676 3.59E-55 1.94E-52 
7 SMS 1.157277 8.558071 330.8652 6.23E-74 1.77E-70 
8 H2AFX -1.03003 8.459112 154.8721 1.49E-35 2.00E-33 
9 MCM7 -1.06535 8.226906 286.1939 3.36E-64 2.54E-61 
10 MICAL1 1.500391 8.011749 399.6633 6.52E-89 7.41E-85 
11 MKI67 -1.19786 7.768959 161.078 6.58E-37 9.97E-35 
12 CBWD1 1.060669 7.492296 184.4621 5.14E-42 1.22E-39 
13 HMGB2 -1.16852 7.56376 214.2192 1.65E-48 5.68E-46 
14 MYBL2 -1.03923 7.505904 181.4944 2.29E-41 5.09E-39 
15 TPX2 -1.21605 7.409799 309.4635 2.86E-69 4.64E-66 
16 SPAG5 -1.01596 7.378592 295.3601 3.38E-66 3.20E-63 
17 MCM2 -1.21199 7.370048 223.1899 1.82E-50 7.14E-48 
18 PCNA -1.04151 7.316584 177.9997 1.32E-40 2.64E-38 
19 TK1 -1.06191 7.319267 151.2888 9.06E-35 1.20E-32 
20 CHRNA2 1.328367 7.192927 246.8557 1.26E-55 7.15E-53 
21 PLK1 -1.02222 7.175124 213.2254 2.72E-48 9.08E-46 
22 CENPF -1.15946 7.146804 144.8989 2.26E-33 2.85E-31 
23 MCM4 -1.20808 7.062613 290.5878 3.70E-65 3.24E-62 
24 LMNB1 -1.0847 7.04996 229.8125 6.55E-52 3.10E-49 
25 CDC20 -1.14647 7.066853 267.8045 3.42E-60 2.16E-57 
26 MCM3 -1.03623 7.015346 194.0438 4.17E-44 1.13E-41 
27 RRM2 -1.27669 7.018513 315.908 1.13E-70 2.14E-67 
28 F5 1.193323 6.905314 174.4316 7.97E-40 1.44E-37 
29 NUSAP1 -1.26706 6.984579 321.8234 5.80E-72 1.32E-68 
30 TCOF1 -1.06926 6.936038 171.7099 3.13E-39 5.56E-37 
31 PRC1 -1.1647 6.878806 234.0694 7.73E-53 3.82E-50 
32 TYMS -1.18347 6.875414 306.6155 1.19E-68 1.69E-65 
33 FEN1 -1.16776 6.856174 302.1943 1.10E-67 1.25E-64 
34 CDK1 -1.1056 6.77637 178.0335 1.30E-40 2.64E-38 
35 MCM5 -1.07627 6.75905 149.1362 2.68E-34 3.50E-32 
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36 TMPO -1.12552 6.683045 164.5448 1.15E-37 1.84E-35 
37 FANCI -1.08779 6.62416 224.3811 1.00E-50 4.07E-48 
38 ST6GALNAC1 1.035249 6.465627 183.1555 9.92E-42 2.25E-39 
39 TONSL -1.04372 6.54392 125.7227 3.54E-29 3.46E-27 
40 CHAF1A -1.00718 6.47708 146.5049 1.01E-33 1.29E-31 
41 KIF20A -1.16897 6.495192 260.3395 1.45E-58 8.66E-56 
42 SMC4 -1.09011 6.403634 123.7541 9.54E-29 9.18E-27 
43 GNMT 1.219482 6.163692 167.4938 2.61E-38 4.36E-36 
44 UGT2B11 1.518936 6.119025 186.6543 1.71E-42 4.22E-40 
45 RECQL4 -1.0609 6.257349 161.6995 4.81E-37 7.49E-35 
46 TCF19 -1.29178 6.252116 228.2471 1.44E-51 6.54E-49 
47 CDCA5 -1.28337 6.238124 277.8941 2.16E-62 1.53E-59 
48 TOP2A -1.40947 6.159168 161.6144 5.02E-37 7.71E-35 
49 UBE2C -1.25634 6.167261 177.2288 1.95E-40 3.76E-38 
50 CCNB2 -1.08107 6.098181 179.9488 4.97E-41 1.07E-38 
51 RACGAP1 -1.06619 6.047303 160.3922 9.29E-37 1.34E-34 
52 CCNF -1.04616 6.00093 158.4234 2.50E-36 3.47E-34 
53 KIFC1 -1.3823 6.000929 297.1907 1.35E-66 1.39E-63 
54 E2F1 -1.17503 5.996343 220.3052 7.76E-50 2.94E-47 
55 KIF2C -1.24228 5.981083 236.2581 2.57E-53 1.33E-50 
56 PKMYT1 -1.16667 5.970537 123.9963 8.44E-29 8.20E-27 
57 CDC6 -1.12952 5.945206 202.602 5.65E-46 1.69E-43 
58 HMMR -1.07546 5.923096 108.5231 2.06E-25 1.59E-23 
59 NCAPG -1.16227 5.917118 185.3473 3.30E-42 7.97E-40 
60 CDCA3 -1.09271 5.893867 118.705 1.22E-27 1.10E-25 
61 MLF1IP -1.12605 5.883664 175.5714 4.49E-40 8.37E-38 
62 HJURP -1.32201 5.888758 217.7788 2.76E-49 1.01E-46 
63 POLA2 -1.07986 5.857153 174.5567 7.48E-40 1.37E-37 
64 FAM83D -1.20972 5.838418 204.0482 2.73E-46 8.39E-44 
65 AURKA -1.05393 5.788678 123.5456 1.06E-28 1.01E-26 
66 BUB1B -1.24551 5.738795 157.6552 3.68E-36 5.04E-34 
67 CADPS2 1.363656 5.627089 156.1036 8.04E-36 1.09E-33 
68 DLGAP5 -1.12252 5.726486 93.95554 3.23E-22 2.03E-20 
69 ASF1B -1.25257 5.735445 197.7686 6.41E-45 1.87E-42 
70 MAF 1.508879 5.575168 137.4348 9.69E-32 1.06E-29 
71 FANCD2 -1.16644 5.646963 164.0542 1.47E-37 2.32E-35 
72 CCNA2 -1.22092 5.643516 143.9444 3.65E-33 4.51E-31 
73 CAMK2N1 -1.13657 5.616474 143.1641 5.41E-33 6.61E-31 
74 ANLN -1.15084 5.608306 98.83844 2.74E-23 1.90E-21 
75 CDT1 -1.08162 5.617058 115.3649 6.55E-27 5.55E-25 
76 WDR62 -1.05034 5.586252 85.81977 1.97E-20 1.10E-18 
77 MELK -1.21792 5.576693 158.7707 2.10E-36 2.95E-34 
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78 NDC80 -1.35382 5.558103 194.5612 3.21E-44 8.90E-42 
79 AURKB -1.10044 5.525203 97.75995 4.72E-23 3.20E-21 
80 ESPL1 -1.37699 5.494887 183.9924 6.51E-42 1.51E-39 
81 PRKCA 1.122294 5.384767 103.5093 2.59E-24 1.89E-22 
82 WIPI1 1.393275 5.320718 140.8564 1.73E-32 1.99E-30 
83 CENPE -1.15521 5.416865 94.29366 2.72E-22 1.73E-20 
84 CDCA8 -1.147 5.409472 179.8694 5.18E-41 1.09E-38 
85 PBK -1.1895 5.352495 131.122 2.33E-30 2.38E-28 
86 NCAPH -1.1707 5.350564 176.9506 2.25E-40 4.25E-38 
87 RFC4 -1.03248 5.343251 117.288 2.48E-27 2.17E-25 
88 ADAM7 1.02902 5.265882 159.1141 1.77E-36 2.51E-34 
89 CDC45 -1.26503 5.344925 138.8939 4.65E-32 5.23E-30 
90 BUB1 -1.08608 5.320551 108.5805 2.01E-25 1.56E-23 
91 GTSE1 -1.00121 5.299098 138.2256 6.50E-32 7.25E-30 
92 BRCA1 -1.32938 5.210567 118.8537 1.13E-27 1.03E-25 
93 AFF3 1.025491 5.101864 74.22527 6.97E-18 3.25E-16 
94 KIF11 -1.24269 5.181224 91.5732 1.08E-21 6.57E-20 
95 PGC 1.437474 5.097379 160.5865 8.42E-37 1.23E-34 
96 PSRC1 -1.00039 5.139266 112.9466 2.22E-26 1.85E-24 
97 UGT2B15 -1.0213 5.06843 89.53838 3.01E-21 1.78E-19 
98 DEPDC1 -1.08531 5.061649 66.14444 4.19E-16 1.62E-14 
99 ARHGAP11A -1.09129 5.052337 61.27484 4.96E-15 1.73E-13 
100 CIT -1.30978 5.062757 194.8121 2.83E-44 8.04E-42 
101 GINS1 -1.21617 5.043659 180.5777 3.62E-41 7.92E-39 
102 RAD54L -1.33744 5.045544 144.1264 3.33E-33 4.16E-31 
103 DDB2 -1.1311 5.021673 125.9661 3.13E-29 3.12E-27 
104 CDKN2C -1.02241 5.018923 88.19348 5.94E-21 3.41E-19 
105 CEP55 -1.16941 4.997699 111.4567 4.70E-26 3.87E-24 
106 CLSPN -1.32154 4.974504 129.0052 6.76E-30 6.86E-28 
107 KNTC1 -1.20081 4.965225 142.1741 8.91E-33 1.05E-30 
108 RFC5 -1.06755 4.949173 86.16157 1.66E-20 9.33E-19 
109 BCHE -1.00441 4.92801 81.65234 1.62E-19 8.50E-18 
110 CDCA7L -1.05264 4.924996 141.3639 1.34E-32 1.55E-30 
111 C9orf100 -1.11235 4.944562 114.9189 8.20E-27 6.90E-25 
112 GINS2 -1.02608 4.922295 79.16132 5.72E-19 2.87E-17 
113 STEAP4 3.740503 4.757507 286.9926 2.25E-64 1.83E-61 
114 SOCS2 1.298868 4.823498 90.77711 1.61E-21 9.72E-20 
115 UGT2B28 2.151729 4.738447 224.7092 8.50E-51 3.58E-48 
116 MCM10 -1.39635 4.855 117.8871 1.84E-27 1.63E-25 
117 UHRF1 -1.24869 4.827836 127.3368 1.57E-29 1.58E-27 
118 INPP4B 1.037968 4.737244 69.23793 8.73E-17 3.58E-15 
119 KIF18B -1.24701 4.830277 94.5038 2.45E-22 1.57E-20 
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120 CDCA2 -1.19934 4.817123 102.1822 5.06E-24 3.64E-22 
121 C21orf58 -1.02692 4.785925 116.885 3.04E-27 2.64E-25 
122 WDHD1 -1.09878 4.763399 137.4265 9.73E-32 1.06E-29 
123 ZNF812 1.188918 4.648766 118.1696 1.59E-27 1.42E-25 
124 SHCBP1 -1.21918 4.72046 101.3271 7.80E-24 5.57E-22 
125 KIF23 -1.15958 4.685966 133.2985 7.78E-31 8.11E-29 
126 ORC6 -1.41043 4.683425 164.9222 9.51E-38 1.54E-35 
127 POLQ -1.45569 4.655492 95.53963 1.45E-22 9.52E-21 
128 NUF2 -1.2725 4.651253 96.92885 7.19E-23 4.78E-21 
129 NEK2 -1.2653 4.648609 104.8892 1.29E-24 9.66E-23 
130 PSMC3IP -1.06282 4.631968 79.07517 5.98E-19 2.98E-17 
131 DTL -1.46799 4.61236 167.9618 2.06E-38 3.50E-36 
132 CDCA4 -1.0423 4.610723 78.2652 9.01E-19 4.43E-17 
133 CDC7 -1.00613 4.595561 82.09577 1.30E-19 6.90E-18 
134 TUBA3D 1.154626 4.537442 86.83625 1.18E-20 6.70E-19 
135 SKA3 -1.19007 4.585329 101.1734 8.43E-24 5.99E-22 
136 TMEM194A -1.07667 4.547988 81.32644 1.91E-19 9.88E-18 
137 PAQR6 1.09006 4.495225 66.83885 2.95E-16 1.16E-14 
138 TARP 1.388336 4.394865 135.0885 3.16E-31 3.35E-29 
139 GINS4 -1.29491 4.410119 95.70459 1.33E-22 8.81E-21 
140 CCDC141 1.189939 4.324552 32.11229 1.46E-08 2.44E-07 
141 DEPDC1B -1.1672 4.373182 79.50803 4.80E-19 2.42E-17 
142 ORC1 -1.19596 4.352869 81.79847 1.51E-19 7.97E-18 
143 SPC24 -1.05033 4.336883 74.50119 6.06E-18 2.85E-16 
144 POLD3 -1.01666 4.315872 65.33273 6.33E-16 2.40E-14 
145 NRM -1.03433 4.31834 63.31645 1.76E-15 6.45E-14 
146 EME1 -1.26083 4.314727 75.8949 2.99E-18 1.42E-16 
147 RFC3 -1.18466 4.302175 67.80551 1.80E-16 7.27E-15 
148 FIGNL1 -1.01857 4.277732 43.21601 4.90E-11 1.13E-09 
149 ASPM -1.4306 4.279402 58.03575 2.57E-14 8.31E-13 
150 CDC25C -1.12305 4.290442 75.37873 3.89E-18 1.84E-16 
151 DIAPH3 -1.24199 4.25633 132.5798 1.12E-30 1.15E-28 
152 TTK -1.24649 4.256631 70.54799 4.49E-17 1.90E-15 
153 ANO7 1.119116 4.185993 53.57236 2.49E-13 7.23E-12 
154 C1orf112 -1.11931 4.174699 76.51285 2.19E-18 1.05E-16 
155 GPSM2 -1.13496 4.158148 67.0086 2.70E-16 1.07E-14 
156 SGOL2 -1.1287 4.126562 73.64056 9.37E-18 4.31E-16 
157 CEP78 -1.16272 4.117113 71.18209 3.26E-17 1.41E-15 
158 KIF20B -1.15605 4.10426 71.55151 2.70E-17 1.19E-15 
159 EXO1 -1.36995 4.094591 109.6295 1.18E-25 9.45E-24 
160 SKA1 -1.24075 4.036338 79.7189 4.32E-19 2.18E-17 
161 C15orf42 -1.24883 4.010447 67.63497 1.97E-16 7.90E-15 
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162 SLITRK3 -1.02532 3.984061 62.39063 2.82E-15 1.01E-13 
163 PLK4 -1.37775 3.956852 71.42752 2.88E-17 1.26E-15 
164 KIF15 -1.54313 3.955213 122.2659 2.02E-28 1.85E-26 
165 FBXO5 -1.19666 3.919201 64.46982 9.80E-16 3.69E-14 
166 PRIM1 -1.21125 3.862068 63.49777 1.61E-15 5.92E-14 
167 RAD51AP1 -1.15768 3.858318 58.05566 2.55E-14 8.25E-13 
168 KIF24 -1.36447 3.858929 81.48532 1.77E-19 9.20E-18 
169 OIP5 -1.14958 3.853208 69.36202 8.20E-17 3.41E-15 
170 HAUS8 -1.02802 3.827204 56.10902 6.86E-14 2.11E-12 
171 TRAIP -1.07542 3.817425 50.27131 1.34E-12 3.64E-11 
172 TTN 1.077946 3.775705 38.66438 5.03E-10 1.01E-08 
173 B3GALT4 1.182619 3.720288 50.97522 9.35E-13 2.57E-11 
174 RAD51 -1.07935 3.756982 72.57113 1.61E-17 7.21E-16 
175 MNS1 -1.09502 3.749475 43.99635 3.29E-11 7.73E-10 
176 E2F2 -1.23445 3.755456 85.18558 2.72E-20 1.49E-18 
177 SH3D21 1.282619 3.671158 51.82665 6.06E-13 1.69E-11 
178 SPC25 -1.07155 3.737694 46.94391 7.30E-12 1.84E-10 
179 GSTCD -1.03503 3.706872 42.86711 5.86E-11 1.32E-09 
180 KIF14 -1.36197 3.700978 68.26926 1.43E-16 5.79E-15 
181 ESCO2 -1.45165 3.678045 55.81356 7.97E-14 2.44E-12 
182 ORM1 2.68578 3.584169 160.9633 6.97E-37 1.04E-34 
183 CASC5 -1.26326 3.668182 48.37091 3.53E-12 9.28E-11 
184 CCNE2 -1.11895 3.647541 39.64711 3.04E-10 6.31E-09 
185 CSGALNACT1 1.467457 3.570962 59.99358 9.52E-15 3.23E-13 
186 HPGD 1.189323 3.546501 44.59851 2.42E-11 5.74E-10 
187 PARPBP -1.0267 3.618575 32.07735 1.48E-08 2.47E-07 
188 LAT2 1.808413 3.494342 81.74352 1.55E-19 8.15E-18 
189 ORM2 2.277915 3.458973 103.6533 2.41E-24 1.78E-22 
190 CKAP2L -1.37663 3.497197 66.26921 3.93E-16 1.53E-14 
191 LOC100128191 -1.10586 3.508863 50.82687 1.01E-12 2.76E-11 
192 SGOL1 -1.285 3.475341 71.60043 2.63E-17 1.17E-15 
193 CENPA -1.16333 3.460974 63.32866 1.75E-15 6.43E-14 
194 DNA2 -1.07637 3.405734 27.57142 1.51E-07 2.12E-06 
195 E2F8 -1.45672 3.392733 66.72104 3.13E-16 1.22E-14 
196 ZNF367 -1.26754 3.380485 38.95944 4.33E-10 8.69E-09 
197 BLM -1.44642 3.366816 68.87758 1.05E-16 4.27E-15 
198 GSG2 -1.15996 3.364504 60.92601 5.93E-15 2.04E-13 
199 MND1 -1.27578 3.307658 44.33562 2.77E-11 6.55E-10 
200 SLC2A3 1.635052 3.21207 43.81152 3.62E-11 8.47E-10 
201 NEIL3 -1.23068 3.264715 57.13893 4.06E-14 1.28E-12 
202 C4orf46 -1.09017 3.184868 29.63386 5.22E-08 8.04E-07 
203 WDR76 -1.40378 3.182243 74.41954 6.32E-18 2.95E-16 
 
177 | P a g e  
 
204 RBL1 -1.17563 3.150147 26.45176 2.70E-07 3.67E-06 
205 ARMC12 1.379683 3.118034 55.38136 9.93E-14 3.00E-12 
206 XRCC2 -1.3023 3.10956 59.86127 1.02E-14 3.42E-13 
207 BRCA2 -1.41478 3.112857 66.44681 3.59E-16 1.40E-14 
208 HELLS -1.53223 3.100935 42.13719 8.51E-11 1.89E-09 
209 CEP128 -1.24395 3.035504 43.14315 5.09E-11 1.17E-09 
210 MMS22L -1.29335 3.000201 39.26095 3.71E-10 7.57E-09 
211 C1QTNF9B-AS1 1.100726 2.922719 27.94559 1.25E-07 1.78E-06 
212 E2F7 -1.58824 2.942007 43.0215 5.41E-11 1.23E-09 
213 AKAP12 1.100638 2.863866 21.66297 3.25E-06 3.62E-05 
214 CENPI -1.10423 2.932829 46.9114 7.43E-12 1.86E-10 
215 CENPK -1.01082 2.918185 22.05818 2.65E-06 3.01E-05 
216 POLE2 -1.12344 2.88688 20.44972 6.12E-06 6.47E-05 
217 LIN9 -1.27168 2.863285 40.22044 2.27E-10 4.75E-09 
218 CENPQ -1.09655 2.832032 32.19487 1.39E-08 2.34E-07 
219 KIF18A -1.30277 2.830089 40.64214 1.83E-10 3.88E-09 
220 BRIP1 -1.41776 2.817232 44.91719 2.06E-11 4.94E-10 
221 LOC100288637 -1.25103 2.787301 27.35663 1.69E-07 2.36E-06 
222 AMACR 1.097843 2.704537 19.25968 1.14E-05 0.000114 
223 RTKN2 -1.08436 2.716191 29.59898 5.31E-08 8.17E-07 
224 RTTN -1.08787 2.656886 33.65603 6.58E-09 1.16E-07 
225 C17orf53 -1.05357 2.658987 29.12903 6.77E-08 1.02E-06 
226 EPS8L1 1.487662 2.587459 28.84377 7.85E-08 1.16E-06 
227 NPPC 1.455035 2.599821 36.19989 1.78E-09 3.35E-08 
228 MYBPC1 1.509729 2.566469 56.84312 4.72E-14 1.48E-12 
229 MYL9 1.044808 2.49094 29.31107 6.16E-08 9.37E-07 
230 DMBX1 -1.30436 2.55599 42.3223 7.74E-11 1.73E-09 
231 C4orf21 -1.11661 2.540547 25.10183 5.44E-07 7.01E-06 
232 SPOCK1 1.424415 2.378154 41.58222 1.13E-10 2.47E-09 
233 FAM54A -1.55824 2.328249 44.20212 2.96E-11 7.00E-10 
234 C1orf135 -1.33165 2.327583 42.16507 8.39E-11 1.86E-09 
235 FAM72B -1.00685 2.327372 27.98112 1.23E-07 1.76E-06 
236 NAV3 -1.30885 2.307982 47.05214 6.91E-12 1.75E-10 
237 ATAD5 -1.30778 2.251379 40.39695 2.07E-10 4.36E-09 
238 C18orf54 -1.37064 2.27838 27.43676 1.62E-07 2.27E-06 
239 TUBA3E 1.058685 2.242307 15.49707 8.26E-05 0.000678 
240 WWTR1 1.058971 2.20958 22.2506 2.39E-06 2.74E-05 
241 FAM81A -1.05907 2.201616 22.58194 2.01E-06 2.34E-05 
242 BAI2 -1.04187 2.210137 19.65704 9.27E-06 9.44E-05 
243 SPTB 1.789417 2.147878 42.50964 7.03E-11 1.58E-09 
244 BORA -1.08328 2.176648 15.66585 7.56E-05 0.000627 
245 RDM1 -1.23917 2.141119 29.91662 4.51E-08 7.02E-07 
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246 LOC100128361 -1.14282 2.14019 13.99811 0.000183 0.001348 
247 DOCK8 1.214777 2.079418 17.03475 3.67E-05 0.000327 
248 C5orf34 -1.24434 2.086564 30.32367 3.66E-08 5.77E-07 
249 FAM83E 1.045876 2.024604 15.80158 7.03E-05 0.000588 
250 FAM72A -1.14168 1.984398 23.18369 1.47E-06 1.75E-05 
251 TERT -1.04564 1.971424 29.50947 5.56E-08 8.52E-07 
252 TLL1 -1.43159 1.876395 39.11432 4.00E-10 8.08E-09 
253 TNS4 1.09081 1.830132 13.78198 0.000205 0.001496 
254 DKFZP586I1420 -1.20672 1.767396 27.97644 1.23E-07 1.76E-06 
255 SCARA3 -1.17827 1.78656 20.50021 5.96E-06 6.33E-05 
256 SNCG 1.540067 1.739804 40.4059 2.06E-10 4.35E-09 
257 CNIH2 -1.14487 1.724738 16.27522 5.48E-05 0.000471 
258 BEST1 -1.11194 1.710968 14.15187 0.000169 0.001258 
259 MTBP -1.01201 1.698324 17.09664 3.55E-05 0.000319 
260 TG 1.618921 1.638793 20.00753 7.71E-06 8.00E-05 
261 PLCH1 -1.60649 1.627385 37.55753 8.88E-10 1.73E-08 
262 SLC38A4 1.052922 1.574071 12.12558 0.000497 0.003258 
263 RIN2 -1.02774 1.548226 15.7213 7.34E-05 0.00061 
264 SLC22A1 1.201327 1.531084 23.64649 1.16E-06 1.41E-05 
265 MIR29C 1.252847 1.517626 14.419 0.000146 0.001116 
266 TMEM92 1.375662 1.424565 24.06239 9.33E-07 1.15E-05 
267 HIST1H1E 1.763121 1.355928 23.05116 1.58E-06 1.87E-05 
268 ELOVL2 1.376338 1.352361 14.32076 0.000154 0.001166 
269 FAM189A2 1.085025 1.351339 9.386104 0.002186 0.011536 
270 LOC100507634 1.070315 1.305097 14.40869 0.000147 0.00112 
271 ZNF726 -1.51561 1.314377 37.2321 1.05E-09 2.01E-08 
272 CCDC150 -1.68177 1.32368 27.76753 1.37E-07 1.93E-06 
273 FLT4 -1.7364 1.275186 43.6101 4.01E-11 9.31E-10 
274 LOC144481 2.239074 1.240202 28.52418 9.25E-08 1.36E-06 
275 FANCB -1.22628 1.266418 24.93974 5.92E-07 7.58E-06 
276 ZNF519 -1.09469 1.252172 19.82199 8.50E-06 8.71E-05 
277 BRDT -1.30824 1.227013 18.47476 1.72E-05 0.000166 
278 REP15 1.131996 1.16051 8.149773 0.004307 0.020351 
279 MYBL1 -1.18515 1.132487 14.21853 0.000163 0.001221 
280 ANTXR1 -1.00703 1.103571 11.32855 0.000763 0.004684 
281 BCL2 -1.31481 1.09301 14.37067 0.00015 0.001139 
282 KCNG3 1.095702 1.072403 14.55977 0.000136 0.00105 
283 LEF1 -1.31681 1.076696 17.32408 3.15E-05 0.000286 
284 TGM3 -1.13365 1.063226 17.29202 3.21E-05 0.00029 
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Direction of change for 
DHT and MeT (TRUE= 
similar/FALSE=diferent) 
Potency of 
MeT vs DHT 
(TRUE= Yes 
/FALSE=No) 
1 KRT8 1.045876342 TRUE 2.755781922 TRUE TRUE TRUE 
2 TMPRSS2 1.034805517 TRUE 1.913299628 TRUE TRUE TRUE 
3 FKBP5 1.332702783 TRUE 2.826146249 TRUE TRUE TRUE 
4 ACSL3 1.359899873 TRUE 2.530338335 TRUE TRUE TRUE 
5 SLC41A1 1.300348613 TRUE 2.693377322 TRUE TRUE TRUE 
6 NDRG1 1.023857137 TRUE 3.390736204 TRUE TRUE TRUE 
7 SMS 1.1572766 TRUE 2.166352624 TRUE TRUE TRUE 
8 H2AFX -1.030028221 FALSE -2.202710294 FALSE TRUE TRUE 
9 MCM7 -1.065352573 FALSE -2.197546713 FALSE TRUE TRUE 
10 MICAL1 1.500391067 TRUE 3.059148889 TRUE TRUE TRUE 
11 MKI67 -1.197863921 FALSE -2.675758539 FALSE TRUE TRUE 
12 CBWD1 1.060669375 TRUE 1.778386773 TRUE TRUE TRUE 
13 HMGB2 -1.168522187 FALSE -1.92991569 FALSE TRUE TRUE 
14 MYBL2 -1.039232839 FALSE -2.268501325 FALSE TRUE TRUE 
15 TPX2 -1.216047638 FALSE -2.550768441 FALSE TRUE TRUE 
16 SPAG5 -1.015957159 FALSE -1.965860952 FALSE TRUE TRUE 
17 MCM2 -1.211990237 FALSE -3.254253329 FALSE TRUE TRUE 
18 PCNA -1.04151328 FALSE -2.290764524 FALSE TRUE TRUE 
19 TK1 -1.061913876 FALSE -2.402434733 FALSE TRUE TRUE 
20 CHRNA2 1.32836714 TRUE 1.634172626 TRUE TRUE TRUE 
21 PLK1 -1.022220803 FALSE -2.342325954 FALSE TRUE TRUE 
22 CENPF -1.159461023 FALSE -2.65802473 FALSE TRUE TRUE 
23 MCM4 -1.208081784 FALSE -3.260585881 FALSE TRUE TRUE 
24 LMNB1 -1.084695629 FALSE -2.848586399 FALSE TRUE TRUE 
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25 CDC20 -1.14647327 FALSE -2.512996723 FALSE TRUE TRUE 
26 MCM3 -1.036232211 FALSE -2.568954992 FALSE TRUE TRUE 
27 RRM2 -1.276686341 FALSE -2.974381993 FALSE TRUE TRUE 
28 F5 1.193322934 TRUE 2.045851997 TRUE TRUE TRUE 
29 NUSAP1 -1.267055087 FALSE -2.614549279 FALSE TRUE TRUE 
30 TCOF1 -1.069263668 FALSE -2.34301276 FALSE TRUE TRUE 
31 PRC1 -1.164698178 FALSE -2.384901748 FALSE TRUE TRUE 
32 TYMS -1.183465165 FALSE -2.708440284 FALSE TRUE TRUE 
33 FEN1 -1.167763126 FALSE -2.365989503 FALSE TRUE TRUE 
34 CDK1 -1.105601811 FALSE -2.718216424 FALSE TRUE TRUE 
35 MCM5 -1.076269501 FALSE -2.677088667 FALSE TRUE TRUE 
36 TMPO -1.125515723 FALSE -2.521116016 FALSE TRUE TRUE 




1.035248874 TRUE 1.77890807 TRUE TRUE TRUE 
39 TONSL -1.043724519 FALSE -2.799302478 FALSE TRUE TRUE 
40 CHAF1A -1.007177729 FALSE -2.076061462 FALSE TRUE TRUE 
41 KIF20A -1.168971285 FALSE -2.477091628 FALSE TRUE TRUE 
42 SMC4 -1.090109412 FALSE -2.106454983 FALSE TRUE TRUE 
43 GNMT 1.219481919 TRUE 2.439455122 TRUE TRUE TRUE 
44 UGT2B11 1.518935699 TRUE 3.381715294 TRUE TRUE TRUE 
45 RECQL4 -1.060902593 FALSE -2.445665156 FALSE TRUE TRUE 
46 TCF19 -1.291775954 FALSE -3.172965797 FALSE TRUE TRUE 
47 CDCA5 -1.283365986 FALSE -3.102866954 FALSE TRUE TRUE 
48 TOP2A -1.409466435 FALSE -3.272675299 FALSE TRUE TRUE 
49 UBE2C -1.256344145 FALSE -2.709209166 FALSE TRUE TRUE 
50 CCNB2 -1.081067384 FALSE -2.379299888 FALSE TRUE TRUE 
51 RACGAP1 -1.066187692 FALSE -2.253279945 FALSE TRUE TRUE 
52 CCNF -1.04615908 FALSE -2.250083003 FALSE TRUE TRUE 
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53 KIFC1 -1.382295762 FALSE -2.971603879 FALSE TRUE TRUE 
54 E2F1 -1.175034137 FALSE -3.036178507 FALSE TRUE TRUE 
55 KIF2C -1.242277497 FALSE -2.924284205 FALSE TRUE TRUE 
56 PKMYT1 -1.16667173 FALSE -3.178917271 FALSE TRUE TRUE 
57 CDC6 -1.129516281 FALSE -2.71456379 FALSE TRUE TRUE 
58 HMMR -1.075463041 FALSE -2.13970401 FALSE TRUE TRUE 
59 NCAPG -1.162266101 FALSE -2.756747891 FALSE TRUE TRUE 
60 CDCA3 -1.09270978 FALSE -2.438049997 FALSE TRUE TRUE 
61 MLF1IP -1.12604774 FALSE -2.595021465 FALSE TRUE TRUE 
62 HJURP -1.322013259 FALSE -2.828667295 FALSE TRUE TRUE 
63 POLA2 -1.079861112 FALSE -2.164926123 FALSE TRUE TRUE 
64 FAM83D -1.209719625 FALSE -2.453405967 FALSE TRUE TRUE 
65 AURKA -1.05393423 FALSE -2.26681424 FALSE TRUE TRUE 
66 BUB1B -1.245511491 FALSE -3.036462965 FALSE TRUE TRUE 
67 CADPS2 1.363656093 TRUE 2.250906321 TRUE TRUE TRUE 
68 DLGAP5 -1.122519594 FALSE -2.210231158 FALSE TRUE TRUE 
69 ASF1B -1.252574853 FALSE -3.830201677 FALSE TRUE TRUE 
70 MAF 1.50887869 TRUE 2.93216193 TRUE TRUE TRUE 
71 FANCD2 -1.166438719 FALSE -2.133415414 FALSE TRUE TRUE 
72 CCNA2 -1.220920171 FALSE -2.989407496 FALSE TRUE TRUE 
73 CAMK2N1 -1.136569859 FALSE -2.143932843 FALSE TRUE TRUE 
74 ANLN -1.150842319 FALSE -2.727502835 FALSE TRUE TRUE 
75 CDT1 -1.081618517 FALSE -2.689396398 FALSE TRUE TRUE 
76 WDR62 -1.050337128 FALSE -2.891531589 FALSE TRUE TRUE 
77 MELK -1.217921829 FALSE -2.759500497 FALSE TRUE TRUE 
78 NDC80 -1.353819497 FALSE -2.660586973 FALSE TRUE TRUE 
79 AURKB -1.100437683 FALSE -2.990827496 FALSE TRUE TRUE 
80 ESPL1 -1.376994473 FALSE -3.355118415 FALSE TRUE TRUE 
81 PRKCA 1.122294464 TRUE 2.027002763 TRUE TRUE TRUE 
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82 WIPI1 1.393274809 TRUE 3.085674519 TRUE TRUE TRUE 
83 CENPE -1.15520954 FALSE -2.555391363 FALSE TRUE TRUE 
84 CDCA8 -1.1470038 FALSE -2.759158596 FALSE TRUE TRUE 
85 PBK -1.189499367 FALSE -2.072426546 FALSE TRUE TRUE 
86 NCAPH -1.170698346 FALSE -3.25505236 FALSE TRUE TRUE 
87 RFC4 -1.03248118 FALSE -1.934632068 FALSE TRUE TRUE 
88 ADAM7 1.029019992 TRUE 1.202613578 TRUE TRUE TRUE 
89 CDC45 -1.265032209 FALSE -3.024323883 FALSE TRUE TRUE 
90 BUB1 -1.086081406 FALSE -2.404529709 FALSE TRUE TRUE 
91 GTSE1 -1.001211741 FALSE -2.466957332 FALSE TRUE TRUE 
92 BRCA1 -1.329380022 FALSE -3.095206837 FALSE TRUE TRUE 
93 AFF3 1.02549085 TRUE 1.782135488 TRUE TRUE TRUE 
94 KIF11 -1.24269003 FALSE -2.75344164 FALSE TRUE TRUE 
95 PGC 1.437473724 TRUE 2.199557138 TRUE TRUE TRUE 
96 PSRC1 -1.000392831 FALSE -2.307361535 FALSE TRUE TRUE 
97 UGT2B15 -1.021296841 FALSE -1.583153089 FALSE TRUE TRUE 




-1.091290913 FALSE -2.798800982 FALSE TRUE TRUE 
100 CIT -1.309782345 FALSE -3.021738838 FALSE TRUE TRUE 
101 GINS1 -1.216166047 FALSE -2.8470779 FALSE TRUE TRUE 
102 RAD54L -1.337438916 FALSE -3.462746647 FALSE TRUE TRUE 
103 DDB2 -1.131098339 FALSE -2.002790306 FALSE TRUE TRUE 
104 CDKN2C -1.022411823 FALSE -1.848961771 FALSE TRUE TRUE 
105 CEP55 -1.169409436 FALSE -2.712221536 FALSE TRUE TRUE 
106 CLSPN -1.321541214 FALSE -3.806210426 FALSE TRUE TRUE 
107 KNTC1 -1.200814389 FALSE -2.787840551 FALSE TRUE TRUE 
108 RFC5 -1.067554271 FALSE -2.383980383 FALSE TRUE TRUE 
109 BCHE -1.004408418 FALSE -2.256506198 FALSE TRUE TRUE 
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110 CDCA7L -1.052642899 FALSE -2.184383218 FALSE TRUE TRUE 
111 C9orf100 -1.112348742 FALSE -2.587372724 FALSE TRUE TRUE 
112 GINS2 -1.026078761 FALSE -2.260594946 FALSE TRUE TRUE 
113 STEAP4 3.740503079 TRUE 6.927834265 TRUE TRUE TRUE 
114 SOCS2 1.298868135 TRUE 2.464368219 TRUE TRUE TRUE 
115 UGT2B28 2.151729029 TRUE 3.893654774 TRUE TRUE TRUE 
116 MCM10 -1.396353967 FALSE -4.324655992 FALSE TRUE TRUE 
117 UHRF1 -1.24868542 FALSE -3.611338214 FALSE TRUE TRUE 
118 INPP4B 1.037968163 TRUE 1.779542035 TRUE TRUE TRUE 
119 KIF18B -1.247012844 FALSE -3.756783914 FALSE TRUE TRUE 
120 CDCA2 -1.19933997 FALSE -2.754714744 FALSE TRUE TRUE 
121 C21orf58 -1.026924267 FALSE -2.359051929 FALSE TRUE TRUE 
122 WDHD1 -1.098778331 FALSE -2.5940982 FALSE TRUE TRUE 
123 ZNF812 1.18891817 TRUE 2.544402562 TRUE TRUE TRUE 
124 SHCBP1 -1.219179322 FALSE -2.768879626 FALSE TRUE TRUE 
125 KIF23 -1.159581868 FALSE -2.973708564 FALSE TRUE TRUE 
126 ORC6 -1.410427813 FALSE -3.347110046 FALSE TRUE TRUE 
127 POLQ -1.45569072 FALSE -3.263259538 FALSE TRUE TRUE 
128 NUF2 -1.272495917 FALSE -2.406721166 FALSE TRUE TRUE 
129 NEK2 -1.265302279 FALSE -2.464440633 FALSE TRUE TRUE 
130 PSMC3IP -1.062822576 FALSE -2.447064317 FALSE TRUE TRUE 
131 DTL -1.467991792 FALSE -4.496685228 FALSE TRUE TRUE 
132 CDCA4 -1.042297429 FALSE -2.953304223 FALSE TRUE TRUE 
133 CDC7 -1.006128916 FALSE -2.086704676 FALSE TRUE TRUE 
134 TUBA3D 1.154626031 TRUE 2.335065764 TRUE TRUE TRUE 
135 SKA3 -1.190066862 FALSE -2.306758982 FALSE TRUE TRUE 
136 TMEM194A -1.076674222 FALSE -2.426610686 FALSE TRUE TRUE 
137 PAQR6 1.090060223 TRUE 1.064693465 TRUE TRUE FALSE 
138 TARP 1.388336182 TRUE 2.008199636 TRUE TRUE TRUE 
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139 GINS4 -1.294914823 FALSE -2.831174567 FALSE TRUE TRUE 
140 CCDC141 1.189938719 TRUE 2.787907738 TRUE TRUE TRUE 
141 DEPDC1B -1.167203464 FALSE -2.693087157 FALSE TRUE TRUE 
142 ORC1 -1.195958423 FALSE -2.92148973 FALSE TRUE TRUE 
143 SPC24 -1.050331491 FALSE -2.634475094 FALSE TRUE TRUE 
144 POLD3 -1.016659061 FALSE -1.930249025 FALSE TRUE TRUE 
145 NRM -1.034326925 FALSE -1.933576918 FALSE TRUE TRUE 
146 EME1 -1.260826713 FALSE -3.065169405 FALSE TRUE TRUE 
147 RFC3 -1.184657999 FALSE -2.857837015 FALSE TRUE TRUE 
148 FIGNL1 -1.018572707 FALSE -2.516167238 FALSE TRUE TRUE 
149 ASPM -1.430598464 FALSE -3.05576722 FALSE TRUE TRUE 
150 CDC25C -1.123047229 FALSE -2.27892595 FALSE TRUE TRUE 
151 DIAPH3 -1.241987969 FALSE -2.229247879 FALSE TRUE TRUE 
152 TTK -1.2464924 FALSE -2.902844566 FALSE TRUE TRUE 
153 ANO7 1.119115697 TRUE 1.582032662 TRUE TRUE TRUE 
154 C1orf112 -1.119308744 FALSE -1.626819576 FALSE TRUE TRUE 
155 GPSM2 -1.134960417 FALSE -2.344259362 FALSE TRUE TRUE 
156 SGOL2 -1.128698025 FALSE -2.272806317 FALSE TRUE TRUE 
157 CEP78 -1.162716799 FALSE -1.879714778 FALSE TRUE TRUE 
158 KIF20B -1.156046882 FALSE -2.91237426 FALSE TRUE TRUE 
159 EXO1 -1.369954807 FALSE -4.222356158 FALSE TRUE TRUE 
160 SKA1 -1.240749167 FALSE -2.957023834 FALSE TRUE TRUE 
161 C15orf42 -1.248834863 FALSE -3.645150154 FALSE TRUE TRUE 
162 SLITRK3 -1.02532286 FALSE -2.738033774 FALSE TRUE TRUE 
163 PLK4 -1.377753449 FALSE -2.601874761 FALSE TRUE TRUE 
164 KIF15 -1.543127387 FALSE -3.320802452 FALSE TRUE TRUE 
165 FBXO5 -1.196655444 FALSE -2.251912723 FALSE TRUE TRUE 
166 PRIM1 -1.211248231 FALSE -2.798704947 FALSE TRUE TRUE 
167 RAD51AP1 -1.157676361 FALSE -3.10514468 FALSE TRUE TRUE 
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168 KIF24 -1.364466375 FALSE -2.956187902 FALSE TRUE TRUE 
169 OIP5 -1.14958276 FALSE -2.262354289 FALSE TRUE TRUE 
170 HAUS8 -1.02802212 FALSE -2.794636226 FALSE TRUE TRUE 
171 TRAIP -1.075419141 FALSE -2.200671601 FALSE TRUE TRUE 
172 TTN 1.077945902 TRUE 2.614607718 TRUE TRUE TRUE 
173 B3GALT4 1.182618545 TRUE 2.83244062 TRUE TRUE TRUE 
174 RAD51 -1.079353332 FALSE -2.983667145 FALSE TRUE TRUE 
175 MNS1 -1.095024374 FALSE -2.440617519 FALSE TRUE TRUE 
176 E2F2 -1.234452908 FALSE -3.574660124 FALSE TRUE TRUE 
177 SH3D21 1.282618699 TRUE 2.647745216 TRUE TRUE TRUE 
178 SPC25 -1.071551589 FALSE -2.544504359 FALSE TRUE TRUE 
179 GSTCD -1.03502589 FALSE -1.996536631 FALSE TRUE TRUE 
180 KIF14 -1.361971458 FALSE -2.713772216 FALSE TRUE TRUE 
181 ESCO2 -1.451654145 FALSE -3.551278606 FALSE TRUE TRUE 
182 ORM1 2.685780251 TRUE 4.646724223 TRUE TRUE TRUE 
183 CASC5 -1.263255053 FALSE -3.545964195 FALSE TRUE TRUE 




1.467457205 TRUE 3.400679736 TRUE TRUE TRUE 
186 HPGD 1.189322791 TRUE 2.10972209 TRUE TRUE TRUE 
187 PARPBP -1.026696093 FALSE -2.44749604 FALSE TRUE TRUE 
188 LAT2 1.808412928 TRUE 2.427610918 TRUE TRUE TRUE 
189 ORM2 2.277914574 TRUE 4.097867053 TRUE TRUE TRUE 




-1.105860761 FALSE -2.648944929 FALSE TRUE TRUE 
192 SGOL1 -1.285003552 FALSE -2.766338523 FALSE TRUE TRUE 
193 CENPA -1.163331502 FALSE -2.929527833 FALSE TRUE TRUE 
194 DNA2 -1.076365642 FALSE -2.766893559 FALSE TRUE TRUE 
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195 E2F8 -1.456717266 FALSE -3.819975362 FALSE TRUE TRUE 
196 ZNF367 -1.267542181 FALSE -4.328131999 FALSE TRUE TRUE 
197 BLM -1.446418778 FALSE -3.413560967 FALSE TRUE TRUE 
198 GSG2 -1.159958704 FALSE -3.462901799 FALSE TRUE TRUE 
199 MND1 -1.275780661 FALSE -3.12209387 FALSE TRUE TRUE 
200 SLC2A3 1.635051806 TRUE 4.014407892 TRUE TRUE TRUE 
201 NEIL3 -1.23067546 FALSE -3.046048434 FALSE TRUE TRUE 
202 C4orf46 -1.090166037 FALSE -3.120734289 FALSE TRUE TRUE 
203 WDR76 -1.403783484 FALSE -2.686839002 FALSE TRUE TRUE 
204 RBL1 -1.175630515 FALSE -2.581728216 FALSE TRUE TRUE 
205 ARMC12 1.379682894 TRUE 2.123023084 TRUE TRUE TRUE 
206 XRCC2 -1.302298458 FALSE -3.573656338 FALSE TRUE TRUE 
207 BRCA2 -1.414784046 FALSE -3.54997446 FALSE TRUE TRUE 
208 HELLS -1.532231649 FALSE -3.389096455 FALSE TRUE TRUE 
209 CEP128 -1.243949596 FALSE -2.23337467 FALSE TRUE TRUE 




1.10072601 TRUE 2.154136878 TRUE TRUE TRUE 
212 E2F7 -1.588243565 FALSE -4.913846077 FALSE TRUE TRUE 
213 AKAP12 1.100637771 TRUE 2.532328524 TRUE TRUE TRUE 
214 CENPI -1.104227625 FALSE -3.011729362 FALSE TRUE TRUE 
215 CENPK -1.010823327 FALSE -3.092695248 FALSE TRUE TRUE 
216 POLE2 -1.123439223 FALSE -2.156420233 FALSE TRUE TRUE 
217 LIN9 -1.271678646 FALSE -2.982933162 FALSE TRUE TRUE 
218 CENPQ -1.096545173 FALSE -2.069731859 FALSE TRUE TRUE 
219 KIF18A -1.30277165 FALSE -2.58675416 FALSE TRUE TRUE 




-1.251034885 FALSE -2.516472719 FALSE TRUE TRUE 
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222 AMACR 1.097842667 TRUE 2.005658133 TRUE TRUE TRUE 
223 RTKN2 -1.084364609 FALSE -2.064782461 FALSE TRUE TRUE 
224 RTTN -1.087868503 FALSE -1.639532367 FALSE TRUE TRUE 
225 C17orf53 -1.053568236 FALSE -2.474477853 FALSE TRUE TRUE 
226 EPS8L1 1.487662116 TRUE 2.620431689 TRUE TRUE TRUE 
227 NPPC 1.455035342 TRUE 2.723004788 TRUE TRUE TRUE 
228 MYBPC1 1.509729064 TRUE 1.523942741 TRUE TRUE TRUE 
229 MYL9 1.044807814 TRUE 2.356211967 TRUE TRUE TRUE 
230 DMBX1 -1.304358586 FALSE -3.318635318 FALSE TRUE TRUE 
231 C4orf21 -1.116614217 FALSE -2.706746464 FALSE TRUE TRUE 
232 SPOCK1 1.424415309 TRUE 1.86288276 TRUE TRUE TRUE 
233 FAM54A -1.558239219 FALSE -2.919502267 FALSE TRUE TRUE 
234 C1orf135 -1.331645648 FALSE -3.514170836 FALSE TRUE TRUE 
235 FAM72B -1.006851967 FALSE -3.141893991 FALSE TRUE TRUE 
236 NAV3 -1.308845358 FALSE -2.872938246 FALSE TRUE TRUE 
237 ATAD5 -1.307776291 FALSE -3.021105108 FALSE TRUE TRUE 
238 C18orf54 -1.370639646 FALSE -3.364205193 FALSE TRUE TRUE 
239 TUBA3E 1.058685319 TRUE 1.54967697 TRUE TRUE TRUE 
240 WWTR1 1.058971357 TRUE 1.395273429 TRUE TRUE TRUE 
241 FAM81A -1.059074227 FALSE -2.049243476 FALSE TRUE TRUE 
242 BAI2 -1.041866526 FALSE -2.082050513 FALSE TRUE TRUE 
243 SPTB 1.789417358 TRUE 3.032925756 TRUE TRUE TRUE 
244 BORA -1.083276266 FALSE -1.725870742 FALSE TRUE TRUE 




-1.14281644 FALSE -2.174185642 FALSE TRUE TRUE 
247 DOCK8 1.214777253 TRUE 1.663145353 TRUE TRUE TRUE 
248 C5orf34 -1.244339471 FALSE -2.760752528 FALSE TRUE TRUE 
249 FAM83E 1.045875529 TRUE 2.570062662 TRUE TRUE TRUE 
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250 FAM72A -1.141683692 FALSE -2.564204856 FALSE TRUE TRUE 
251 TERT -1.045640638 FALSE -4.156096455 FALSE TRUE TRUE 
252 TLL1 -1.431590211 FALSE -2.608579968 FALSE TRUE TRUE 




-1.206721235 FALSE na na na na 
255 SCARA3 -1.178270901 FALSE -2.282576928 FALSE TRUE TRUE 
256 SNCG 1.540067338 TRUE 2.141418164 TRUE TRUE TRUE 
257 CNIH2 -1.144865495 FALSE -1.211409805 FALSE TRUE TRUE 
258 BEST1 -1.111941307 FALSE -2.169326688 FALSE TRUE TRUE 
259 MTBP -1.012011262 FALSE -2.650291204 FALSE TRUE TRUE 
260 TG 1.618921061 TRUE 4.164600171 TRUE TRUE TRUE 
261 PLCH1 -1.606490775 FALSE -2.493679618 FALSE TRUE TRUE 
262 SLC38A4 1.052921933 TRUE 1.956430774 TRUE TRUE TRUE 
263 RIN2 -1.027735094 FALSE -1.087612492 FALSE TRUE TRUE 
264 SLC22A1 1.201327452 TRUE 1.779196776 TRUE TRUE TRUE 
265 MIR29C 1.252846758 TRUE na na na na 
266 TMEM92 1.375662294 TRUE 2.26777347 TRUE TRUE TRUE 
267 HIST1H1E 1.763121375 TRUE 2.965480185 TRUE TRUE TRUE 
268 ELOVL2 1.376338484 TRUE 3.171632272 TRUE TRUE TRUE 




1.070314585 TRUE 1.30328445 TRUE TRUE TRUE 
271 ZNF726 -1.515607382 FALSE -1.792125284 FALSE TRUE TRUE 
272 CCDC150 -1.681765513 FALSE -2.978122952 FALSE TRUE TRUE 
273 FLT4 -1.736401302 FALSE -2.637010841 FALSE TRUE TRUE 
274 LOC144481 2.239074443 TRUE 3.840201325 TRUE TRUE TRUE 
275 FANCB -1.226284941 FALSE -3.293278214 FALSE TRUE TRUE 
276 ZNF519 -1.094688579 FALSE -1.761359961 FALSE TRUE TRUE 
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277 BRDT -1.308242704 FALSE -2.042411341 FALSE TRUE TRUE 
278 REP15 1.131995532 TRUE 3.918908125 TRUE TRUE TRUE 
279 MYBL1 -1.18514824 FALSE -2.584986562 FALSE TRUE TRUE 
280 ANTXR1 -1.007032067 FALSE -1.864352091 FALSE TRUE TRUE 
281 BCL2 -1.314809671 FALSE -2.225353599 FALSE TRUE TRUE 
282 KCNG3 1.095702456 TRUE 1.628504918 TRUE TRUE TRUE 
283 LEF1 -1.316811997 FALSE na na na na 
284 TGM3 -1.133649271 FALSE -3.30532901 FALSE TRUE TRUE 
285 LGI2 -1.236536649 FALSE -4.032093846 FALSE TRUE TRUE 
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Supplementary Table S1. Primer sequences for qRT-PCRs 
Primer  Sequence Application 
STING-Fwd AGCATTACAACAACCTGCTACG qRT-PCR 
STING-Rev GTTGGGGTCAGCCATACTCAG qRT-PCR 
ERV3-env-Fwd CCATGGGAAGCAAGGGAACT  qRT-PCR 
ERV3-env-Rev CTTTCCCCAGCGAGCAATAC  qRT-PCR 
HERV‐W-Fwd TGAGTCAATTCTCATACCTG qRT-PCR 
HERV‐W-Rev AGTTAAGAGTTCTTGGGTGG qRT-PCR 
HERVE Fwd GGTGTCACTACTCAATACAC qRT-PCR 
HERVE-Rev GCAGCCTAGGTCTCTGG qRT-PCR 
HERV F-Fwd CCTCCAGTCACAACAACTC qRT-PCR 
HERV F-Rev TATTGAAGAAGGCGGCTGG qRT-PCR 
ERVL-Fwd ATATCCTGCCTGGATGGGGT qRT-PCR 
ERVL-Rew GAGCTTCTTAGTCCTCCTGTGT qRT-PCR 
HERV-F-Fwd CCTCCAGTCACAACAACTC  qRT-PCR 
HERV-F-Rev TATTGAAGAAGGCGGCTGG qRT-PCR 
HERV-K-Fwd ATTGGCAACACCGTATTCTGCT  qRT-PCR 
HERV-K-Rev CAGTCAAAATATGGACGGATGGT qRT-PCR 
DNMT1-Fwd GCGTTCCGGCTGAACAAC qRT-PCR 
DNMT1-Rev GCATCTCCACGTCTCCCT qRT-PCR 
EZH2--RT-fwd GTGGAGAGATTATTTCTCAAGATG qRT-PCR 
EZH2-RT-Rev CCGACATACTTCAGGGCATCAGCC qRT-PCR 
B2M-RT-fwd TGACTTTGTCACAGCCCAAG qRT-PCR 
B2M-RT-Rev AGCAAGCAAGCAGAATTTGG qRT-PCR 
HLA-A-RT-fwd GGCCCTGACCCAGACCTG qRT-PCR 
HLA-A-RT-Rev GCACGAACTGCGTGTCGTC qRT-PCR 
HLA-B-RT-fwd ACTGAGCTTGTGGAGACCAGA qRT-PCR 
HLA-B-RT-Rev GCAGCCCCTCATGCTGT qRT-PCR 
HLA-C-RT-fwd CTGGCCCTGACCGAGACCTG qRT-PCR 
HLA-C-RT-Rev CGCTTGTACTTCTGTGTCTCC qRT-PCR 
IFN-β-RT-fwd GCCATCAGTCACTTAAACAGC qRT-PCR 
IFN-β-RT-Rev GAAACTGAAGATCTCCTAGCCT qRT-PCR 
ISG15-RT-fwd CCTTCAGCTCTGACACC qRT-PCR 
ISG15-RT-Rev CGAACTCATCTTTGCCAGTACA qRT-PCR 
IRF7-RT-fwd GTGGACTGAGGGCTTGTAG qRT-PCR 
IRF7-RT-Rev TCAACACCTGTGACTTCATGT qRT-PCR 
MAVS-RT-fwd AGGAGACAGATGGAGACACA qRT-PCR 
MAVS-RT-Rev CAGAACTGGGCAGTACCC qRT-PCR 
RIG-I-RT-fwd CCAGCATTACTAGTCAGAAGGAA qRT-PCR 
RIG-I-RT-Rev CACAGTGCAATCTTGTCATCC qRT-PCR 
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Mouse-IRF7-fwd CCACACCCCCATCTTCGA qRT-PCR 
Mouse-IRF7-Rev CCTCCGAGCCCGAAACTC qRT-PCR 
Mouse-psmb9-fwd TAGTAGCTGGCTGGGACCAA qRT-PCR 
Mouse-psmb9-Rev GATGGTAAAGGGCTGTCGAA qRT-PCR 
Mouse-HPRT-fwd GGCCAGACTTTGTTGGATTT qRT-PCR 
Mouse-HPRT-Rev ACTGGCAACATCAACAGGACT qRT-PCR 
Mouse-STING-Fwd GGTCACCGCTCCAAATATGTAG qRT-PCR 
Mouse-STING-Rev CAGTAGTCCAAGTTCGTGCGA qRT-PCR 
Mouse-DDX58(RIG-I)-Fwd AAGAGCCAGAGTGTCAGAATCT qRT-PCR 
Mouse-DDX58(RIG-I)-Rev AGCTCCAGTTGGTAATTTCTTGG qRT-PCR 
Mouse-DNMT1-Fwd CCAGGCATTTCGGCTGAA qRT-PCR 
Mouse-DNMT1-Rev CGTTGCAGTCCTCTGTGAACA qRT-PCR 
Mouse-LINE1-fwd GGACCAGAAAAGAAATTCCTCCCG qRT-PCR 
Mouse-LINE1-rev CTCTTCTGGCTTTCATAGTCTCTGG qRT-PCR 
Mouse-ERV-MTA-fwd TCTGTGGGATGTTGTGTAGGAG qRT-PCR 
Mouse-ERV-MTA-Rev CCACAGATCTTCACAATCCAAA qRT-PCR 
Mouse-ERV-RLTR1B-fwd GGTCCACACAAACACCTACCTT qRT-PCR 
Mouse-ERV-RLTR1B-Rev  TTTGAGATACACCCTTCGAGGT qRT-PCR 
Mouse-ERV-RLTR45-fwd ACCTTGGACCTTTCTCAATACAT qRT-PCR 
Mouse-ERV-RLTR45-Rev GACCTCCTCCTAATAACCAAATG qRT-PCR 
Mouse-ERV-IAPEZ-fwd AAATCAATCTGTTGTGTTTCCAC qRT-PCR 
Mouse-ERV-IAPEZ-Rev  ACCACATAACAGGAATCTGACAC qRT-PCR 
 
Supplementary Data2. GSEA report for top enriched Hallmark genesets (p ≤ 0.05) with a 
positive NES 
 Name NES FDR q-val 
1 HALLMARK_ANDROGEN_RESPONSE 2.8952408 0 
2 HALLMARK_PROTEIN_SECRETION 2.3557687 0 
3 HALLMARK_APICAL_JUNCTION 1.8830771 0.02535794 
4 HALLMARK_CHOLESTEROL_HOMEOSTASIS 1.7936019 0.03255346 
5 HALLMARK_ESTROGEN_RESPONSE_EARLY 1.788912 0.02765674 
6 HALLMARK_XENOBIOTIC_METABOLISM 1.7781266 0.02561309 
7 HALLMARK_COAGULATION 1.7351228 0.02783313 
8 HALLMARK_FATTY_ACID_METABOLISM 1.7211664 0.02772199 





Supplementary Data3. GSEA report for top enriched Hallmark genesets (p ≤ 0.05) with a 
Negative NES 
 
 Name NES FDR q-val 
1 HALLMARK_E2F_TARGETS -3.283671 0 
2 HALLMARK_G2M_CHECKPOINT -3.0368714 0 
3 HALLMARK_MYC_TARGETS_V1 -2.536929 0 
4 HALLMARK_MITOTIC_SPINDLE -2.4192386 0 
5 HALLMARK_MYC_TARGETS_V2 -2.110342 0 
6 HALLMARK_DNA_REPAIR -1.8421776 8.29E-04 
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4.1. Introduction  
Enhancer of Zeste Homolog 2 (EZH2) is a histone methyl-transferase that forms the catalytic 
subunit of Polycomb Repressive Complex 2 (PRC2). As part of the canonical function of PRC2, 
EZH2 mediates tri-methylation of histone H3 lysine 27 (H3K27me3), which causes compaction 
of chromatin and transcriptional silencing of target genes (Jiao, Shubbar et al. 2020). In 
proliferative cells, the interplay between Rb and E2Fs govern EZH2 function and thereby 
regulate the inheritance of H3K27me3 patterns during DNA replication and cell proliferation 
(Bracken, Pasini et al. 2003, Lanzuolo, Sardo et al. 2011, Mu, Starmer et al. 2018). For example, 
it has been shown that in skeletal muscle cells, Rb-mediated EZH2 binding to cell cycle genes 
leads to irreversible cell cycle exit and cell differentiation (Blais, van Oevelen et al. 2007). 
Additionally, it has been reported that RB protein can recruit PRC2 complex to repress the 
expression of genes associated with repetitive elements (Ishak, Marshall et al. 2016) and 
pluripotency (Kareta, Gorges et al. 2015) by tri-methylation of histone H3 at lysine 27. EZH2 
can also regulate the expression of genes involved in stem cell differentiation and tumour 
immunogenicity by altering the ratio of H3K27me3 to H3K4me3; these are referred to as 
bivalent genes because their promoters harbour histone marks associated with both positive 
(H3K4me3) and negative (H3K27me3) transcriptional outcomes (Ezhkova, Pasolli et al. 2009, 
Blanco, González-Ramírez et al. 2020). In short, the canonical function of EZH2 and 
subsequently the level of H3K27me3 is an important determinant of the balance between cell 
differentiation and proliferation (Ezponda and Licht 2014).  
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Dysregulation in the expression and function of EZH2 can lead to carcinogenesis and cancer 
progression in multiple tumour types. For example, overexpression of EZH2 in prostate cancer 
tumours is associated with the progression of clinically localized solid tumours to a lethal, 
therapy-resistant state (Varambally, Dhanasekaran et al. 2002, Yu, Yu et al. 2007). 
Mechanistically, several mechanisms can cause dysregulation of both the expression and 
function of EZH2 in prostate cancer: TMPRSS2-ERG fusion genes can cause the overexpression 
of EZH2, inducing a stem-cell-like dedifferentiation program (Yu, Yu et al. 2010), while SOX4 
overexpression in cancer cells can directly upregulate the expression of EZH2, which 
subsequently leads to re-distribution of H3K27me3 and de-repression of genes required for 
epithelial-mesenchymal transition, a key process in tumour metastasis (Tiwari, Tiwari et al. 
2013). Interestingly, overexpression of EZH2 in castration-resistant prostate cancer has been 
associated with lower global levels of H3K27me3 suggesting that EZH2 has activity beyond 
histone modification; indeed, it was found that EZH2 interacts with AR and in this context can 
act as a transcriptional activator (Xu, Wu et al. 2012). Consistent with this notion, 
phosphorylation of partially disordered transactivation domain (TAD) in EZH2 causes the 
recruitment of P300, leading to gene activation rather than repression (Jiao, Shubbar et al. 
2020). However, these findings were not supported by mass spectrometry-based analysis of 
the EZH2 interactome, which recovered all PRC2 related components but did not identify an 
interaction with AR (Wassef, Luscan et al. 2019). In short, the precise function of EZH2 in PCa 
cells remains to be fully elucidated. 
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Other studies of EZH2 have potentially important implications for this project and the results 
presented in Chapter 3. First, a CRISPR/CAS9 screen revealed that EZH2 depletion can make 
prostate cancer cells sensitive to high-dose androgen therapy (Nyquist, Corella et al. 2019), 
suggesting that it has a role in mediating resistance to this therapeutic strategy. Moreover, it 
has been shown that EZH2 inhibition can lead to the enhanced immunogenicity of tumours 
through de-repression of ERVs and activation of a viral mimicry response (Deblois, 
Tonekaboni et al. 2020, Janin and Esteller 2020, Ishiguro, Kitajima et al. 2021). EZH2 inhibition 
can also directly increase tumour immunogenicity by enhancing the expression and 
presentation of major MHC-I molecules (Burr, Sparbier et al. 2019, Zhou, Mudianto et al. 
2020). Consistent with this idea, we showed in Chapter 3 that Decitabine-induced dsRNAs are 
less strong than MeT 1 nM, suggesting that dsRNA induction by MeT is also amplified by 
another mechanism. With this background in mind, I hypothesised that the viral mimicry 
response elicited by MeT (as described in Chapter 3) could at least in part be mediated via 
reduced expression and/or activity of EZH2. In this Chapter, I tested this hypothesis by 
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4.2. Materials and Methods 
Details of cell lines, Western blotting, q-RT-PCR and RNA-seq are described in Chapters 2 and 
3. 
4.2.1. Histone extraction 
Total nucleoplasmic histones were extracted using the acid extraction protocol 
recommended by Abcam. Briefly, after harvesting the cells, they were washed twice with ice-
cold PBS and cell pellets were re-suspended in Triton Extraction Buffer (TEB) (please see 
Chapter 2), at a cell density of 107 cells per ml for 10 min with gentle stirring on ice. Then, the 
lysate was centrifuged at 6,500 × g for 10 min at 4°C to spin down the nuclei. After discarding 
the supernatant, cell pellets were washed in half the volume of TEB and centrifuged at 6,500 
× g for 10 min at 4°C. Subsequently, cell pellets were re-suspended in 0.2 N HCl at a density 
of 4 ×107 nuclei per ml overnight. Samples were centrifuged at 6,500 × g for 10 min at 4°C and 
the supernatant containing total nucleoplasmic H3K27me3 was moved into a new tube. 
Finally, HCl in samples was neutralised with 2M NaOH at 1/10 of the volume of the 
supernatant. Protein concentration was measured using the Bradford assay described in 
Chapter 2 and samples were kept at -80 °C.  
 
4.2.2. H3K27me3 ChIP-seq experiment, analysis and DATA 
H3K27me3 ChIP-seq experiment was carried out as described in Chapter 2. Peak calling in 
Galaxy was performed essentially as described in Chapter 2, except that the “broad” peak 
parameter was used, with a cutoff for the broad region of 0.1. H3K27me3 ChIP-seq data are 
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from Augello, M. A et al. (Augello, Liu et al. 2019): GEO accession GSE117430, and Xu K et al. 
(Xu, Wu et al. 2012): GEO accession GSM969571. 
 
4.2.3. Integrating RNA-seq and H3K27me3 ChIP-Seq data 
Integration of H3K27me3 ChIP-seq data with transcriptomic analyses was carried out using 
the CisGenome software system (Ji, Jiang et al. 2008). The CisGenome software and hg19 
genome build were used to annotate H3K27me3 peaks to proximal (+/- 10kb from TSS) genes. 
Genes marked with H3K27me3 were compared with the list of log normalized counts of 
genes, generated from the RNA-seq experiment described in Chapter 3.  
 
4.2.4. GO analysis 
The PANTHER online platform version 16.0 (Released 2020-12-01) (http://geneontology.org/) 
was used for gene ontology (GO) analysis (Mi, Muruganujan et al. 2019). 
 
4.2.5. Tag density analysis using HOMER software. 
BAM files from the ChIP-seq experiment were converted to bed files using bedtools (version 
2.18 (Quinlan and Hall 2010)); “bamToBed.” Bed files were converted to tag directories using 
HOMER (version 4.11 (Heinz, Benner et al. 2010)); “makeTagDirectory.pl.” Tag density plots 









DiffReps (version 1.55.4) (Shen, Shao et al. 2013) was run according to the developer’s 
protocol using bed files from the androgen-treated samples as the --treatment group and bed 
files from the vehicle-treated samples as the --control group. The G-test method was used for 
differential analysis (--meth gt). 
 
4.2.7. H3K27me3 deposition on repetitive elements 
To measure H3K27me3 at repetitive elements, genomic coordinates of these elements were 
directly downloaded from The UCSC Table Browser (Karolchik, Hinrichs et al. 2004). More 
specifically, after specifying the February 2009 human reference sequence (GRCh37) as a 
reference genome, RepeatMasker was applied in the annotation track to filter the 
coordinates of different families (repFamily) of repetitive elements. HOMER (Heinz, Benner 
et al. 2010) was used to generate histograms of tag density at repetitive elements. 
 
4.2.8. Visualisation of H3K27me3 deposition  
The density of H3K27me3 deposition at previously reported coordinates associated with 
H3K27me3 modification was visualised using deepTools2 (Ramírez, Ryan et al. 2016). 
Reported gene sets in LNCaP was from Hawkins RD et al. (Hawkins, Hon et al. 2010) and Xu K. 
et al (Xu, Wu et al. 2012). ComputeMatrix was used to prepare an intermediate Matrix file 
containing the scores for the signal distribution associated with the centre of genomic regions 
(reference point). The generated Matrix file was used with plotProfile to plot the signal 
distributions across genomic regions.  
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4.2.9. Venn diagram generation for comparing the intervals of two datasets 
To compare the overlapping of H3K27me3 ChIP-seq peaks, The Galaxy/Cistrome Venn 
diagram (version 1.0.0) tool (Liu, Ortiz et al. 2011) was used to compare the overlapping of 
peaks. 
 
4.2.10. Upset plots 
UpSet diagram tool (Galaxy Version 0.6.4) (Conway, Lex et al. 2017) was used to illustrate the 
unique intersection of genomic regions between different treatment groups as an upset plot 
based on the order of intersections frequency. 
 
4.2.11. Pairwise intervention analysis  
Pairwise intersection tool (Galaxy Version 0.6.4) was used to compute and visualize 
intersections of multiple sets of genomic regions (Khan and Mathelier 2017). Calculation of 
overlapping fraction was applied as the metric for the generated heatmap containing the 
overlapping fraction number. Coordinates associated with H3K27me3 peaks were generated 
by DiffReps and TSS-associated coordinates were downloaded from UCSC table browser 
(Karolchik, Hinrichs et al. 2004) as follows: “February 2009 human reference sequence 
(GRCh37)” was specified as a reference genome, “Regulation” was applied in the group, 
“SwitchGear TSS” was applied in track,  and BED file was generated after adding 100, 1000, 
and 10,000bp to the upstream. CpG islands coordinates were similarly downloaded from the 
UCSC Table Browser (26). 
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4.2.12. Number and location of H3K27me3 deposition 
CisGenome software system (Ji, Jiang et al. 2008) was used to assess the genome-wide 
location of H3K27me3 peaks after specifying the hg19 as a reference genome build. 
 
4.3. Results 
4.3.1. Potent activation of AR repressed EZH2 expression in prostate cancer cells 
To assess the hypothesis that antiproliferative effects of high-dose androgens could be 
mediated by altered EZH2 expression and/or activity, we first checked the expression status 
of PRC2 subunits including EZH2/1, SUZ12, EED, and RBBP4/7 in our RNA-seq data (described 
in Chapter 3). The analysis of differentially expressed genes in LNCaP cells shows that EZH2, 
EED, SUZ12, and RBBP4/7 were all significantly repressed by both androgens, whereas EZH1 
was not changed significantly (Figure 4.1A to F). This suggests that androgens modulate the 
function of the PRC2 complex. EZH2 downregulation in RNA-seq analysis was confirmed using 
qRT-PCR (Figure 4.2A). Consistent with PRC2 downregulation, GSEA analysis shows that 
expression of EZH2 target genes (Liao, Chen et al. 2020) was downregulated by MeT (1 nM) 
and DHT (1 nM) (Figure 4.2B). Also, RNA-seq results showed that the expression of genes 
associated with growth inhibitory effects of EZH2 inhibitor was repressed by MeT (Figure 
4.2C), indicating that MeT caused the repression of genes activated by EZH2.  
 
Mechanistically, overexpression of EZH2 is reported to be caused by the transcription factors 
E2F1 or SOX4 (Bracken, Pasini et al. 2003, Tiwari, Tiwari et al. 2013, Mu, Starmer et al. 2018). 
To test whether these known associations could explain EZH2 downregulation by high-dose 
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androgens in our experiments, we examined our RNA-seq data. This revealed that MeT 1 nM 
and DHT 1nM significantly repressed the expression E2F1; however, significant repression of 
SOX4 was only mediated after MeT 1 nM treatment (Figure 4.2D). These observations suggest 












Figure 4.1. Androgens repress the expression of the PRC2 complex in LNCaP cells. A. The expression 
level of PRC2 complex subunits was assessed based on normalised read counts generated from the 
RNA-seq experiment described in Chapter 3; in this experiment, the expression of EZH2 (A), SUZ12 (B), 
EED (C), RBBP4 (D), RBBP7 (E), and EZH1 (F) were examined 24 hours after treatment. ANOVA with 
Dunnett multiple comparison test was used to determine significant changes in expression (∗p < 0.05; 
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To validate the repressive effects of MeT on the expression of EZH2 in other prostate cancer 
models, a panel of prostate cancer cell lines (LNCaP, VCaP, C42B, MR49F, and V16D) were 
treated with different doses of MeT and DHT and expression of EZH2 was examined at the 
protein level. We found that potent activation of AR using MeT (1 and 100 nM) or high-dose 
DHT (100 nM) caused down-regulation of EZH2 in the LNCaP, VCaP and V16D models, but not 
























Figure 4.2. Hyper-activation of AR leads to the suppression of EZH2 in LNCaP cells. A. A. Validation 
of EZH2 suppression using qRT-PCR in LNCaP cells treated with MeT or DHT. RNA was extracted 24 
hours after treatment. p values were determined using ANOVA with Dunnett multiple comparison 
tests (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001); B. MeT and DHT treatments caused 
significant repression of EZH2 target genes in LNCaP cells as determined by GSEA analysis, using a 
published EZH2-regulated gene set (Kamminga, Bystrykh et al. 2006). C. MeT repressed the expression 
of genes crucial for growth inhibitory effects of EZH2 inhibitor. Heatmap generated based on 
normalised read counts from RNA-seq experiments described in Chapter 3 (24h time-point). Gene set 
has been reported previously by Liao, Yiji, et al. (Liao, Chen et al. 2020); D. The expression level of 
SOX2 and E2F1 were assessed based on normalised read counts generated from RNA-seq experiment 
described in Chapter 3; in this experiment, gene expression was examined 24 hours after treatment. 
ANOVA with Dunnett multiple comparison test was used to determine significant changes in 
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Figure 4.3. Potent activation of AR represses the expression of EZH2 in prostate cancer cell lines. A. 
Assessment of EZH2 expression was carried out using Western blotting in a panel of prostate cancer 
models including LNCaP, VCaP, C42B, MR49F, and V16D, which were treated with different doses of 
MeT or DHT doses; each sample was pooled from two replicates. B. Quantification of detected bands 
was carried out using the ImageLab software. Signal intensity in the Vehicle sample at 24h time-point 
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4.3.2. Androgen treatment alters H3K27me3 distribution in LNCaP cells 
Current evidence suggests that the oncogenic activity of EZH2, either through canonical and 
non-canonical functions, can lead to prostate cancer progression (Kim, Lee et al. 2018, Liao, 
Chen et al. 2020). To identify the consequence of EZH2 repression by androgens, we first 
assessed H3K27me3 protein levels - as a read-out for the canonical activity of EZH2-by 
Western blotting in LNCaP cells. Consistent with decreased EZH2, androgens reduced the 
global level of H3K27me3 at 24 and 72 hours post-treatment (Figure 4.4 A and B). These 
findings suggest that the canonical activity of EZH2 is affected by high-dose androgens in 
LNCaP cells. Subsequently, to evaluate H3K27me3 status at specific loci, we undertook ChIP-
seq as a means to examine the genome-wide deposition of this histone mark. The LNCaP cell 
line, which was the most sensitive model to MeT/high-dose DHT in terms of growth-inhibitory 
effects, repression of EZH2, and viral mimicry response (Chapter 3), was chosen for this 
experiment. A 72-hour treatment of LNCaP cells cultured in 10% FBS supplemented RPMI-
1640 was chosen for the ChIP-seq experiment since MeT-induced loss of H3K27me3 (Figure 
4.4) and viral mimicry response (Chapter 3) was detected at this time-point. Following the 
preparation of nuclear lysate for the ChIP experiment, we checked the status of EZH2 
expression and H3K27me3 in the nuclear lysates that were to be used for ChIP, which 
confirmed repression of EZH2 and a decrease in H3K27me3 level by MeT and high-dose DHT 
(100 nM) (Figure 4.4C). We subsequently performed H3K27me3 immunoprecipitation and 
sequenced the co-precipitating DNA.  
 
 




Figure 4.4. Androgen treatments alter the global level of H3K27me3 in LNCaP cells. A. Total 
nucleoplasmic level of H3K27me3 histone modification and histone H3 24 hours and 72 hours after 
treatment with MeT or DHT; each sample was pooled from two replicates. B. Quantification of 
detected bands detected in the assessment of global H3K27me3 level using the western blotting. 
Quantification was carried out using ImageLab software. Quantification of detected bands was carried 
out using the ImageLab software. Signal intensity in the Vehicle sample at 24h time-point was set to 
1. C. Western blotting-based assessment of EZH2 expression and H3K27me3 histone modification 
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In vehicle-treated LNCaP cells, 40,367 consensus H3K27me3 peaks were identified. 
Surprisingly given the loss of bulk H3K27me3, treatment with DHT 1 nM led to an increase in 
the number of peaks to 46,288. To confirm whether our data was consistent with other 
reported studies, we first compared the number and locations of H3K27me3 peaks in vehicle 
and DHT 1 nM treatment groups with two publicly available H3K27me3 ChIP-seq data, 
GSM969571 and GSE117430. The GSM969571 dataset was generated from LNCaP cells 
treated with DHT 10 nM (for 24h) in Charcoal DCC-FBS-supplemented media and GSE117430 
data was generated from LNCaP cells treated with DHT 10 nM (for 3h) in FBS-supplemented 
media (Table 4.1). Overall, our H3K27me3 cistrome was more similar to that from GSE117430 
in terms of the number of peaks (Table 4.1) but overlapped more strongly with GSM969571 
(Table 4.1; Figure 4.5). Notably, the overlap between GSM969571 and GSE117430 was 
minimal (Table 4.1; Figure 4.5). Collectively, these studies suggest that our H3K27me3 data is 


















H3K27me3 peaks Vehicle DHT 1 nM 
GSE117430 
(Augello, Liu et 
al. 2019) 
GSM969571  
(Xu, Wu et al. 2012)  




10% FBS/RPMI 5% FBS/RPMI 10% DCC-FBS/RPMI 
Treatment - DHT 1 nM (72h) DHT 1 nM (3h) DHT 1 nM (24h) 















61.58 61.88 65.93 57.58 
Intragenic (%) 
38.41 38.11 34.06 42.41 
Exon (%) 
6.43 5.83 2.78 7.49 
Intron (%) 
32.60 32.82 31.47 35.65 
CDS (%) 
4.17 3.76 1.92 5.31 
UTR (%) 
2.34 2.13 0.89 2.30 
5'UTR (%) 
1.49 1.29 0.26 1.40 
3'UTR (%) 
0.86 0.84 0.63 0.89 
     
 





Figure 4.5. Cell growth condition can change the deposition pattern and distribution of H3k27me3 
histone modification. Venn diagrams illustrating the overlap of consensus H3K27me3 peaks with 
other LNCaP H3M27me3 ChIP-seq datasets ((Augello, Liu et al. 2019), GEO accession GSE117430; (Xu, 
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Having used published data to provide confidence in our H3K27me3 ChIP-seq experiment, we 
next evaluated the effect of DHT and MeT treatments on this histone mark in LNCaP cells.   
Androgen treatment did not dramatically alter the level of chromatin-bound H3K27me3, as 
determined by a relatively consistent number of H3K27me3 peaks detected in each of the 
different treatment groups (Table 4.2). Figure 4.6 shows the deposition status of H3K27me3 
on FOXC1 and LHX6 genes, two genes reported being regulated by EZH2 and H3K27me3 
(Boshans, Factor et al. 2019, Zheng, Li et al. 2020). Evaluation of the H3K27me3 signal 
proximal to genes reported to be marker by this histone mark in LNCaP cells (Hawkins, Hon 
et al. 2010) and hESCs (Xu, Wu et al. 2012) (Figure 4.7) provided further evidence that 
androgen treatment had minimal effect on this histone mark. Although H3K27me3 did not 
dramatically change with any of the treatments, we did observe a slight decrease in terms of 
peak number and signal with the higher dose treatments (Table 4.2 and Table 4.3). In all 
treatment groups, the vast majority of peaks were in intergenic regions and introns, with only 
on average ~37% found at intragenic regions (Table 4.2). Overall, these findings suggest that 
H3K27me3 is not significantly altered, either at a qualitative or quantitative level, by 
MeT/DHT, which was unexpected due to significant repression of EZH2 at RNA and protein 











Table 4.2. Number and location of H3K27me3 deposition 72 hours after treatment with MeT 
and DHT 
 











Consensus H3K27me3 peaks* Vehicle MeT 1 nM MeT 100 nM DHT 1 nM DHT 100 nM 
Total Peak number (FDR < 0.05) 40367 43389 37351 46288 40138 
Intergenic (%) 61.5825 61.7161 62.1001 61.8821 63.2493 
Intragenic (%) 38.4175 38.2839 37.8999 38.1179 36.7507 
Exon (%) 6.4384 6.5961 6.3666 5.8309 4.2304 
Intron (%) 32.6058 32.3146 32.0928 32.8228 32.9513 
CDS (%) 4.1717 4.2522 4.1123 3.7634 2.4864 
UTR (%) 2.341 2.4223 2.3293 2.1345 1.7863 
5'UTR (%) 1.4913 1.5672 1.5662 1.2984 1.293 
3'UTR (%) 0.8646 0.8666 0.7711 0.8447 0.5008 
 





























Figure 4.6. Androgen treatments did not attenuate the level of chromatin-bound H3K27me3 
deposition at key EZH2 target genes. Genome browser images showing H3k27me3 ChIP-seq signals 
at binding sites associated with FOXC1 and LHX6 in two replicates of LNCaP cells treated with Vehicle, 








Figure 4.7.  Androgen treatments did not change the genome-wide binding profile of H3K27me3. 
Heatmaps show the enrichment of H3K27me3 around the TSS (+/-6kb) of previously reported gene 
sets associated with H3K27me3 in LNCaP (Hawkins, Hon et al. 2010) and hESCs cells (Xu, Wu et al. 
2012).  
 




















Consensus H3K27me3 peaks Vehicle MeT 1 nM MeT 100 nM DHT 1 nM DHT 100 nM 
Shared with Vehicle (%) 100 71.43 75.06 68.66 57.27 
Shared with MeT 1 nM (%) 75.83 100 78.57 66.22 57.36 
Shared with MeT 100 nM (%) 67.07 66.12 100 58.52 56.85 
Shared with DHT 1 nM (%) 81.12 73.16 76.80 100 61.73 
Shared with DHT 100 nM (%) 54.66 51.50 59.97 50.56 100 
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4.3.3. Functional analysis of genes associated with H3K27me3 histone mark  
Although our ChIP-seq data did not identify any major quantitative change to genome-wide 
H3K27me3 in response to MeT or DHT, we did observe a certain level of re-distribution with 
androgen treatments (Figure 4.8). To measure loss and gain of H3K27me3 more 
quantitatively, we used the Diffreps (Shen, Shao et al. 2013), which identified 1,502, 2,031, 
1,446, and 7,681 regions with differential levels of H3K27me3 after treatment with MeT 1 
nM, MeT 100 nM, DHT 1 nM, and DHT 100 nM, respectively. Analysis of intersections between 
gained or lost H3K27me3 sites revealed that the vast majority were treatment-specific (Figure 
4.9). We annotated the lost/gained sites to genomic regions known to be associated with 
H3K27me3: CpG islands, transcriptional start sites (TSSs), and promoters (100 to 10,000bp 
from TSS) (Deblois, Tonekaboni et al. 2020). This analysis reinforced that most H3K27me3 
sites were distal from genes and only a small proportion was in CpG islands (Figure 4.10). 
More importantly, this analysis revealed that in cells treated with a low dose (1 nM) of MeT 
or DHT, there were more gained H3K27me3 peaks relative to lost peaks at intergenic DNA 
regions, suggesting that low-dose androgens caused an enrichment of H3K27me3 peaks at 
regulatory regions of DNA. Inversely, treatment with a high-dose of androgens caused more 
lost H3K27me3 peaks relative to gained peaks at the same regions. Collectively, these findings 
suggest that androgens exerts a dose-dependent effect on re-distribution of H3K7me3 at 
intergenic regions.  
 
We then annotated the differentially marked regions with proximal genes and determined 
whether specific gene ontology (GO) groups were particularly associated with re-distributed 
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H3K27me3 (Mi, Muruganujan et al. 2019). This functional analysis strategy showed significant 
enrichment of genes involved in development (the nervous system, differentiation, and 
embryogenesis) having “re-distributed” H3K27me3 (Figure 4.11), a finding consistent with 
other studies suggesting the role of H3K27me3 in the development of the nervous system 
























Figure 4.8. Androgen treatments changed the genome-wide distribution of H3k27me3 histone 
modification. UpSet plots illustrated the overlap of consensus H3K27me3 peaks in LNCaP cells treated 
in vitro with Vehicle, MeT (1 and 100 nM) or DHT (1 and 100 nM). 
 




Figure 4.9. The difference in type and doses of androgens causes unique differentially modified DNA 
regions by H3K27me3. The overlapping of differentially gained or lost H3K27me3 by MeT and DHT 
was illustrated using the UpSet plots.  
 





Figure 4.10. Treatment with high-dose androgens causes an increase in differentially lost peaks at 
intergenic regions. A pairwise plot was used to compare the overlapping of differentially gained or 
lost H3K27me3 peaks with each other and also with some regulatory regions including TSS, upstream 
of TSS, and CpG islands. The fraction of regions in the X-axis which is shared with regions in the Y-axis 
was shown as a fraction of 1, which is equal to 100% overlapping.  
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Figure 4.11. Gene ontology enrichment analysis showed the significant enrichment of 
developmental pathways for regions marked by H3K27me3. The heatmap shows significantly 
overrepresented biological processes in different treatment groups, which was analysed using online 
PANTHER overrepresentation platform (Mi, Muruganujan et al. 2019). Enrichment test was performed 
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4.3.4. No evidence for altered H3K27me3 at endogenous retrovirus elements  
As shown in Chapter 3, MeT and high-dose androgens caused hypo-methylation of DNA and 
dysregulation of repetitive elements, resulting in activation of a viral mimicry response in 
prostate cancer cells. The repressive histone mark H3K27me3 has also been linked to 
repression of ERV transcription (Walter, Teissandier et al. 2016). Therefore, we examined 
H3K27me3 at different repetitive elements. Surprisingly, the analysis of the different class of 
repetitive elements including DNA class, Long interspersed nuclear elements (LINEs), long 
terminal repeat (LTR), Short interspersed nuclear elements (SINEs), and SINE-VNTR-Alus (SVAs) 
revealed two distinct shapes of H3K27me3 signals (Figure 4.12). Interestingly, in DNA, LINE, 
and LTR classes, the peak densities were very low, exhibiting a peak-valley-peak signal pattern 
with depletion of H3K27me3 towards the centre of these elements. By contrast, in SVA and 
SINE classes, which are generally enriched with GC content (Gu, Jin et al. 2016), H3K27me3 
formed sharp peaks at the centre. Similar to SINEs and SVAs, H3K27me3 was also enriched in 
CpG islands with sharp peaks at the centre, suggesting that the distribution pattern of 
H3K27me3 in LNCaP cells depends on the GC content of the targeted region. Interestingly, in 
the majority of regions with H3K27me3 peaks, the H3K27me3 signal from the MeT 1 nM 
treatment group was higher than other treatments, which is consistent with the results of 
pairwise analysis. Treatment with higher doses of MeT or DHT did not cause any substantial 
decrease to the level of H3K27me3 deposition at these elements, which is consistent with our 
earlier analyses but inconsistent with the hypothesis that altered distribution of this histone 
mark at repetitive elements results in changes to their transcription.  
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Figure 4.12. Deposition status of H3K27me3 at repetitive elements. HOMER was used to visualise the 
deposition status of H3K27me3 at repetitive elements in LNCaP cells treated with vehicle, MeT (1 nM 
and 100 nM) or DHT (1 nM and 100 nM) for 72h. Average read density plots were generated for 
H3K27me3 binding to DNA class, LINE class, LTR class, SINE class, CpG islands, SVA family members, 
Alu family members (AluSq, AluSq, and AluYb8), ERVL, HERVK-int, HERV3-int (ERV3-1), and HERVH-int. 
The coordinates of repetitive elements were downloaded from the UCSC Table Browser (Karolchik, 
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4.3.5. Deposition pattern of H3K27me3 was not associated with enhanced expression of MHC-I 
and MHC-II  
As demonstrated in Chapter 3, MeT and high-dose DHT increased the expression of MHC-I 
proteins. Previous studies demonstrated that the expression of HLA genes in colorectal cancer 
cells can be induced by decreasing the levels of H3K27me3 by pharmacological inhibition of 
EZH2 (Burr, Sparbier et al. 2019). Therefore, we speculated that androgen-mediated 
repression of EZH2 may be a reason for observed up-regulation of MHC-I and MHC-II genes 
(refer to Chapter 3, Figure 7A). Therefore, we examined the distribution of H3K27me3 at the 
promoter of gene sets associated with MHC-I and MHC-II (Reactome). However, as shown in 
Figure 4.13, we did not observe a loss of H3K27me3 signal at the promoters of MHC-I and 
MHC-II genes in response to androgen treatments. Figure 4.14 shows an example of the 




























Figure 4.13. Promoter analysis showed that androgens did not change the deposition pattern of 
H3K27me3 at the promoter of genes associated with MHC-I and MHC-II. Average read density plots 
for H3K27me3 to genes associated with MHC-I and MHC-II in LNCaP cells treated with vehicle, MeT (1 
nM and 100 nM) or DHT (1 nM and 100 nM) for 72h. 
 
 


















Figure 4.14. Androgen treatment did not change the deposition pattern of H3K27me3 at HLA-B in 
LNCaP cells. Genome browser image showing H3k27me3 ChIP-seq signals at binding sites associated 










Epigenetic modifications, including DNA methylation and histone modifications, regulate the 
accessibility of chromatin for gene expression (Adam and Fuchs 2016). One of the 
mechanisms underlying chromatin compaction is the deposition of H3K27me3 by the PRC2 
complex, which has EZH2 and EZH1 as its catalytic subunits (Rizq, Mimura et al. 2017). 
Overexpressed in CRPC tumours, EZH2 is considered a bona fide oncogene in PCa and CRPC, 
with its primary oncogenic function thought to be silencing of tumour suppressor genes 
(Varambally, Dhanasekaran et al. 2002).  
 
Given the notion that EZH2 inhibition can make prostate cancer cells vulnerable to high-dose 
androgens (Nyquist, Corella et al. 2019), we were therefore intrigued to understand how EZH2 
suppression by androgens affects prostate cancer cell growth. In this study, we have shown 
that hyper-activation of AR causes down-regulation of EZH2 in different prostate cancer cell 
lines. Also, we found that down-regulation of EZH2 was associated with reduced total levels 
of nucleoplasmic H3K27me3 (as shown by Western blotting of histone acid extracts) but did 
not have a substantive effect on the level and distribution of chromatin-associated H3K27me3 
(as shown by ChIP-seq). This finding indicates that EZH2 repression by high-dose androgens 
caused a reduced level of H3K27me3 in soluble nucleoplasmic fraction rather than insoluble 
chromatin compartments. We envision a number of possible explanations for this apparently 
contradictory finding. Given that methylation of pre-deposition H3 soluble histones has been 
described for H3K9 histones (Loyola, Bonaldi et al. 2006), one possibility is that in LNCaP cells, 
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non-DNA bound H3K27 histones may be targeted by EZH2. However, this hypothesis is not 
consistent with previous findings in mouse embryonic stem cells (Ferrari, Scelfo et al. 2014, 
Juan, Wang et al. 2016), indicating that H3K27 histones are not methylated before 
nucleosome assembly. Therefore, in future studies, I propose that high-dose androgens 
effects on methylation of H3K27 should be examined in cytoplasmic, nucleoplasmic, and 
chromatin-bound fractions of PCa cells.  
 
Second, the disparity between total H3K27me3 and chromatin-bound H3K27me3 may relate 
to DNA methylation status.  Mechanistically, it has been shown that in the absence of DNA 
methylation, the canonical activity of EZH2 underlies a compensation mechanism, 
reallocating H3K27me3 to maintain the repressive chromatin state (18). With this background 
in mind, we showed in Chapter 3 that androgens affect the global methylation level of DNA, 
so it is possible that this leads to a re-distribution of H3K27me3 to compensate for DNA 
hypomethylation. Demonstrating the importance of this compensation mechanism in 
sustaining the repression of repetitive elements, Deblois G, et al., (Deblois, Tonekaboni et al. 
2020) showed that in taxane-resistant triple-negative breast cancer cells, inhibiting 
H3K27me3 deposition through pharmacologic inhibition of EZH2 can re-activate the 
expression of hypo-methylated transposon elements through viral mimicry response. 
Supporting this possibility, we found that H3K27me3 was gained at GC rich regions such as 
CpG islands and SVA elements, which can be potentially related to their low DNA methylation 
level. In future studies, the deposition pattern of H3K27me3 should be examined after DNA 
hypomethylation with DNA demethylating agents in the presence and/or absence of EZH2, 
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which would determine how the canonical activity of EZH2 changes in hypo-methylated DNA 
condition. Also, genome-wide DNA methylation should be investigated to more precisely 
determine the interplay between H3K27me3 deposition pattern and DNA methylation status.  
 
Finally, the simplest explanation for the apparent disparity between H3K27me3 levels in 
soluble nuclear fractions versus chromatin-bound could relate to experimental conditions i.e. 
time-point and growth conditions. It is known that the interaction of PRC2 with chromatin 
and deposition of H3K27me3 is a highly dynamic process that is influenced by growth 
conditions (Adriaens, Prickaerts et al. 2016).  To overcome this issue, in future work I propose 
to carefully tailor the experimental conditions to decrease variability resulting from the 
mechanism of action of EZH2/PRC2. 
 
The basis for the work in this chapter was that modulation of EZH2 and H3K27me3 could 
explain the induction of ERVs. This hypothesis was based on previous studies in other cancer 
models showing that this histone mark plays a key role in repressing ERV transcription 
(Deblois, Tonekaboni et al. 2020). Unexpectedly, we found that ERVs in this model were not 
marked by H3K27me3. This suggests that DNA methylation could be the key mechanism 
controlling the expression of ERVs, as described in Chapter 3. Other reports are consistent 
with this hypothesis:  for example, low-resolution analysis of chromosome 17 in a mouse 
model revealed that H3K27me3 is depleted at ERVs, but enriched at broad localized regions 
termed BLOCs that were found primarily within SINEs (Pauler, Sloane et al. 2009). This study 
also revealed that repressive H3K27me3 BLOCs were distributed over genes and intergenic 
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regions and H3K27me3 peaks rarely marked the gene promoters, accounting for only 10%–
15% of the promoters, which is also consistent with our findings. Another study also 
demonstrated that PRC2 complex / H3K27me3 is not involved in silencing repetitive elements 
in spermatocytes (Mu, Starmer et al. 2014) showed. Taken together, our findings do not 
support H3K27me3 playing a major role in ERV transcription in PCa cells. Notably, other 
histone modifications, such as H3K9me3 and/or H4K20me3, have been reported to play a role 
in the transcription of repetitive elements (Mikkelsen, Ku et al. 2007); I propose that a more 
comprehensive analysis of the epigenome is required to accurately determine how MeT leads 
to de-repression of ERVs and other repetitive elements (e.g. LINEs).  
 
It is important to note that both catalytic (canonical) and non-catalytic (non-canonical; i.e. 
collaboration with AR) activities of EZH2 have been identified in PCa cells (Kim, Lee et al. 
2018). Given that MeT repressed the expression of genes that are activated by EZH2; this 
supports the hypothesis that high-dose androgens may primarily disrupt the non-canonical 
activity of EZH2, as opposed to the canonical function. To test this hypothesis, I propose that 
assessing EZH2 interaction with AR and also its genome-wide DNA binding profile (i.e. using 
ChIP-seq) could be examined in response to MeT treatment. 
 
Gene ontology analysis suggested a significant overrepresentation of biological processes 
involved in development, differentiation, and lineage-specification process, which are 
consistent with the proposed role of H3K27me3 in regulating the expression of genes involved 
in of nervous system and anatomical structures (Hawkins, Hon et al. 2010, Zeng, Zhang et al. 
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2019). However, in future studies, to examine any association between H3K27me3 re-
distribution and alteration in the function of a pathway, matched transcriptomic data is 
needed. Unfortunately, the RNA-seq we carried out (see Chapter 3) was done at a much 
earlier time-point compared to the H3K27me3 ChIP-seq, which precluded integration of these 
datasets.  
 
Overall, our study showed that potent activation of AR caused down-regulation of EZH2 and 
a concomitant decrease in the global H3K27me3 level. However, the lack of substantial impact 
on the level and distribution of chromatin-associated H3K27me3 means that it is not possible 
to know whether repression of EZH2 has any role in mediating the growth-suppressive or 
immunomodulatory effects of MeT. Since EZH2 inhibitors are being developed to treat PCa 
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5. General Discussion  
Prostate cancer is the second most common cancer worldwide in men and has one of the 
highest age-standardized incidence and mortality rates of all cancers in Australian men 
(Organization 2012). Current treatment strategies for patients with localized prostate cancer, 
including radical prostatectomy and radiotherapy, are curative in a substantial proportion of 
men; however, approximately 30% experience recurrence with metastatic disease (Singh, 
Febbo et al. 2002). As described in chapter 1, ADT is a standard-of-care treatment for 
metastatic PCa, which aims to inhibit the activity of a major oncogenic driver of this disease, 
AR. However, ADT is never curative, with all patients eventually acquiring resistance to 
therapy and relapsing with lethal castration-resistant prostate cancer (CRPC). Enigmatically, 
recent studies have suggested that potent activation of AR using high doses of androgens can, 
similarly to AR suppression, also inhibit the growth of CRPC (Schweizer, Antonarakis et al. 
2015). However, the exact tumour suppressive effect(s) of high-dose androgen therapy 
remain largely uncharacterised. This study aimed to investigate the mechanisms underlying 
PCa growth suppression in response to hyperactivation of AR by a potent androgen, 
methyltestosterone (MeT). 
 
5.1. MeT potently suppresses the growth of PCa cells  
Investigation into the effects of MeT on prostate cancer cell growth revealed that MeT 
suppressed the growth of AR-positive PCa cell line models more potently than the 
physiological androgen DHT. Consistent with this finding, transcriptional activation assays 
showed that MeT is a more potent transcriptional activator of AR, an observation supported 
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by earlier studies (Sonneveld, Jansen et al. 2005, Wolf, Diel et al. 2011, Wang, Lawless et al. 
2020), indicating that MeT shows more AR agonistic effects in comparison with DHT. Given 
the higher AR binding affinity of DHT relative to MeT (Liao, Liang et al. 1973, Saartok, Dahlberg 
et al. 1984, Fang, Tong et al. 2003), this was an unexpected result. However, it has been 
reported that MeT cannot be metabolised by Glucuronyl-transferase enzymes, which are the 
major mediators of androgen inactivation in prostate cancer cells (Smith, Ballard et al. 1994, 
Kuuranne, Kurkela et al. 2003, Chouinard, Barbier et al. 2007). Thus, I propose that MeT’s 
greater androgenic potency is largely related to its increased stability in the models used in 
my project. However, in future studies, I propose that MeT and DHT should be measured in 
PCa cells to validate this hypothesis. Toward this end, the androgen levels can be measured 
in cell culture media by liquid chromatography tandem mass spectrometry (LC-MSMS), which 
is considered the gold standard method (Matsumoto and Bremner 2004, Harwood and 
Handelsman 2009).  
 
Using an integrated genomic approach that includes ChIP-seq and RNA-seq, I found that MeT 
regulates a canonical set of AR-regulated genes and leads to a similar genome-wide AR DNA 
binding profile, but it does so much more potently than DHT. Molecularly, extreme activation 
of AR with MeT is linked to the repression of previously reported AR target genes that are 
associated with cell cycle, DNA replication, and DNA repair (Gao, Gao et al. 2016, Chatterjee, 
Schweizer et al. 2019, Lam, Nguyen et al. 2020). Supporting the idea that these are direct 
target genes, I found that MeT-activated AR was strongly recruited to the promoter of these 
genes. Mechanistically, repression of genes associated with cell cycle and DNA replication is 
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linked to cell cycle arrest (Engeland 2018), which we confirmed with FACS analysis following 
treatment of cells with MeT.  
 
Preclinical studies have proposed that AR-mediated repression of genes associated with DNA 
damage response is linked to the therapeutic effects of high-dose androgens (Chatterjee, 
Schweizer et al. 2019, Lam, Nguyen et al. 2020). Consistent with this idea, some clinical studies 
also suggested that patients with deficiency in DNA repair genes may exhibit a better 
response to high-dose androgen therapies (Teply, Kachhap et al. 2017). Indeed, a prevailing 
dogma posits that AR-induced DNA damage is the major therapeutic mediator of high-dose 
androgen treatment and hence that deficiency in the DNA repair system can enhance 
therapeutic benefit (Chatterjee, Schweizer et al. 2019, Nyquist, Corella et al. 2019). However, 
we did not observe an increased level of γH2AX in response to MeT treatment. This 
observation aligns with other studies indicating that AR activation by androgens cannot 
induce persistent dsDNA breaks (Lin, Yang et al. 2009, Polkinghorn, Parker et al. 2013, Nyquist, 
Corella et al. 2017). Moreover, genomic analysis of circulating-tumour DNA isolated from 
CRPC patients who were treated with high-dose androgen therapy revealed that there was 
no significant association between baseline AR and DNA repair alterations with PSA response 
(Chatterjee, Schweizer et al. 2019, Moses, Koksal et al. 2020). Regarding the relevance of AR-
induced DNA damage to BAT response in CRPC patients, next-generation sequencing of 
samples from patients who received BAT revealed an enormous variation among patients 
with different genomic aberrations (Schweizer, Antonarakis et al. 2019). Overall, the question 
as to whether AR-induced DNA damage is the key mechanism exerting anti-proliferative 
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effects in prostate cancer cells remains unanswered. Therefore, in future studies, DNA repair 
defects should be measured in much larger cohorts of men treated with BAT to provide 
definitive evidence that such defects could be used to predict response. Also, DNA damage 
should be examined more directly (eg using a COMET assay) in both cells and patient tumours 
treated with high-dose androgens. 
 
5.2. Hyper-activation of AR triggers viral mimicry response in PCa cells 
Prostate cancer is immunologically characterised as a “cold tumour”, indicating that tumour 
cells cannot be effectively killed by immune cells. Mechanistically, the immunological 
“coldness” of PCa tumours, which mediates resistance to immunotherapies, can be induced 
by a network of different but intertwined factors including the presence of 
immunosuppressive cells in the tumour microenvironment, low expression of tumour-
associated antigens, and dysfunctional antigen presentation system in cancer cells (Bronte, 
Kasic et al. 2005). Immunosuppressive cells that are enriched in prostate tumours include 
cancer-associated fibroblasts (CAFs), regulatory T cells, tumour-associated macrophages 
(TAMs), and myeloid-derived suppressor cells (MDSCs), all of which can induce immune 
evasion phenotypes by impeding the differentiation, activation, and interaction of cytotoxic 
T cells against tumour cells (Lu, Rong et al. 2019, Zhao, Lehrer et al. 2019, Li, Jiang et al. 2020). 
Another important immune evasion mechanisms in prostate cancer cells is loss of major 
histocompatibility complex (MHC) expression, which can be potentially impaired either by 
tumour microenvironment or intrinsic factors such as genetic/epigenetic aberrations (Sanda, 
Restifo et al. 1995, Bander, Yao et al. 1997, Dhatchinamoorthy, Colbert et al. 2021). It has 
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been reported that in primary prostate cancer tumours, low expression of MHC-I genes was 
associated with high Gleason score, bone metastasis, and short cancer-specific survival 
(Ylitalo, Thysell et al. 2017). Expression of MHC-I genes can be induced by different 
mechanisms including IFN signalling, which can cause a robust immune response by CD8+ T 
cells (Martini, Testi et al. 2010). However, it has been demonstrated that in metastatic 
prostate cancer cells tumour‐intrinsic type I IFN and associated immune signalling is 
epigenetically suppressed (Owen, Gearing et al. 2020).  
 
In my PhD studies, RNA-seq data revealed that MeT treatment induced the expression of 
interferon-stimulated genes (ISGs), suggesting that extreme activation of AR leads to the 
activation of IFN signalling pathways. Indeed, I found in multiple in vitro prostate cancer 
models that potent activation of AR induced expression of IFN-β and ISGs concomitantly with 
dysregulation in the expression pattern of repetitive elements. More specifically, my PhD 
work demonstrated that potent activation of AR triggers the activation of a viral mimicry 
response in prostate cancer cells, which was characterised by upregulation of ERVs, 
accumulation of viral dsRNAs in cells, activation of interferon signalling, upregulation of MHC 
Class I and activation of T cells (Figure 5.1).  
 
 





Figure 5.1. Schematic depicting the role of AR in immunosensitizing of PCa cells 
 
Mechanistically, the expression of repetitive elements is primarily regulated by epigenetic 
modifications, and DNA methylation is a key mechanism conferring long-term epigenetic 
silencing of transposons (Yoder, Walsh et al. 1997, Reik 2007). We were therefore intrigued 
to discern whether high-dose androgen-mediated ERVs expression is associated with 
epigenetic changes in prostate cancer cells. In my PhD studies, I showed that treatment with 
MeT repressed the expression of key enzymes involved in the maintenance (DNMT1) and de 
novo methylation (DNMT3b) of DNA. Following this finding, we also demonstrated that 
treatment with androgens leads to DNA hypomethylation. Although to the best of my 
knowledge this is the first report of androgen-mediated hypomethylation, it should be noted 
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that a negative correlation between AR activity and DNA methylation status has been 
reported previously (Dhiman, Attwood et al. 2015). Therefore, we postulate that androgen-
induced hypomethylation of DNA is the key mechanism dysregulating the expression of 
repetitive elements, leading to activation of viral mimicry response in prostate cancer cells. 
However, with current data, we cannot conclude the exact mechanism of epigenetic 
alterations by AR. To verify the role of DNMTs in the MeT-mediated viral mimicry response, a 
powerful experiment would be to treat prostate cancer cells over-expressing DNMTs with 
MeT and see whether ERV induction and viral mimicry response is lost or weakened. 
Additionally, examining whether MeT can synergise with DNA de-methylating agents such as 
Decitabine could provide more evidence of the importance of DNMTs in these processes. 
Understanding how androgens suppress DNMTs could also shed light on these questions. 
DNMT1 is an E2F1 target genes and our transcriptomic data showed that E2F1 and its target 
genes were strongly repressed by MeT (33, 34). Demonstrating loss of E2F1 binding to the 
DNMT1 gene (e.g. by ChIP) would provide further evidence for its role in MeT-mediated 
alterations to DNA methylation. Importantly, if this hypothesis could be confirmed, it would 
suggest that MeT could be applied in combination with CDK4/6 inhibitors, which also 
inactivate E2F1 and can cause a viral mimicry response (Goel, DeCristo et al. 2017). 
 
As reported in previous studies, detection of viral dsRNA by intracellular dsRNA sensors (TLR3, 
RIG-I and MDA5) or dsRNA/dsDNA sensor (STING) is the trigger of innate immune response 
activation (Liu, Ohtani et al. 2016, Goel, DeCristo et al. 2017, Liu, Thomas et al. 2018). In 
prostate cancer cells, we showed that that potent activation of AR leads to the induction of 
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RIG-I and STING, which potentially detect the androgen-induced dsRNAs leading to activation 
of viral mimicry response. However, proving that dsRNA sensing is required for MeT-mediated 
viral mimicry is a crucial mechanistic experiment that I was unable to complete during my 
PhD. In the future, I propose to use genetic methods (i.e. siRNA, CRISPR) or pharmacological 
methods (i.e. STING inhibitor) for inhibition of STING/RIG-I to determine whether these 
factors are required for induction of innate immune responses by MeT.   
 
Activation of innate interferon signalling in tumours cells can enhance the expression of MHC-
I expression and cause the infiltration of tumour-specific cytotoxic CD8+ T cells (Corrales, 
Matson et al. 2017). My PhD studies identified a similar mechanism whereby potent 
activation of AR in cancer cells caused induction of MHC-I molecules (i.e. HLA-B and HLA-C), 
led to enhanced tumour cell immunogenicity as demonstrated by enhanced recognition of 
cancer cells by tumour-specific CD 8+ T cells. This is an important finding suggesting potential 
clinical implications, which was supported by a case report study suggesting that bipolar 
androgen therapy may have immune activation effects on prostate cancer tumours 
(Markowski, Shenderov et al. 2020). To confirm that immunomodulatory effects of MeT are 
mediated by activation of IFN signalling, I propose that future studies should conduct 
equivalent studies using genetically engineered models that are deficient for IFN signalling 
(e.g C57BL/6 Ifnar1 -/- (Owen, Gearing et al. 2020)). Specifically, loss of immune response in 
such a model can confirm the role of the proposed mechanism for IFN signalling. More 
broadly, the tumour microenvironment’s role in immune evasion is critical and the lack of in 
vivo studies in my study was a major limitation. Therefore, to determine whether high-dose 
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androgen therapy can exert the proposed immunomodulatory effects in the presence of 
immunosuppressive prostate tumour microenvironment in vivo studies (e.g B6-Hi-MYC model 
(Morel, Sheahan et al. 2021)) are essential. Finally, given the reported anticancer and 
immunomodulatory effects of IFN-γ on tumour cells and also on tumour microenvironment, 
it would be worth considering whether a combination treatment comprising MeT and IFN-γ 
may cause an additive benefit in terms of immune surveillance (Selleck, Canfield et al. 2003, 
Cheon, Borden et al. 2014, Galon and Bruni 2019, Jorgovanovic, Song et al. 2020). 
 
5.3 Androgen treatments modulate EZH2 function and re-distribute H3K27me3  
In Chapter 4, I reported that potent activation of AR caused repression of the histone 
methyltransferase EZH2 in prostate cancer cells, suggesting that EZH2 repression by high-
dose androgens could induce epigenetic alterations beyond DNA hypomethylation. 
Interestingly, genome‐wide studies have shown that there is an anti‐correlated relationship 
between DNA methylation level and H3K27 methylation enrichment (Fu, Bonora et al. 2020). 
Given that potent activation of AR with androgens induces a global DNA hypomethylation 
(please see Chapter 3), we were therefore intrigued to examine the consequence of EZH2 
repression by androgens on the deposition of H3K27me3. Interestingly, H3K27me3 ChIP-seq 
showed a minor re-distribution of H3K27me3 by MeT and DHT but not an overall loss of 
chromatin-bound H3K27me3. Possible explanations for this unexpected finding were 
described in Section 4.4.  
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As shown in Chapter 3, androgen-induced DNA hypomethylation causes the activation of the 
viral mimicry response in prostate cancer cells. More interestingly, we showed that 
Decitabine-induced dsRNA are less strong than MeT 1nM, suggesting that dsRNA formation 
by MeT is also amplified by another mechanism. We postulated that the strong induction of 
dsRNAs by MeT could be potentially related to the modulation of the EZH2-associated 
compensation mechanism. Analysis of H3K27me3 deposition at different classes of repetitive 
elements, however, revealed that androgen (MeT or DHT) did not cause a significant 
difference in H3K27me3 profile. Despite this result, I propose that future work should 
evaluate how a DNA de-methylating agent (e.g. Decitabine) influences H3K27me3 to 
determine if a compensation mechanism is active in prostate cancer and influences 
expression of transposable elements. 
 
5.4. Overall conclusion 
Collectively, the work described in this thesis sheds new light on the anti-tumour mechanism 
of action of high dose androgens in prostate cancer cells. Most importantly, the concept for 
immunosensitisation of prostate tumours using MeT is pioneering and warrants further pre-
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